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Abstract 
The exploration of humoral responses to cancer may reveal diagnostic and prognostic 
biomarkers and may help to discover potential immunotherapeutic targets. In a previous 
study aiming to identify a comprehensive set of antigens eliciting IgG antibody production 
in melanoma, breast, gastric and prostate cancer patients by using T7 phage display-based 
SEREX approach, we isolated over 1300 serum-reactive clones comprising (i) antigens 
translated in the natural open reading frames (ORF) including known cancer-testis (CT) 
antigens, antigens previously detected by conventional SEREX and uncharacterised 
antigens representing wild-type non-mutated proteins, (ii) several putatively novel genes 
and splice variants with an undefined ORF, as well as (iii) peptides translated in an 
unnatural ORF. In the current study we tried to determine whether any of the novel 
antigens are potentially applicable as targets for immunotherapy and to get an insight into 
the mechanisms of their immunogenicity by detecting the frequency of antigen-specific 
humoral responses in cancer patients and healthy controls, by analysing the expression 
pattern in various normal and cancerous tissues, as well as by characterising naturally 
occurring T cell responses for two immunotherapy candidate antigens. 
Autoantibody profiling assay for melanoma, breast and gastric cancer patients and 
healthy donors were performed using our custom developed antigen microarrays. To select 
the most promising novel antigens recognised by cancer-related antibodies for further 
experimental analyses we established a prioritisation scheme where the antigens were 
evaluated and ranked by their frequency of cancer autoantibodies, EST profile, as well as 
functional and structural properties. The top 30 ranked natural and undefined ORF antigens 
were selected for further mRNA expression analysis, and revealed six annotated genes and 
four novel genes that were predominantly expressed in testis among various normal 
tissues. Two of these genes – LRRC50 and ESCO1, were significantly upregulated in 
cancers and represented novel CT antigens with potential use in immunotherapy. Two 
novel testis-associated splice variants were identified for CFL1, and COX6B2, and their 
upregulation was observed in some tumours suggesting that immunoprivileged tissue-
specific splice sites can be recognised in cancer contributing to cancer antigenicity. 16 
genes showed ubiquitous expression and four of them were significantly upregulated in 
tumours – ACTR2, LIG1, NOL8, and SPARC, however not exceeding the level in other 
normal tissues and the reasons of immunogenicity of these wild type proteins remains 
elusive. 
Among the cancer-related natural ORF antigens was SPAG8 – a member of 
heterogeneous group of proteins called sperm associated antigens (SPAG) that are 
commonly expressed in male germ cells, are capable to elicit immune response underlying 
infertility, and several of them recently have been shown to be expressed in cancers and 
may have oncogenic properties. This prompted us to investigate further the expression 
pattern and humoral immune response against SPAG proteins. Several of SPAG genes 
previously proposed as targets for cancer immunotherapy were found to be ubiquitously 
expressed in normal human tissues, while SPAG1, SPAG6 and alternative splice variants 
of SPAG8, SPAG16 and SPAG17 were predominantly expressed in testis and elevated in 
various tumours with frequencies ranging from ~10% ~70%, further supporting the idea of 
testis-associated splice site recognition in cancer. The upregulation of SPAG6 in cancer 
was confirmed by immunohistochemical analysis of tissue microarrays. Cancer-associated 
spontaneous humoral immune response was detected against SPAG1, SPAG6, SPAG8 and 
a novel testis-restricted splice variant SPAG17-A1 and ascribe these genes as novel CT 
antigens that potentially are applicable as immunotherapeutic targets and serological 
biomarkers. In the case of SPAG17-A1 we demonstrated that the humoral response is 
 2!
directed against the novel alternative testis-restricted splice variant and we propose to 
designate these antigens as CT-spliced antigens. 
In order to establish a robust and reproducible assay for the analysis of spontaneous 
T cell responses, we participated in the international study aiming to standardize ELISPOT 
procedure what resulted in the generation of a reference protocol. Next, an assay for the 
isolation of CD4+ and CD8+ T cells from peripheral blood and in vitro pre-sensitisation of 
T cells was elaborated and tested with positive control viral peptides and well-known 
tumour antigen NY-ESO-1, and the results demonstrated that it allows the detection of 
tumour antigen specific CD8+ T cells in the peripheral blood mononuclear cells after in 
vitro pre-sensitisation. The initial CD8+ T cell activation analyses of two candidate 
antigens LRRC50 and SPAG8 showed a plausible SPAG8-specific naturally occurring 
CTL response in one gastric cancer patient suggesting that it could be possible to achieve 
also a therapy-induced response. 
In conclusion we have characterised the mRNA expression and humoral immune 
response of novel cancer antigens revealing novel potential immunotherapy target genes, 
and antigens representing testis-associated alternative splice variants that could form a 
novel cancer antigen category called CT-spliced antigens. 
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Introduction 
Malignant disease has a severe impact on the overall public health substantially 
shortening the lifespan of the ill despite various medical advances and still is a heavy 
burden for sustainable healthcare development. Breast cancer is the most frequent tumour 
type in Latvia and its incidence has increased by around 10% in the last ten years with 
more than 1000 new cases per year (from Latvian Central Bureau of Statistics). Gastric 
cancer is the third most frequent type of malignancy in Latvia with around 700 new cases 
per year and the second most frequent reason of cancer mortality (from Latvian Cancer 
Register). Melanoma although with comparatively low incidence in Latvia among 
European countries (data of year 2006 from European Cancer Observatory) is one of the 
most aggressive tumours affecting all age groups of society and the incidence has also 
increased during the last ten years reaching over 180 cases in 2008 (from Latvian Cancer 
Register). The major treatments of these malignancies are surgical, hormone, radio or 
chemotherapies that significantly decrease patients’ quality of life during treatment, and 
the curative outcome for certain tumour subtypes and late stages is rare. 
One of the modalities of cancer treatment utilising the natural defence mechanisms 
of the human body called tumour immunotherapy holds great promise for the clearance of 
malignant cells due to highly specific targeting against tumour-specific and tumour-
associated antigens, and for the possibility to substantially increase patients’ quality of life 
due to low toxicity. The first line of clinical application of tumour immunotherapy has 
been the administration of stimulatory cytokines like interleukin 2 (IL-2) and interferon 
alfa (IFN!) as well as monoclonal antibodies against tumour antigens either conjugated to 
a therapeutic agent or with opsonising effect1. The application of the cellular compartment 
of the immune system in clinics, however, has not been so straightforward and has 
experienced a full spectrum of fluctuations from the disbelief in the capability of immune 
cells to control cancer to the first cellular therapy receiving FDA approval in spring 2010 
marking a cornerstone in the development of adoptive immunotherapy. Hitherto a lot of 
effort has been put into various strategies of adoptive tumour immune response activation 
mainly divided into two different approaches depending on the used antigenic 
determinants. The activation of immune response can be achieved through either (i) 
tumour antigen-specific targeting by vaccination with antigen-encoding DNA, mRNA, 
peptide/protein, or by administration of in vitro propagated antigen-specific T cells, or (ii) 
against whole tumour, when the stimulant is tumour cells, dendritic cells pulsed with total 
tumour cell biomaterial, tumour cell HSP-peptide pool vaccines, or in vitro propagated 
tumour infiltrating lymphocytes (TILs)1. Either modality has struggled with (i) innate 
and/or adaptive suppression of the induced immune response by myeloid-derived 
suppressor cells, tolerogenic dendritic cells and inducible T regulatory cells, as well as 
suppressive cytokines produced by tumour or its stroma, and (ii) the selection of tumour 
escape variants by decreasing antigen presentation or losing antigen expression2,3. 
However, the combination of vaccines with adjuvants and blockers of tolerance, that skews 
the balance from tolerogenic to activating conditions, or with chemotherapy or 
radiotherapy that dampen the activity of suppressor cells and promote the immunogenicity 
of tumours by increasing antigen diversity and expression have shown promising trends4,5. 
Regardless of either antigen-specific or whole tumour targeting methods, the 
endpoint of a successful adaptive response is the expansion of cells specific to a cancer 
antigen capable of controlling and destroying the tumour with a higher curative probability 
if the response is polyclonal and against many antigens. A large number of tumour-specific 
and associated antigens has been identified by using B and T cell based approaches, 
nevertheless, the field still lacks sufficient knowledge of the true protective antigens as 
! "!
well as tools for monitoring the therapy induced immune response, hence there is a 
continuous necessity for the identification and characterisation of cancer proteins that the 
immune system can recognise. A wide expert panel has recently elaborated guidelines of 
prioritising antigens for immunotherapy to discern the ones that could successfully be 
targeted in clinical trials and name the specificity and oncogenicity of a novel antigen as 
the dominant criteria for choosing it for further immunogenicity and therapeutic function 
evaluations6. Previously we applied a high-throughput serological antigen identification 
approach - the phage-display SEREX, to characterise humoral cancer immunome - a 
comprehensive set of proteins that are recognised by autoantibodies in sera of melanoma, 
breast, prostate and gastric cancer patients, which resulted in the collection of over 1300 
antigenic clones. The aim of this doctoral study was to define whether any of the identified 
novel humoral cancer antigens may serve as immunotherapeutic targets by characterising 
their expression pattern in various normal tissues and looking for evidence of 
overexpression in tumours, as well as analysing the frequency of spontaneous humoral and 
cellular immune response in cancer patients. 
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1 Literature overview 
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The adaptive immune system has evolved as a means to improve the host’s defences 
against all sorts of pathogens, and is based on the generation of cells with a plethora of 
receptors capable to bind different biological macromolecules called antigens that mediate 
the further protective effector functions7. The enormous receptor diversity is created 
through an intense genomic reorganisation of the corresponding genes, which is a “blind” 
process that inevitably creates not only receptors recognising molecules which are 
characteristic to the pathogen – the so-called “non-self” or foreign antigens, but also 
receptors recognising molecules of the host’s body called “self” or autoantigens8. There are 
two major lineages of effector cells executing the adaptive protection namely B and T 
lymphocytes that underlie the humoral and cellular immunity possessing highly destructive 
potential capable of clearing large amounts of parasites, bacteria, virally infected cells or 
cancer cells. The activation of the adaptive immunity is essential for survival, while the 
tolerance mechanisms ensure that immune cells bearing self-recognising receptors won’t 
be propagated and prevent severe damage to the host defined as autoimmune diseases8. 
The balance between activation and tolerance is kept by a milieu of regulator mechanisms 
that together underlie normal tissue homeostasis.&
1.1.1 The ignorance of “self”, establishment of immune tolerance 
Both effector cell lineages derive from hematopoietic stem cells in the bone marrow 
but differ in the further maturation fates. The differentiation of B cells (here and further 
designating the B2 lineage lymphocytes) takes place in the bone marrow, whereas T cell 
precursors migrate and mature in the thymus, and the first and most stringent control of 
self-reacting receptors named the central tolerance takes place in these primary lymphoid 
organs9. The central tolerance is based on the selection of cells for either purging or further 
maturation by evaluating the binding affinity of both, developing T and B cells receptors 
named pre-BCR and pre-TCR to self-antigens presented in the primary lymphoid tissues. 
The mechanisms through which thymus presents peripheral tissue self-antigens during T-
cell development include the expression of autoimmune regulator AIRE in thymic 
medullary epithelial cells that causes promiscuous expression of various genes or by the 
immigration of antigen-presenting immature dendritic cells10. Much less is known about 
the autoantigen presentation to developing B cells, but in both cases strong receptor 
binding leads to receptor editing, clonal deletion, or anergy9,11 with receptor editing being 
the predominant mechanism for pre-B cells and the other two for pre-T cells10. The effects 
of intermediate avidity binding of the pre-receptors differ for pre-B and pre-T cells leading 
to receptor editing or positive selection, respectively, while no pre-receptor binding 
induces apoptosis due to the lack of survival signals for pre-T cells but ensures pass of pre-
B cells9,12. Lymphocytes that have passed the central tolerance then continue their 
differentiation, and T cells depending on the TCR stimulation properties diverge into 
distinct subtypes like CD8+ cytotoxic T lymphocytes (CTL), CD4+ T helper (Th) cells, as 
well as so-called natural CD4+ T regulatory (nTreg) cells that evolve as a second scenario 
in case of a strong autoreactivity of the pre-TCR and possess strong suppressive activities 
against self-antigen specific lymphocytes in the periphery10. Cells that leave to periphery 
are from this point described as naïve or antigen-inexperienced10. 
Although very efficient, central tolerance cannot eliminate all self-reactive cells as 
not all self-proteins are displayed by the primary lymphoid organs as well as the positively 
selected T cells that bind self-antigens with intermediate affinity can possess a threat, 
hence further control mechanisms are applied after lymphocytes have exited the primary 
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lymphoid organs called the peripheral tolerance that further diminish the autoreactive 
repertoire, control the activation of naïve effectors as well as control the course of immune 
response13.  
The number of autoreactive B cells is further decreased through the negative 
selection of high avidity autoantigen-binding BCRs in the spleen where the transition from 
immature to mature B cells takes place10. This selection is additionally fine-tuned by 
integrating signals from the engaged BCR and antigen-independent receptor BAFFR that is 
crucial for B cell survival and differentiation14, and introduces a certain degree of freedom 
in this censoring step resulting in about 20% of autoreactive B cells in the mature naïve 
repertoire in the periphery12. Also Th cells recognising the self-peptide-MHCII complexes 
presented on the stimulated B cells but not being activated themselves can induce 
apoptosis of B cells through Fas-FasL interactions11, as well as by activated Treg cells15. 
During adoptive immune response B cells that receive proper activation from Th cells 
undergo somatic hypermutation or affinity maturation of their BCRs that can result not 
only in enhanced BCR affinity towards the foreign antigen eliciting the activation, but also 
in the generation of autoreactive receptors. At this point B cells that have acquired such a 
de novo self-reactivity are controlled by a distinct Th cell subset called the T follicular 
helper (TFH) cells that are also crucial for mounting of proper B cell activation16. 
Peripheral T cell tolerance and the principles of self-non-self discrimination are 
described by the so-called “Danger model”17. In order for a T cell to bind its antigen, it 
must be firstly taken up, then intracellularly processed, and finally presented to the T cell 
on the major histocompatibility complex (MHC) II by antigen-presenting cells18. The most 
important cell with this capacity is the dendritic cell (DC), which collects the surrounding 
material while circulates in tissues and scans the environment for the so-called danger 
signals such as conserved pathogen molecules like lipopolysaccharides or tissue damage 
signals like HMGB1, DNA or purine metabolites (termed as pathogen-associated 
molecular patterns, PAMPs, and danger-associated molecular patterns, DAMPs, 
respectively), and if these signals are encountered by corresponding receptors (like Toll-
like receptors), DCs differentiate from immature to mature state necessary for proper T cell 
activation19. DCs that present antigens collected from healthy tissue environment and 
haven’t encountered any danger signals are in an immature or incomplete maturation state 
that is characterised by the lack of co-stimulatory molecules on their surface and no or 
poor stimulatory cytokine production. Immature DCs induce anergy or death in T cells 
recognising presented antigens13 or induce their differentiation into regulatory subtypes 
like inducible T regulatory (iTreg) cells, which have the same censor functions as the 
nTreg cells20. 
Next line of control are the Treg cells that, if activated by antigen-presenting cells, 
inhibit both, effector CD4+ and CD8+ T cells in either contact-independent manner by 
secreting suppressive cytokines IL-10, TGF" and IL-35, or in contact (or at least a very 
close proximity)-dependant manner by (i) modulation of antigen-presenting cells from 
activating to tolerogenic, (ii) induction of apoptosis of effector T cells through granzyme 
B, perforin, TRAIL or survival cytokine IL-2 deprivation, and by (iii) the metabolic 
disruption of effector T cells through the release of adenosine nucleosides or IDO by 
dendritic cells21. Lately the stromal cells of lymphoid organs like lymph node fibroblastic 
reticular cells22 and lymph node-resident endothelial cells23 have been shown to express 
peripheral tissue-restricted antigens in either AIRE-dependant or independent manner, 
respectively, and present them to CD8+ T cells inducing tolerance24.  
Besides Treg activities, several T cell control mechanisms take place in the periphery 
that are intrinsic to the effector cells: (i) repeated TCR activation causes activation-induced 
cell death (AICD) (this also contributes to T cell selection in thymus)25, (ii) activating TCR 
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engagement for prolonged periods of time causes apoptosis or desensitisation of TCR 
signalling in CD4+ T cells termed adaptive tolerance13, or functional exhaustion for CD8+ 
T cells26, as well as (iii) TCR engagement abrogates initial proliferation of CD8+ T cells if 
no additional Th stimulation in terms of mitogenic cytokine IL-2 is received called 
antigen-induced non-responsiveness (AINR)27. 
 Another “mechanical” way of peripheral tolerance is the mode of the migration of 
naïve lymphocytes that is restricted to the blood-lymph system, and the anatomical barriers 
such as blood-brain, eye, testis or placenta ensuring immunological ignorance by reduced 
level of adhesion molecules on draining blood vessels necessary for antigen-experienced 
lymphocyte exit to tissues, as well as in testis decreased MHCI expression and apoptotic 
ligand expression in case an attacking lymphocyte did arrive, and such tissues are termed 
as immunoprivileged13,28. 
Additional B and T lymphocyte subsets have been identified with inhibitory capacity 
like regulatory B cells secreting immunosuppressive cytokine IL-1029 and regulatory CD8+ 
T cells (both, naturally occurring and inducible30) that kill or anergise activated T cells 
antigen-specifically or inhibit antigen presenting cells31,32. The latter has yielded a novel 
model describing the principles of peripheral self-tolerance named “Avidity Model of Self-
Nonself Discrimination”, which encompasses the idea that the immune system achieves 
self-non-self discrimination not by recognising the structural differences between self 
versus foreign antigens (as underlined by the “Danger model”, where the maturation of 
dendritic cells is mounted as a result of PAMP or DAMP recognition), but rather by 
perceiving the avidity of TCR-antigen interaction33. Taking into account that there are no 
high avidity self-reacting T cells passing the central tolerance or Treg surveillance, the 
positively selected peripheral T cells may bear low or intermediate avidity TCRs to self 
antigens as well as low, intermediate or high avidity TCRs to foreign antigens. The model 
predicts that all low or intermediate avidity T cells are anergised or deleted in the periphery 
regardless to their self or foreign specificity, while all high avidity TCRs overcome the 
suppressive barrier, thus not only are the potentially autoimmune T cells downregulated, 
but also the strongest foreign antigen-specific T cells are selected enhancing the protective 
response33. This model is also supported by a recent review reporting that suboptimal 
engagement of the TCR by a variety of peptide-MHC ligands (such as antigens with 
intermediate avidity) triggers T-cell anergy34. 
1.1.2 The recognition of “non-self”, mounting of protective immune response 
According to the “Danger model” the initial key event of immune response 
activation is the induction of DC maturation by danger signals. Upon maturation DCs 
increase migration towards lymph nodes, upregulate co-stimulatory molecules and secrete 
a stimulating cytokine profile depending on the danger signal type20. The role of lymphoid 
organ stromal cells as antigen presenters and important regulators of immune cell 
trafficking and activation by chemokine and cytokine production have also been 
increasingly acknowledged35 and together with mature DCs ensure all necessary signals for 
effector cell activation.  
CD4+ or Th cells are the first lymphocytes that need to be activated to further 
properly mount both, the cellular cytotoxicity effector (CTL) and humoral effector (B cell) 
activation. To induce the proliferation and effector functions of a naïve Th cell three 
signalling checkpoints have to be fulfilled: it needs to bind to the complementary antigen 
in an MHCII context (compatible with the CD4 co-receptor) (signal 1) on a matured 
dendritic cell that expresses co-stimulatory molecules like B7-1/2 binding to stimulatory 
co-receptors on the Th cell like CD28 (signal 2) as well as produces stimulating cytokines 
(signal 3)20. After all three signals have been received, Th cell proliferates and 
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differentiates into various functionally different effector subtypes like Th1, Th2, Th17, 
follicular helper T (TFH) cells etc. (Figure 1) depending on the received signal 3 cytokine 
profile as well as the strength and duration of TCR engagement36. These subtypes are 
epigenetically determined and can switch their phenotype to other subtypes in response to 
dynamically changing cytokine profile provided by antigen-presenting and regulatory cells 
to orchestrate the course of the immune response37. 
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Antigen-inexperienced CD8+ T cells can be activated only if their TCR has 
encountered a compatible antigen presented in an MHCI (compatible with the CD8 co-
receptor) context on matured DCs (called cross-presentation) that also provide analogous 
signals 2 (co-stimulatory surface molecules) and 3 (cytokines). For a dendritic cell to 
provide the necessary activating signals to the CTL, it needs to be conditioned by an 
activated Th cell to produce the proper cytokines like IL-12 and IFN!27. Th cells can also 
produce cytokines directly providing signal 3 to naïve CTLs, for example IL-21 that is 
mostly produced by activated Th1739 or TFH cells55 is found to be a potential alternative 
signal 3 cytokine capable of inducing naïve CD8+ T cell activation and differentiation into 
highly cytolytic effectors56. Other cytokines produced by Th cells can enhance or modify 
naïve CTL activation and induce differentiation into several effector subtypes (Figure 2), 
for example Th2 cytokine IL-4 skews the differentiation to a Tc2 effector subtype that 
produces IL-4 (so-called type 2 cytokines and type 2 response), while Th1 cytokines IL-2 
and IFN# promote conventional CTL or Tc1 subtype differentiation and clonal expansion  
(so-called type 1 cytokines and type 1 response)27. After activation effector CTLs migrate 
out of the lymphatics following the signals of tissue damage and inflammation and search 
for cells presenting the specific antigen on their MHCI complexes and once encountered 
induce their apoptosis by direct (Fas-FasL or granzyme B and perforin) or indirect (TNF!, 
IFN#) mechanisms57. 
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The major activation checkpoints necessary for high affinity antibody-producing B 
cell generation also follow the sequential signal paradigm64. The presence of (1) 
corresponding BCR ligand (the antigen) that is internalized after binding to the BCR and 
presented in the context of MHCII to Th cells, and (2) activated T helper cells bearing 
TCRs specific for the presented internalized antigen and producing stimulatory cytokines 
ensures cognate activation of effector B cells, and their further differentiation fate is 
determined by the kind and dose of the antigen, the location of the encounter and by the 
combination of available cytokines yielding either cells with or without somatically 
hypermutated BCRs (following follicular or extrafollicular pathways, respectively), short 
or long-lived antibody secreting plasma cells or memory B cells64-66. Other subtypes of B 
cells like marginal zone B cells of the spleen can produce low affinity antibodies without T 
cell help and ensure a first line of defence and rapid response to blood born antigens65. The 
antigens are brought to naïve T cells by the DCs, while B cells can encounter antigens 
diffused in the blood or lymphatics. Lately also lymphoid organ cells as subcapsular sinus 
macrophages, follicular dendritic cells, as well as marginal zone B cells and B cells them 
selves have been shown as capturers and concentrators of immune complexes containing 
antigen-bound natural or early response low affinity antibodies together with complement 
components in the lymph nodes and spleen to facilitate their recognition by antigen-
specific B cells67. The major Th cell subset to provide the second signal is the TFH cells 
that provide essential stimulation for the induction of receptor affinity maturation and 
antibody class switching through cell-cell contacts as well as cytokines like IL-21, and 
ensure the selection of the fittest BCRs after somatic hypermutation55. Cytokines secreted 
by other Th cell subtypes as Th1 and Th2 also influence the functional properties of B cells 
like the choice of produced class switched antibodies as well as B cell secreted cytokine 
profile that corresponds to the type 1 and 2 response, respectively68. Together with 
cytokine secretion, B cells can reciprocally influence the choice of Th subtype 
differentiation due to their antigen-presenting functions providing additional stimulation to 
T cells69. The most important effector function of B cells, however, is the production of 
antigen-specific antibodies, which exert various protective effects like inactivation of 
soluble toxic products of pathogens or blocking of pathogen surface receptors necessary 
for infection, induction of antibody dependant cellular cytotoxicity (ADCC) or 
complement dependant cytotoxicity (CDC), as well as opsonisation (marking the bound 
cells for phagocytotic destruction by the innate immunity cells like macrophages, 
neutrophils, etc.), as well as promote the uptake of the immune complexes by antigen 
presenting cells facilitating further B and T cell activation70. The cytotoxic outcome of 
antibody binding through ADCC is ensured by cytotoxic immune cells (such as CTL as 
well as cells of the innate immunity like natural killers (NK), natural killer T cells (NKT), 
etc.) that carry receptors for antibody heavy chain constant regions like Fc# for IgG class 
antibodies and induce their lytic activities upon receptor stimulation in contact with the 
antibody-covered cells71. CDC is underlined by the capability of the complement 
component C1q to bind to the constant regions of antibodies covering a target cell and 
induce further activation of the complement system resulting in membrane attack complex 
formation and target cell lysis; alternatively, complement-bound antibodies can be 
recognised by immune cells possessing complement receptors that can lyse or phagocytose 
the covered cells71. 
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1.2.1 Cancer immune recognition, the immunosurveillance  
Cancer cells are characterised by considerable genetic instability that impacts the 
produced proteins both in a qualitative and quantitative way. Mutations, chromosomal 
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translocations and deregulation of alternative splicing, translation, and post-translational 
modifications (PTMs) can all create structurally altered proteins that have not been 
centrally tolerated. As well changes in gene expression regulation by epigenetic 
aberrations, microRNA deregulation, and decreased protein degradation cause elevated 
levels of proteins otherwise present in minor amounts in normal cells leading to increased 
presentation on MHCI of tumour cells as well as increased release in tissue fluids due to 
tumour cell death leading to increased uptake and presentation by DCs what can surpass 
the peripheral tolerance barriers. The immune system can recognise such “altered-self” 
proteins or cancer antigens and mount adaptive response targeted against the cells 
containing them2. 
According to the Danger model, the dendritic cell has to receive signals reporting 
about stress in the environment in order to be able to activate protective adaptive humoral 
or cellular immune response. Such danger signals in the evolving tumour 
microenvironment are various molecules released from dying tumour cells due to hypoxia 
and unbearable genetic instability causing death by mitotic catastrophe, apoptosis or 
necrosis and thus delivering a message of tissue damage through such released molecules 
as calreticulin, uric acid, high-mobility group box 1 (HMGB1), heat shock proteins, etc.72. 
Stress signals are also sensed by the innate immunity cells like tissue residing 
macrophages, mast cells and other that release pro-inflammatory cytokines, tissue 
remodelling enzymes, reactive oxygen species, histamine etc. additionally harming tumour 
cells and stimulating the maturation of dendritic cells, tumour antigen presentation and 
immigration of lymphocytes to the tumour site together inducing the first protective 
response, the acute inflammation73. Many studies have underlined the importance of both, 
innate and adaptive immunity in recognising and eliminating cancer cells every day74, and 
the presence of activated adaptive immunity cells in the tumour microenvironment have 
been shown to be a strong positive prognostic factor with a higher predictive capacity than 
any current markers routinely used in clinics75. 
The effector mechanisms dealing with tumour cell eradication are the direct cell 
contact-dependant or indirect soluble factor-dependant tumour cell killing by (i) cellular 
immunity effectors like CTLs of both Tc1 and Tc2 subtypes76 as well as NKs and NKTs 
among the innate effectors77, and by (ii) humoral immunity through antibody-mediated 
blocking of survival receptors on tumour cells, opsonisation, ADCC and CDC 
mechanisms71. Additionally cytokines produced by activated immune cells like INF# 
induce increased MHCI expression and antigen presentation by tumour cells facilitating 
their further recognition73. 
1.2.2 The “altered-self”, cancer antigens and reasons of immunogenicity 
The adaptive immunity effectors need to meet the corresponding antigens that 
activated them in the lymphoid organs on tumour cells to be able to exert their protective 
activity. The realisation of the concept of tumour antigens that are specifically recognised 
by the immune system causing tumour regression led to idea to stimulate the immune 
response in a target dependant manner78, however the field lacked substantial progress 
until Thierry Boon’s group developed an approach to identify cancer antigens recognised 
by T cells, the pioneer being melanoma-associated antigen-1 MAGEA179. Many studies 
since then have made a great effort in identification of such tumour-related targets utilising 
both, B cell and T cell-dependant strategies and yielded a large number of tumour antigens 
recognised by the adaptive immunity80. 
There are several classification approaches of cancer antigens. One way is by their 
molecular type, comprising protein, carbohydrate, lipid, glycolipid or glycoprotein 
antigens81. The antigens of non-protein nature are less immunogenic than their protein 
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counterparts as they are merely B cell or innate immunity antigens due to the capacity of 
MHCI and MHCII to display mainly peptide molecules82. However they represent a 
substantial part of altered phenotype of tumours and are important in cancer 
immunosurveillance83. The shift from the previous dogma of one-antigen-one-antibody to 
the realisation of the polyreactivity of antibodies with various epitopes as long as they fit 
into the pockets or corresponding paratope also called cross-reactivity or mimotope 
recognition, meaning that a peptide is able to mimic an epitope of non-protein or protein 
nature, has provided a novel approach to enhance the immunogenicity of such antigens by 
using synthetic peptide mimics conjugated to immunogenic carriers, and make the basis of 
the so-called mimotope therapy84. 
Antigens are most often classified by their specificity to cancer cells. The group of 
tumour-specific antigens can be further divided into (i) foreign antigens encompassing 
viral proteins in cases of virus-induced tumours or (ii) structurally altered self proteins 
(also called neo-antigens) that are formed due to the abovementioned mechanisms of 
genetic instability and deregulation of post-transcriptional events that create unique 
epitopes not met in normal cells. The second group called tumour-associated antigens are 
structurally unaltered self proteins with subcategories of (i) overexpressed antigens 
encompassing proteins that are ubiquitous but profoundly upregulated in tumours, (ii) 
cancer-immunoprivileged tissue antigens representing proteins present only in 
immunologically ignored tissues like germ cell development organs (commonly referred to 
as cancer-testis, CT antigens), retina, brain, placenta etc., (iii) differentiation antigens 
comprising terminally differentiated peripheral tissue proteins, and (iv) oncofoetal 
antigens85,86. 
Another way of antigen division is into conventional antigens translated from 
primary or natural open reading frames (ORF) of the corresponding genes and 
unconventional or cryptic peptide antigens encoded by introns of genes, exon-intron 
junction regions, regions created by chromosomal translocations or splicing defects, 
peptides translated from alternative ORFs (frame 2 or 3 of the coding region of mRNA) or 
subdominant ORFs (located in the untranslated regions of mRNAs)80 or protein splicing87. 
The conventional antigens encompass the abovementioned tumour-associated antigens as 
well as part of the structurally altered tumour-specific antigens like the ones with missense 
mutations and altered post translational modifications, while the unconventional antigens 
are most often tumour-specific with an exception of deregulated alternative splicing if the 
created splice variant is characteristic to specific tissues and not a product of cryptic and/or 
non-canonical splice site recognition88. The immunogenicity of tumour-specific antigens is 
considered to be potentially higher than for the tumour-associated antigens due to the lack 
of any TCR-based tolerance, and protective antigens have been identified among them1, 
however, one of the most immunogenic proteins to date is the CT antigen NY-ESO-1 
(CTAG1B)89 showing that tumour-associated antigens can also be potent activators of anti-
cancer immune response90. 
1.2.3 Tumour evasion, the immunoescape 
The current paradigm of tumour-immune system mutual interaction predicts the 
existence of three sequential phases: protection or elimination of tumour, an equilibrium 
state, and tumour escape together termed as cancer immunoediting74. The onset of 
clinically detectable cancer means that cells have acquired all six physiological properties 
or six hallmarks of cancer necessary for uncontrollable spread of tumour cells including 
self-sufficiency of growth signals, insensitivity to growth inhibitory signals, evasion from 
apoptosis, limitless replicative potential, induction of angiogenesis and capability to invade 
surrounding tissues and metastasize91. The appreciation of the role of immune system in 
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the control of cancer has introduced the capability of tumours to escape from immune 
protection as the 7th hallmark of cancer92. There are many strategies utilized by tumours to 
evade immune response affecting again both, innate and adaptive mechanisms. 
The equilibrium phase is described as a latent period during which the tumour is not 
eradicated but is kept under control74. This phase is thought to be the time when tumours 
can develop escape phenotypes in response to the immunological pressure and implies the 
immune system as a tumour-promoting factor77. The selective pressure can result in clonal 
expansion of less immunogenic cells through two processes differing conceptually in the 
mechanisms ensuring the eventual escape called immunoselection that implies avoidance 
or hiding from immune response, and immunosubversion implying active suppression of 
immune response74. Immunoselection strategies used by tumour to become invisible or 
insensitive to immune recognition include (i) alterations of recognised epitopes (antigenic 
drift)93, (ii) decreased expression of recognised antigens, (iii) diminishing antigen 
presentation, and (iv) downregulating death receptor signaling94. Immunosubversion is 
defined by the capability of tumour to suppress immune response either systemically (i) by 
facilitating the development of tumour antigen-specific Treg cells through secretion of the 
same suppressive cytokines95, (ii) by promoting the development of myeloid derived 
suppressor cells96 through tumour exosome secretion97 that further orchestrate the 
downmodulation of DCs and adoptive effectors98, or locally (iii) by expressing apoptotic 
ligands directly inhibiting immune cells, (iv) through production of suppressive cytokines 
as TGF" and inhibitors as IDO, nitric oxide and arginase-1 that impair the maturation of 
dendritic cells2, and (iii) by promoting innate inflammatory responses75,99-101. Indeed, while 
the acute inflammation is crucial for the induction of protective immune response, a large 
body of evidence shows that, if uncontrolled and turning into chronic states, inflammation 
has profound tumour promoting abilities participating in every aspect of tumour 
development and that elevated risk of tumour incidence is observed in patients with 
various chronic inflammatory conditions of various aetiologies including persistent 
infection, environmental irritants, or genetic alterations in genes orchestrating the 
resolution of immune response99. The low oxygen tension response is one of important 
oncogenic factors in chronic inflammation when macrophages upregulate hypoxia-
inducible factors (HIFs) 1 and 2 that promote neovascularisation at the oxygen deprived 
sites inducing angiogenesis102. The released free radicals promote DNA damage and 
exacerbate the genetic instability facilitating the selection of escaping tumour cells as well 
as suppress the adaptive effector cell activity, while secreted tissue remodelling factors as a 
response to tissue damage promote the metastatic potential of tumour cells73. 
Besides the chronic inflammatory responses, also the local dominant subtype of 
activated adoptive cellular and humoral effectors has been shown to be either protecting or 
tumour-promoting with the polarisation between type 1 and type 2 responses contributing, 
respectively103,104. Recently also the role of tumour stroma as a promoter of inflammation 
and tumourigenic environment has been acknowledged105. Another viewpoint of the 
reasons of tumour escape is the poor immunogenicity of cancer stem cells that are believed 
to derive from normal stem cells, which are known to be immunosuppressive and poor 
self-antigen presenters also termed as immunoprivileged28. These tumour-intrinsic together 
with stroma and immune system-intrinsic properties peak at the onset of the escape phase 
when clinically detectable tumours are formed, which often are refractory to therapy due to 
the stringent immune-mediated selection process, and at this point it is very rare that a 
“spontaneous” tumour regression is observed74. 
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1.3.1 Modes of adaptive immunotherapy 
The induced activation of protective cancer-specific adaptive immunity has been the 
hope of oncologists and immunologist for over two decades, and recently the first 
milestone success has been reached with the first FDA approved adoptive cell transfer 
regimen called “Provenge” for prostate cancer treatment. The road has been long and 
winding, and there is still a lot of unresolved questions regarding the induction and 
sustaining of protective immune response by therapy. 
The adoptive immunotherapy approaches can be classified into two major groups 
depending on the used target stimulant comprising antigen-specific and undefined antigen-
based therapies106. The concept of undefined antigen therapy is based on the application of 
the whole tumour immunome (all antigens in a tumour that can be recognised) for the 
induction of immune response without the knowledge of the actual protecting antigens, 
hence letting the immune system to choose the most appropriate targets, and the only 
determinant of therapy success is the evaluation of clinical development106. Such therapies 
include (i) whole tumour cell vaccines based on the administration of tumour cells that are 
modified to be immunogenic rather than tolerogenic107, (ii) heat-shock protein (HSP)-
based vaccines that utilize the capability of HSP to serve as the “danger signal” for DC 
activation and form complexes with tumour peptides hence delivering cancer antigens in 
an immunostimulating fashion108, (iii) DC-based vaccines encompassing various whole 
tumour antigen delivery ways like  loading of DCs with whole tumour peptides, proteins, 
mRNA, DNA, whole tumour cell lysates, and necrotic or apoptotic tumour cells109, as well 
as (iv) administration of in vitro propagated autologous tumour infiltrating lymphocytes 
(TILs)1. While such approaches can readily induce a potent adaptive immune response 
with high specificity against tumour, it is impossible to assess the immunological events 
that underlie either protection or failure to benefit without the information about the 
recognised antigen110. A second modality of adoptive immunotherapy that overcomes this 
limit utilizes a specific tumour antigen for the activation of anticancer response and allows 
to monitor the therapy induced immunological effects, which is crucial for the 
understanding of protective mechanisms in vivo110. Again various approaches have been 
developed and comprise vaccination with (i) antigen peptides, proteins, naked or 
incorporated in viral vectors antigen encoding RNA or DNA, (ii) DCs transfected with 
antigen encoding viral vectors, (iii) microparticle carriers conjugated with the antigen106, as 
well as administration of (iv) in vitro expanded antigen-specific T cells111. Another 
antigen-specific targeting approach is by administration of monoclonal antibodies against 
the antigen, which either have a direct therapeutic effect (and such antibodies have 
successfully been used in clinics for already a couple of decades) or as anti-idiotype 
antibody-based vaccines. The latter also uses monoclonal antibodies specific to an antigen, 
but with a purpose to induce autologous antibody formation called anti-idiotype antibodies 
against the antigen-binding variable region of the administered monoclonal antibody, and 
if the paratope of the formed anti-idiotype antibody falls within the paratope of the original 
monoclonal antibody, it can mimic the original antigen and serve as a surrogate antigen to 
stimulate immune response106. 
The necessity to induce a specifically cancer-targeted immune response as well as 
the attractive opportunity to evaluate the course of immune response by assessing the 
dynamics of antigen-specific T cells has prompted the identification of a large number of 
tumour antigens, and guidelines for prioritisation of candidate antigens have been 
elaborated by introducing various evaluation criteria that each have a certain power or 
importance in the established rating system in order to discern those with the highest 
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potential to be successfully used in cancer immunotherapy6. The requirements named in 
the order of importance for the “ideal” cancer antigen as a therapy target are: efficacy in 
immunotherapy, immunogenicity, specificity to cancer cells, oncogenicity, high expression 
in all cancer cells including putative cancer stem cells, sharing among tumours of many 
patients, possession of multiple epitopes, location on cell surface or efficient presentation 
on MHC6, and the search for this “ideal” antigen is not yet over if it ever will. 
1.3.2 Major problems and possible solutions 
The obstacles met by any type of initially developed immunotherapy approaches are 
the above described tumour-intrinsic and extrinsic (stromal and immune system-
dependant) factors that initially caused fundamental doubt whether anticancer adaptive 
immunotherapy can be developed at all. For example, several studies have shown that, 
despite the activation and expansion of antigen specific CD8+ effector T cells, no clinical 
benefit was observed112. However, the acquired knowledge of immune escape mechanisms 
has now yielded additional weapons for immunologists in this battle. Both, the antigen-
specific and unknown antigen-targeting approaches can be improved by combinations with 
(i) attenuators of the activity of regulatory cells113,114 and the inhibitors of their chemotaxis 
and secreted suppressive molecules115, (ii) adjuvants enhancing DC maturation and antigen 
cross-presentation116,117, (iii) chemo and radio therapy that increases the death, antigen 
diversity and presentation of tumour cells and ablates myeloid suppressor cells5,118, (iv) 
chemokines promoting effector cell trafficking to tumour sites119, (v) co-stimulatory 
molecules to skew the activation of effector subtypes to Th1 type120, as well as (vi) 
utilising different modes of antigen delivery121, to name the most obvious. 
One of the most successful examples is the addition of myeloablating total-body 
irradiation to lymphodepleting regimen prior to in vitro expanded adoptive tumour 
infiltrating T lymphocyte transfer of metastatic melanoma patients, which increased the 
response rates from 49% to 72% putting this combination as the most effective therapy of 
these patients refractory to other treatments122. And the currently first FDA approved 
adoptive cell transfer regimen “Provenge” is based on ex vivo processed dendritic cells 
expressing a key tumour antigen, prostate acid phosphatase, showing a statistically 
significant survival extension of at least 4 months in late-stage randomized trials increasing 
the life span for about 20% of these patients refractory to any other treatment123. 
Additionally, recent antigen-specific therapy advancements have been the generation 
of T cells with genetically engineered TCRs specific to any antigen of choice as a means to 
overcome difficulties related to the in vitro propagation of a few antigen-specific T cells 
till therapeutic numbers as well as increase the specificity and efficacy of TCR signalling, 
and have shown promising results124,125. 
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2 Materials and Methods 
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2.1.1 Tissue samples 
Tissues of melanoma, gastric, colon, and breast cancer and adjacent normal samples 
were obtained from patients undergoing surgery in Latvian Oncology Centre and stored in 
RNALater$ (Applied Biosystems, USA). Samples of lung tumour tissues were obtained 
during standard diagnostic bronchoscopy procedure at Pauls Stradins Clinical University 
Hospital and stored in RNALater$. All collected samples were stored at -20°C before 
further processing. All patients have signed an informed consent and the study has been 
approved by the Central Commission of Medical Ethics of Latvia. The information about 
the collected biological samples for each patient together with clinical data is shown in 
Table 1.  
Paraffin embedded tissue microarrays (TMAs) comprising duplicates of 45 various 
normal tissues or triplicates of 33 various normal tissues were purchased from Accu Max 
Array, USA (A700 (III)) and US Biomax, Inc., USA (FDA994), respectively. TMAs 
comprising single 40 various melanoma and 8 normal skin samples, and single 51 gastric 
cancer, 17 metaplastic, dysplastic and gastric inflammatory samples and 12 normal 
stomach samples were purchased from US Biomax, Inc., USA (ME481t and ST805t, 
respectively). TMAs comprising paired tumour and normal samples of 12 lung and 12 
breast cancer patients were purchased from Accu Max Array, USA (A716(III) and 
A712(13), respectively). 
2.1.2 Serum samples 
Serum samples of melanoma, lymphocytic leukaemia, gastric, lung, colon, breast and 
thyroid cancer patients as well as healthy donors were provided by the Genome Database 
of the Latvian Population. Additional melanoma, gastric and prostate cancer patients’ sera 
were kindly provided by Skin Cancer Unit in German Cancer Research Centre, Norwegian 
Radium Hospital and Onyvax Vaccine Therapies Ltd, UK, and Clinic of Gastroenterology, 
Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Germany. 
The serum collection comprises 39 breast, 24 lung, 33 colon, 28 thyroid, 173 gastric (stage 
I – 32, II – 20, III – 31, IV – 37, not determined – 53), 52 prostate cancer, 190 melanoma 
(stage I – 22, II – 23, III  – 21, IV – 22, not determined – 102), and 28 lymphocytic 
leukaemia patients as well as 126 patients of gastrointestinal inflammatory diseases 
(gastric ulcer – 17, duodenum ulcer - 20, gastritis and duodenitis – 10, acute hemorrhagic 
gastritis – 13, chronic atrophic gastritis – 48, dyspepsia – 11, Crohn’s Disease – 8) and 153 
healthy donors with no history of cancer or autoimmune disorders, infertility and chronic 
inflammatory diseases during last two years. All serum samples were stored at -80°C. 
2.1.3 PBMC samples 
Peripheral blood mononuclear cells (PBMCs) were obtained from 10 gastric cancer, 
9 breast cancer patients and 5 healthy donors by Ficoll density gradient centrifugation 
using BD Vacutainer$ CPT% Cell Preparation Tubes (BD Biosciences, USA) containing 
sodium citrate as anticoagulant, Ficoll Hypaque solution and a gel layer separating Ficoll 
from the blood sample (Figure 3) according to manufacturers protocol. Briefly, 
approximately 8ml venous blood was drawn in each CPT% vacutainer, using two 
vacutainers per individual. Blood samples were stored in room temperature in dark with 
gentle agitation until further preparation. No more than 5h after blood collection the tubes 
were centrifuged at 1700g for 20 minutes to separate peripheral mononuclear cells from all 
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other blood cellular constituents ensured by the Ficoll density gradient solution. 
Immediately after centrifugation the vacutainers were sterilized with ethanol and further 
processed in a sterile environment using sterile materials. The density gradient 
centrifugation causes the separation of blood in three layers – the top plasma layer, the 
middle PBMC and platelets layers and the bottom erythrocyte and granulocyte layer 
(Figure 1). Using a 3.5ml transfer pipette the middle layer is carefully removed and placed 
into a separate 50ml tube for each vacutainer. Collected PBMCs were washed as follows: 
warm (37°C) PBS (SIGMA-Aldrich, Germany) solution was added to the cells up to the 
30ml mark, and tubes centrifuged 10 minutes 330g. The PBS was then removed not 
disturbing the cell pellet, and cells were immediately resuspended in the remaining drops 
by gentle taping not to let them sit in the pellet, and this was done always following 
centrifugation. The second washing step was done using warm 5ml RPMI1640 medium 
(Invitrogen, Norway) with 1x CTL Wash Supplement (CTL Ltd., USA) for each washing 
tube. At this point all tubes of the same donor were pooled together and number of cells 
counted under UV microscope using ethidium bromide/acridine orange (EB/AO) (SIGMA-
Aldrich, Germany) staining to evaluate the proportion of live and dead cells. Cells were 
centrifuged as in the first wash and followed by slow resuspension in warm CryoABC 
media (CTL Ltd., USA) containing DMSO as the antifreeze according to the 
manufacturers protocol with adjusted cell concentration to 5-10x106cells/ml (usually 
around 2ml of final cell suspension per donor). Cells were then sampled in 1ml per 
cryovial tube and placed into Naglene$ cooling tray that ensures slow temperature 
dropdown during the next 24h in -80°C. After 24h or not later than after 72h the cryovials 
were transferred to liquid nitrogen (liquid phase) for indefinite storage. 
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Previously we applied phage-display SEREX to define a repertoire of antigens 
eliciting humoral responses in cancer patients that resulted in the identification of 1328 
different phage clones representing 1158 non-redundant antigens as described in original 
paper I. 
All of the identified antigens were entered in our custom antigen database that has 
built-in direct links to (i) NCBI nucleotide BLAST, to determine the identity of the clone, 
(ii) ExPASy Proteomics server (http://www.expasy.org/tools/dna.html) to obtain the amino 
acid sequence of the phage-displayed peptide, and (iii) NCBI protein BLAST, to determine 
the identity of the peptide. The antigens were then classified according to the translated 
peptide into three main categories including natural ORF antigens, unnatural ORF antigens 
comprising clones translated out-of-frame, and undefined ORF antigens comprising clones 
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that represent novel genes for which the ORF has not been characterised or novel splice 
variants representing alternative ORFs if there was any evidence that such ORFs can be 
generated as determined by (i) translation of predicted alternative exon combinations using 
Spidey tool (http://www.ncbi.nlm.nih.gov/spidey/), or by (ii) predictions of putative 
internal ribosome entry sites (IRES) using online tool IRSS (http://140.135.61.9/ires/) 
developed by Wu et. al126 upstream of the possible translation initiation codon. 
A built-in application was introduced to analyse EST tissue distribution. The EST 
sequences with E-value <1e-30, >70% coverage and >97% identities with an antigen clone 
were downloaded from ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/; repeat sequences were 
masked by applying filters for low complexity regions and human specific repeats; ESTs 
were classified as “cancer” (Ca), “cell line” (CL), “normal” (N), “embryonic” (E), “germ 
cell” (GC) and “brain” (B) by extracting tissue source information from their annotations. 
The ESTs frequency of each antigen clone per category was calculated relatively to the 
total number of ESTs for that antigen normalized against the number of EST per each 
category and a graphical output of relative EST distribution among the categories is 
generated indicating the total number of EST in each category. 
Also information about the predicted protein structure motifs and coiled-coil 
domains was entered for natural ORF antigens, which was obtained by using MOTIF 
Search (http://motif.genome.jp/) and http://www.russell.embl-heidelberg.de online 
software tools. 
5"< 63(9;)*)&+,&$21+4(9&*1123%&4%).+3)%&
2.3.1 Screening of phage-displayed antigen microarrays 
The autoantibody responses were analysed using our custom developed phage-
displayed antigen microarray. The microarray production and screening were done as 
described in original papers I and III. Briefly, all identified recombinant antigen phage 
clones were amplified, purified and printed in duplicates on nitrocellulose-coated slides 
(Whatman, USA) to create the microarray that was screened with 1:200 diluted sera from 
190 melanoma, 173 gastric, and 13 breast cancer patients, as well as 153 healthy 
individuals. 
Besides the identified antigen collection, T7Select Phage Display vector (Novagen, 
USA) was used to clone full or partial reading frames of sperm associated antigens 
SPAG1, SPAG6, SPAG8, SPAG9, SPAG16 and SPAG17 including alternative splice 
variants. StrepII tag (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) was inserted downstream of the 
cDNA cloning site in the vector DNA to monitor the copy number of the recombinant 
proteins on each phage. The obtained recombinant phages were used for the production of 
SPAG antigen microarray that was screened with sera from 167 melanoma, 172 gastric, 52 
prostate, 29 breast, 24 lung, 33 colon, 28 thyroid cancer, and 28 lymphocytic leukaemia 
patients, 126 patients with gastrointestinal inflammatory diseases as well as 147 healthy 
individuals. 
To monitor the amount of phage per printed spot mouse anti-T7 phage tail antibody 
(Novagen, USA) was used. The serum reactivity was detected by Cy5 conjugated goat 
anti-human IgG antibody (Jackson ImmunoResearch, USA) and the ratio against the total 
amount of printed phage, which was detected by Cy3 conjugated goat anti-mouse IgG 
antibody (Jackson ImmunoResearch, USA) was calculated. Microarray data processing 
was performed elsewhere (Zayakin P, et. al, 2010, article in preparation). Briefly, a two-
step normalisation strategy was used for the fluorescent signal ratios in order to eliminate 
variations introduced by custom production of microarrays and variable background 
intensities of different sera. At first, the values in each slide (each serum) were normalized 
by the median of all printed spots for each fluorescent channel separately. Next, the Cy5 
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and Cy3 signal intensities for each spot were divided by the median value of that spot 
within the print lot. The threshold value of a specific antibody response for each antigen 
was defined as four standard deviations above the average of 70 empty phage controls. 
Statistical significance was calculated using &2 test. 
The validation of SPAG17-A1 splice variant specific antibodies was done as 
described in the original paper III. Briefly, an antigen array comprising phage particles in 
five replicates expressing the dominant transcripts of SPAG17 called SPAG17-A, its minor 
transcript called SPAG17-A1, an unrelated antigen HORMAD1 and empty phages was 
tested with serial 3-fold dilutions of two SPAG17-A1 positive gastric cancer sera. The 
normalised values were further normalized against StrepII signal detected by anti-Sterp II 
tag antibody (StrepMAB-Immo, IBA, Germany) in order to correct for variations in the 
copy numbers of recombinant proteins per phage particle. 
2.3.2 Characterisation of unnatural ORF antigen antibody specificity 
The confirmation of the recognition of the unnatural ORF phage-displayed proteins 
as compared to their natural ORF counterparts was done as described in original paper I. 
Briefly, antigens translated both, in their natural ORF as well as in the reading frame 
displayed on serum-reactive phage clones were cloned in a prokaryotic GST expression 
vector pGEX- 4T-1 (GE Healthcare, USA). Purified recombinant proteins (500 ng) were 
used for Western blot analysis and detected by 1:20 000 diluted HRP conjugated goat anti-
GST antibody (GE Healthcare, USA) or 1:200 diluted patient's sera followed by incubation 
with HRP conjugated goat anti-human IgG antibody 1:10000 (SIGMA-Aldrich, Germany) 
using ECL Plus Western Blotting Detection Reagents (GE Healthcare, USA). 
5"= >?/4(7/*+3&+,&@A6&(3-&.4%.(4(/*+3&+,&7BA6&
Bead-based tissue homogenisation was performed by using the FastPrep-24 
instrument and Lysing Matrix A (MP Biomedicals, USA) in 1ml of TRIsolution$ 
(Applied Biosystems, USA) followed by the extraction of total RNA according to 
manufacturers protocol. RNA from melanoma cell lines was kindly provided by Skin 
Cancer Unit in German Cancer Research Center. RNA of various normal tissues was 
purchased (Applied Bisystems, USA; Biocat, Germany). cDNA was synthesized by 
random hexamer priming from 2ug of total RNA by using RevertAidTM First Strand 
cDNA Synthesis Kit (Fermentas, Lithuania) according to manufacturers protocol. 
5"C >?.4%))*+3&(3(9;)%)&
2.5.1 mRNA expression analysis  
Qualitative mRNA expression analyses were done as described in original papers II 
and III. Briefly, RT-PCR reaction mixtures contained 1x reaction buffer, 2.5mM MgCl2, 
0.1!M primers, 0.75U Taq DNA polymerase (Fermentas, Lithuania), and 1/60th of the 
prepared cDNA. Amplification of all target and reference genes was performed at the same 
cycling conditions (30 s at 94°C, 30 s at 60°C, 30 s at 72°C), except for the number of 
cycles that was adjusted individually according to mRNA abundance. Table 2 displays the 
used primer sequences. 
Quantitative mRNA expression analyses were done as described in original papers II 
and III. Briefly, real-time RT-PCR (qPCR) reactions were performed using 1/60th of cDNA 
reaction mixtures, ABSolute Blue' SYBR green Low ROX (Thermo Scientific, USA) and 
ABI7500 sequence detection system (Applied Biosystems). Appropriate primer 
concentrations were established by cDNA 4 log serial dilution curves to ensure 
amplification efficiency over 95%. To normalize the expression data in the sets of various 
normal or cancer tissues a normalisation factor was calculated for each cDNA from the 
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expression values of three most stable reference genes in each set determined among 7 
most often used house keeping genes (GAPDH, ACTB, POLR2A, TUB3A, TBP, 
YWHAZ, PGK1) by using geNorm software. The calculated most stable genes were (i) 
ACTB, POLR2A, TUB3A in the set of various normal tissues, (ii) YWHAZ, PGK1, 
GAPDH in the breast cancer set, (iii) YWHAZ, ACTB, TBP in the gastric cancer set, and 
(iv) YWHAZ, TBP, POLR2A in the melanoma set (Figure 4). All reactions were 
performed in duplicates. The expression level of each target gene was determined relative 
to its expression in testis. Statistical analysis of expression data was performed by non-
parametric Mann-Whitney test. 
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2.5.2 Protein expression analysis 
The level of SPAG6 and SPAG8 protein expression was studied by 
immunohistochemistry (IHC) as described in the original paper III. Briefly, paraffin 
embedded TMAs of various normal tissues as well as melanoma, lung, gastric and breast 
cancers (ISU ABXIS, Korea; US Biomax Inc, USA) were processed according to 
manufacturer’s protocol. Commercial antibodies: mouse monoclonal anti-SPAG6 antibody 
(SantaCruz Inc, USA) and rabbit polyclonal anti-SPAG8 antibody (Proteintech Group, 
Inc., USA) were used at the dilution 1:50 and incubated overnight at +4°C. Corresponding 
secondary antibodies – HRP conjugated anti-mouse IgG antibody and anti-rabbit IgG 
antibody, (SIGMA-Aldrich, Germany) were used at the dilution 1:50 for 1h at +37°C. 
Followed by dehydration, xylene saturation, mounting in Canada Balsam (SIGMA-
Aldrich, Germany) and examination under light microscope (Leica DM3000, Germany). 
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2.6.1 Peptide predictions 
Peptides that could bind MHCI were predicted for tumour antigens LRRC50, SPAG8 
and NY-ESO-1 using the open access software SYFPEITHY (http://www.syfpeithi.de/), 
BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind/), and Immune Epitope Database 
(IEDB) software tools (http://tools.immuneepitope.org/analyse/html/mhc_binding.html) 
for the most common alleles of the two MHCI genes HLA A and B in the European 
Caucasians potentially covering 80% of population (A0201 (27%), A03 (>14%), A0101 
(16%), B0702 (14%), B08 (12%), B4402 (11%)). Peptides with the highest predictive 
score for each allele as well as the published MHCI-binding peptides of NY-ESO-1 were 
purchased (purity >90%) (PiProteomics, USA) (see Table 3 for the obtained peptides). 
Hydropathicity parameters of peptides were determined using EXPASY Proteomics server 
software tool ProtParam (http://www.expasy.ch/tools/protparam.html), and only 
hydrophobic peptides were diluted in DMSO, while hydrophilic peptides were diluted in 
ice-cold PBS to diminish the possibility of oxidation of M and C residues caused by 
DMSO. Peptide pools were prepared for each antigen containing 20µM each peptide (20x 
stock), and immediately divided in aliquots on ice to avoid degradation by repeated 
freeze/thaw cycles. 
For positive control stimulations commercially available viral peptide pool (32 
peptides from CMV, EBV) was used (CTL Ltd., USA). 
2.6.2 In vitro pre-sensitisation 
To detect tumour antigen-specific effector T cells of low frequency in PBMCs 
(<0.01%), it is necessary to amplify the existent effector cells prior to functional analyses, 
and to do that (i) they need to be separated from the total PBMCs, (ii) antigen-presenting 
cells need to be prepared, and (iii) target cells for effector function analyses need to be 
prepared. 
For each patient one cryovial of PBMCs (5-10x106 cells) was rapidly thawed in 37°C 
water bath, reconstituted in 10ml of warm complete T cell medium comprised of 
RPMI1640 medium with 10% human AB serum, 1% non-essential amino acids, 1% L-
glutamine, 1% antibiotic/antimycotic, 1% sodium pyruvate, 25U/ml recombinant human 
IL-2 (all from Invitrogen, Norway), adding the medium slowly drop by drop to avoid 
osmotic shock of the cells caused by the concentration drop of DMSO. Cells were then 
centrifuged at 330g for 10 minutes, reconstituted in warm complete medium and counted 
using EB/AO fluorescent dyes under a UV microscope. CD8+ T cells were extracted from 
total PBMCs by Dynal$ CD8-specific magnetic beads (Invitrogen, Norway) according to 
the manufacturer’s protocol. Briefly, total PBMCs were incubated in 1.5ml tubes with anti-
CD8+ antibody coated magnetic beads on ice for 20 minutes with gentle tilting and 
agitation at 4°C to decrease the phagocytic activity of cells. Cells bound to the beads were 
separated by placing the tubes in a magnet, aspirating off the non-bound cells, and washed 
three times while on the magnet. To release cells from the beads they were incubated for 
40 minutes at room temperature (RT) with an antibody against the variable region of bead-
bound anti-CD8 antibody that outcompetes the attached CD8+ T cells. The released cells 
were collected by placing the tube in a magnet to fix the released beads and the cells were 
transferred to a new tube for washing and counting. The same principle was used to 
separate the CD4+ T cells from the CD8- PBMCs using beads conjugated with anti-CD4 
antibody. 4x105 CD8+ T cells were transferred to one well of a 96-well plate in 100 µl of 
2x complete T cell medium for stimulation with tumour antigen, and 4x104 CD8+ T cells 
were used for stimulation with positive control viral peptides. 
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CD8-CD4- PBMCs were used as autologous antigen-presenting cells. First, 4x105 
cells were reconstituted in 100 µl serum free CTL-Test medium (CTL Ltd., USA) and 
incubated with the pool of peptides containing 1µM each peptide for 1h. During this time 
the added peptides bind to the MHCI molecules on the surface of PBMCs as they are in a 
great molar excess replacing peptides that were bound naturally. Next, the cells were 
irradiated with 30Gy using linear photon accelerator “Oncor Impression Plus” (Siemens, 
Germany) at Pauls Stradins Clinical University Hospital to prevent them proliferating in 
culture, and added to the prepared CD8+ T cell well for stimulation. The CD8+ T cell/APC 
stimulation culture was grown for 10 days by replacing half of the medium with fresh 
medium every 2-3 days. 
All of the extracted CD4+ T cells were used for the preparation of autologous target 
cells (PHA blasts). After separation from total PBMCs, they were seeded in complete T 
cell medium in a well of a 96-well plate, not exceeding 5x105 cells per well. Their 
proliferation was stimulated with 10 µg/ml (final concentration) phytohemagglutinin PHA-
L (SIGMA-Aldrich, Germany), and cells were grown in parallel with the CD8+ T cell 
culture. Cells were fed as described above and split if necessary. 
2.6.3 ELISPOT assay 
The presence of antigen-specific effector cells was analysed after 10 days of in vitro 
propagation by IFN# ELISPOT (Mabtech, Sweden). The principle of this detection system 
is similar to ELISA. A capture antibody specific to the cytokine of interest is sorbed into 
the nitrocellulose-covered bottom of the ELISPOT plate wells. If there are activated 
effector cells in the sample, the produced cytokine will be captured and the presence of 
activated cytokine-secreting cells can then be visualized by using chromogen like HRP or 
SAP-conjugated detection antibody against the target cytokine (see Figure 5 for schematic 
display). 
On the day of analysis the complete medium from each CD8+ T cell stimulation well 
was removed as much as possible not disturbing the cells and reconstituted in 200 µl of 
serum free CTL-Test medium (CTL Ltd., USA). 20 µl of the virally stimulated cells and 
60 µl of cells stimulated with tumour antigen peptides were seeded in three wells of 
ELISPOT plate for duplicated activation analysis and one negative control. Amplified 
autologous PHA-stimulated CD4+ T (target) cells were washed and counted and 105 cells 
were pulsed with peptide pool in 100 µl serum free medium as described above and added 
to each activation analysis well. Autologous target cells without peptide were seeded in 
each negative control well of the ELISPOT plate. Effector/target cell culture was incubated 
in the ELISPOT plate overnight avoiding any movement of the plate during this time. 
On the next day the cells were removed from ELISPOT plates and the signal 
detection was performed according to the manufacturer’s protocol. Briefly, wells were 
washed 5 times with PBS, incubated with 1 µg/ml biotin-conjugated anti-IFN# detection 
antibody for 2h at RT, washed again 5 times, and incubated with 1:1000 Streptavidin-SAP 
conjugate for 1h at RT, washed as previously and the presence of IFN# was visualized by 
BCIP/NBT-plus substrate solution. To stop colour development, plates were extensively 
washed in tap water. The coloured spots were analysed after the plates were completely 
dry. The plates were scanned, quality checked and analysed by the ImmunoSpot® 
ScAnalysis service (CTL Europe GmbH, Germany). Plates were scanned using CTL-
ImmunoSpot® Analyzer and "ImmunoCapture™Software". Counting was made with 
"ImmunoSpot™ Professional Software" version 5.0.3. in the Smart-Count Mode (all from 
CTL Ltd, USA). 
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Table 2. Primers used for the qPCR amplification. 
 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
PGK1 CTTAAGGTGCTCAACAACATGG ACAGGCAAGGTAATCTTCACAC 
POLR2A GGGTCATCTTCCCAACTGGAG CACCAGCTTCTTGCTCAATTCC 
TBP CCACTCACAGACTCTCACAAC CTGCGGTACAATCCCAGAAC 
ACTB AATCTCATCTTGTTTTCTGCGC AGTGTGACGTGGACATCCG 
GAPDH GGGTCTTACTCCTTGGAGGC GTCATCCCTGAGCTAGACGG 
TUBA3-R TATGGCAAGAAGTCCAAGCTG TACCATGAAGGCACAATCAGAG 
YWHAZ CCTGCATGAAGTCTGTAACTGAG GACCTACGGGCTCCTACAAC 
ACTR2 ATTGCTGGGAGGGATATAAC TTTCTAAGGCCAGTTTCTGC 
AIF1 CATGTCCCTGAAACGAATGC TAGGATGGCAGATCTCTTG 
ALLC ACTGCTTCCAGTGACCAAGT GTGTGTTAAGGGTTTGCTTTG 
C11ORF20 AGCCTTCGAAAGTGTCGCTC CCTCGCAGACCTCGGACAG 
c16orf82 GAATGAAGCAGGAAGGAGAG GCTGCACGCTGGAAACAT 
C21ORF66 CTGGAGAACAGGATGAAGAG CTATAAGGAATGCCATAGG 
CCDC92 AGCTGGAAGCCCAACTGAAAG CAGGTAGGCGATGGTGCTG 
CFL1 GGTATGCTCTGCAAGGCCTC CTTCTTGCGCTTCTTCACCTC 
Clone #167 TGGCTTTGATGTTGAGTCTCC AAAATACGAAAACCAGTCAGG 
Clone #200 CCAAATAGCTGGATTACAGAA GTGGTTGATGTCATTGTTTG 
Clone #232 GAGGCGAGGGGCAGAATC GCACTTAATGAACGAAGGGGAG 
COPS4 CTGGAGCAGAACAACTAGAAG CAAATGAAATGACTCTAGGCTG 
COX6B2 CCAGAGCCTTGACGAATGCAC CAGGAGGCTGCTGTGGCTG 
ESCO2 CTGCAATCTGCGGGATCAGTC GTACTGTGTTGCAAACAGC 
EVI5L AGCTACAGGAGCAGCAGG GCGCTTGTCTCTGGGTTC 
LIG2 AGGAGTGGAATGGAGTGGTG TGGGAGAGGTGTCAGAGAGG 
LO392843 CCCCGCTGAGGTCTTTGTG CCAAATGTATCCCTATGATCTG 
LOC284861 TTCTCCAGTGTCAATGGCTCA ACACTGTACAAGACATCTGTAA 
LRRC50 CAAAGAGATGCTGCACCACTC CTATGATGCTTTCGGTGCTGG 
NOL8 TTTACCACAGTCCTCATTCC ACAAACAGAGGATCAGTAGC 
R3HDM2 GAGCAGCACAGACAGCGAAC GACCTGGTTGCACACTTCTG 
RFWD2 AGTCTCTAGTATTGAATTTGACC CATTCTCAGGGTAATGAATATCC 
RNF14 GGAACTCCCATAGAGAAATTAG CCCAAATATCGTCGTCAACATC 
RPL7A GAATTTTGGCATTGGACAGG CTGGGTGAACTGGTTAATCG 
RPLP1 CCAACGTCAACATTGGGAG GGTTTAGTCAAAAAGACCAAA 
RPS19 GGAAAAGGACCAAGATGGC GTTCTAATGCTTCTTGTTGGC 
SENP1 CAGTGAAGCATTTCGCCTGAC AACGTTTCACTGCCTGATAACC 
SLU7 TCCAGATGAACATGTCCAGCC TCTCCCCACTGGTGTTTTGG 
SPARC GCAGAGGTGACTGAGGTATC CCGTGTTTGCAGTGGTGGTT 
TEF-ASV AGGCGCGCCTCGAATCTTC AGCAAACTTGTGCTTCCGAGG 
ZNF282 GAAGAACCTTGTGTGTGGGAG CAGAAATTGGGGAGTCGGT 
SPAG1 GAAAAGCATCTTCAAGCCTTGG GGAGGTCAAGCACCAAGTTTG 
SPAG4 TGGGTCTCCAGTAGTCTCTGA TCCTCTGCACGACCAGTCG 
SPAG5 CGCAGAGCAGGTTCAAACAC GGAGAGGCACTTGAATGGGA 
SPAG6 AGCAATGGCAGTCATCATTTC GGATGAATGGTCGGGAACTT 
SPAG8 CAAGCATGCAGGATGGCTCT ATGGCTTCACGCTTCCCTCG 
SPAG8-e2L CTACAACTGGGAGGAAGAGAG GTGGCTGGTACGAGTCTTTC 
SPAG9 AGACCCGAGTGGAATCTTTAG GTTGATCACTCCCTGAGAGC 
SPAG9-C CTCATACCAGCCTGAAGGTC CCATCGGGTCCTTTGATCTT 
SPAG11B CACCCAGCCTCACTCCATC CACTTTGCCCTGGAGAATGG 
SPAG12 CAAGAAGCTACTGGACCTCG GATGCACAAACACGCGAGG 
SPAG13 GCACCACTGACAATACCATCC CACGACTATCAACACTGTCACT 
SPAG15 GTTGCTCTGGGTGCTTCTG GGTCCTCGTTCCTCACACA 
SPAG16 CGGAAAACAGTTCTTCCTTC AGACTGAAAGCAATCAAGAG 
SPAG16-L CTGTCTATATGGGATGCAAGAAC GACCGTTACTCCACTTAAAACTA 
SPAG17 AACAGAAATCCTCAAGTGTGC TGTGTTCACTTTTCCTCCAAC 
SPAG17-A GGAACATTGCTCTCCACTCC GCTAATCGTCTTCTCCTCGC 
SPAG17-A1 CAACATGAGTCTCTGGGTAA GCTAATCGTCTTCTCCTCGC 
SSX2 GCTCAAATACCAGAGAAGATCC GTGGCCTTGAAACCTAGTTTAG 
 
Table 3. Predicted MHCI biding peptides used for T cell activation assays. 
 
LRRC50 SPAG8 NY-ESO-1 
EEINDPKEI EMGSKKTV RLLEFYLAM 
GPRMTKSSL GSRSRSRSL MPFATPMEA 
EPLQKLDAL KLMVCYETL AADHRQLQL 
FPKDRACAE MLLQHQICK SLLMWITQC 
AEKEERQQW TPFRKNCSF APRGPHGGAA 
LLLSSPVEV LSLGKLLPY APPLPVPGV 
SPRPLIQEL KLLPYEPENY PLPVPGVLLK 
CAEAWARGGY YQLGEISSL KEFTVSGNIL 
TLSNIFAVSK QPPGNVYWPL RGPESRLLEFY 
LSDDSDPELDY AEQEPTRKLF  
 EVESVTHHDY  
 APQLPTWWPL  
 PTQVPAAEDY  
 AEDYLTWKEW  
 RLCHQEMGSK  
 TPVPLSLGKL  
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3 Results 
The results are presented here as original publications and as unpublished 
results. 
The author’s contribution to the enclosed original publications: 
 
Original paper I 
Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles 
in cancer patients. Kalni!a Z, Sili!a K, Meistere I, Zayakin P, Rivosh A, Abols A, Leja M, 
Minenkova O, Schadendorf D, Lin" A. J Immunol Methods. 2008 May 20;334(1-2):37-50. 
Epub 2008 Feb 21. 
Contribution: performed experimental work described in methods chapter 2.4. 
(Production of GST fusion proteins and Western blot analysis) and used for the result 
chapters 3.2. (Comparison of serum reactivity against TAA displayed on lambda and T7 
phages) and 3.5. (Sequence analysis and characterisation of the identified antigens). 
 
Original paper II 
Molecular analysis of serologically defined tumor antigens reveals novel cancer-testis 
antigens as potential targets for cancer immunotherapy. Sili!a K, Zayakin P, Kalni!a Z, 
Ivanova L, Meistere I, Stengr"vics A, Wex T, Inderberg Suso E M, Leja M, Malfertheiner P, 
Gaudernack G, Schadendorf D, Lin" A (manuscript submitted to Cancer Immunology, 
Immunotherapy) 
Contribution: prepared the tumour tissue RNA and cDNA collection, performed 
antigen selection and mRNA expression analyses, and partly the serological screening of 
antigen microarrays; wrote the manuscript. 
 
Original paper III 
Sperm associated antigens as targets for cancer immunotherapy: expression pattern and 
humoral immune response in cancer patients. Sili!a K, Zayakin P, Kalni!a Z, Ivanova L, 
Meistere I, Endzeli!# E, $bols A, Stengrevics A, Leja M, Ducena K, Kozirovskis V, Lin" A. 
J Immunother. 2011 Jan;34(1):28-44. 
Contribution: prepared the tumour tissue RNA and cDNA collection, performed 
mRNA and protein expression analyses, growing and purification of recombinant phages, 
antigen microarray screening with sera from leucocytic leucosis, breast, colon, lung, thyroid 
cancer and partly melanoma, gastric and prostate cancer patients; wrote the manuscript. 
 
Original paper IV 
Alterations of pre-mRNA splicing in cancer. Kalnina Z, Zayakin P, Silina K, Lin" A. 
Genes Chromosomes Cancer. 2005 Apr;42(4):342-57. 
Contribution: prepared the graphical information and partially the manuscript. 
 
Original paper V 
ELISPOT assays provide reproducible results among different laboratories for T-cell 
immune monitoring-even in hands of ELISPOT-inexperienced investigators. Zhang W, 
Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, 
Dudzik P, Georgakopoulou K, Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV, 
McArdle S. J Immunotoxicol.  2009 Dec;6(4):227-34. 
Contribution: performed experimental work as one of the international laboratory 
participants described in the methods chapter “ELISPOT assays” and used for the result 
chapters “Establishing Inter-Laboratory Variability of Test results” and “Influence of Serum 
on the Test Results”. 
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Previously using phage display-based SEREX approach we identified 1328 antigens 
recognised by autoantibodies from melanoma, breast, prostate and gastric cancer patients. 
198 antigens were translated in their natural open reading frames (ORF) including well-
known cancer-testis (CT) and known autoantigens as well as 79 previously uncharacterized 
antigens, 21 antigens were encoded by uncharacterized genes or novel splice variants 
termed as undefined ORF antigens, while the remaining clones were translated as 
unnatural ORF peptides. The current study was aimed to find out whether any of the novel 
natural and undefined ORF antigens could serve as targets for cancer immunotherapy. 
First, their autoantibody frequency was assessed in sera from 376 cancer patients and 153 
healthy individuals using phage-displayed antigen microarrays. Next, antigens with cancer-
related humoral response were prioritized according their EST tissue distribution, 
functional significance and structural motifs and 30 top-ranked antigens were subjected to 
mRNA expression analysis in 14 various normal tissues and melanoma, breast, and gastric 
cancer-normal tissue pairs. Normal tissue analysis revealed eight testis-selective and four 
testis-restricted transcripts. Two of them represented novel splice variants of CFL1 and 
COX6B2 and were detectable in cancer samples suggesting that deregulated alternative 
splicing in cancer can generate germ cell-associated isoforms contributing to cancer 
antigenicity. Another four testis-selective antigens – ALLC, C11ORF20, C16ORF82, and 
LOC284861, were upregulated in ~10% of cancer specimens, while two antigens – 
LRRC50 and ESCO1, were significantly overexpressed in 25-60% of various cancers 
revealing them as novel members of the CT antigen category with potential application in 
immunotherapy. 
 
 
Keywords: CT antigen, CT-spliced antigen, phage-display SEREX, antigen microarray, 
cancer immunotherapy 
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The genetic and epigenetic instability of cancer cells underlies not only their 
malignant phenotype, but also their immunogenicity creating tumor-specific neo-antigens 
characterized by structural alterations of proteins and tumor-associated antigens 
characterized by ectopic or elevated expression in tumours. The structural changes are 
introduced through mutations, chromosomal translocations, altered protein modifications 
as well as splicing defects and aberrant translation regulation. The latter two mechanisms 
can create the so-called unconventional antigens and include cryptic peptides that are 
formed by exon/intron junctions, translation of alternative open reading frames (ORF), 
subdominant ORFs located in the 3’or 5’ untranslated regions (UTR) of cDNAs, and 
intronic sequences [1]. Tumor-associated antigens are created by aberrant expression of 
genes normally expressed only in immunoprivileged sites and fetal tissues such as the 
cancer-testis (CT) and oncofetal antigens, terminally differentiated particular cell types as 
the differentiation antigens, or by overexpression of genes that are normally expressed in 
much less amount than in tumor cells as the overexpressed antigens [2].  
Tumor immunotherapy offers an appealing strategy to conquer cancers bearing such 
antigens in a specific and non-toxic manner, and promising therapy targets have been 
found in both, qualitatively and quantitatively altered antigen groups [3]. However, the 
documented overall success rate is low due to factors that subvert the therapy-induced 
immune response like the activation of innate or adaptive tolerogenic immune cells and the 
selection of tumor escape variants through the downregulation of the elements of antigen 
presentation pathway, the loss of antigen expression and the production of 
immunosuppressive cytokines by tumor or its stroma [4, 5]. The search for protective 
antigens is still a burning task in order (i) to develop polyepitopic targeting to diminish the 
possibility of tumor escape variant selection through antigen downregulation, and to cover 
for the antigenic heterogeneity of each tumor as well as for the tumors that don’t express 
the currently acknowledged target antigens, and (ii) to develop tools for monitoring 
immunotherapy induced anti-tumor T cell response. 
Recently guidelines of prioritizing antigens as targets for immunotherapy have been 
elaborated by a wide panel of experts [3] defining that an ideal cancer antigen is such that 
is effective in immunotherapy, immunogenic, specific to cancer cells, oncogenic, highly 
present in all cancer cells including putative cancer stem cells, present in tumors of many 
patients, multiepitopic, and is located on cell surface. The SEREX technology allows to 
identify proteins that have elicited the formation of class switched antibodies, which may 
indicate to spontaneous T helper cell activation against the particular antigens[6]. Tumor 
antigen-targeted immunotherapy trials have shown that the expansion of antigen-specific 
cytotoxic T lymphocytes does not necessarily correlate with tumor regression [7], while 
the proper activation of antigen specific T helper cells has a great potential to eradicate 
tumors and might be the missing piece in the successful immunotherapy puzzle [8]. We 
applied phage-displayed SEREX in our previous study to identify a comprehensive set of 
antigens eliciting humoral responses in melanoma, gastric, breast and prostate cancer that 
could be used as cancer serum biomarkers for diagnosis, prognosis and prediction of 
immunotherapy outcome, and this resulted in the collection of over 1300 antigenic clones 
([9] and unpublished results). The objective of the present study was to determine whether 
any of the identified antigens could serve as novel immunotherapeutic targets matching the 
above criteria.  
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Patient material and RNAs 
Tumor and adjacent histologically normal tissue specimens were obtained from 
operation material of melanoma, gastric and breast cancer patients undergoing surgery in 
Latvian Oncology Centre and stored in RNALater! (Applied Biosystems, USA). Tissue 
sections were evaluated by pathologists and clinical information was collected. The 
specimens were collected after the patients’ informed consent was obtained in accordance 
with the regulations of Central Commission of Medical Ethics of Latvia. 
Normal human tissue RNA panels were purchased from Applied Biosystems, USA 
and Biocat, Germany. RNA from melanoma cell lines was kindly provided by Skin Cancer 
Unit in German Cancer Research Center. 
Sera were collected from the same patients whose tissue specimens were collected. 
Additional serum samples of breast cancer patients and healthy individuals with no known 
history of cancer and autoimmune disorders were provided by the Genome Database of the 
Latvian population and sera from melanoma and gastric cancer patients were kindly 
provided by the Skin Cancer Unit in German Cancer Research Center, the Clinic of 
Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University 
Magdeburg, and Norwegian Radium Hospital. 
Autoantibody profiling assay 
Production of phage-displayed antigen microarray, its processing and data analysis is 
described elsewhere (Zayakin P et al., article in preparation, 2011). Briefly, a custom 
antigen microarray comprising 1158 recombinant and 71 non-recombinant T7 phage 
clones was produced as described previously [9] and was screened with sera from 190 
melanoma, 173 gastric cancer, 13 breast cancer, and 153 healthy individuals. The 
microarray slides were incubated with patients’ sera at dilution of 1:200 and with a mouse 
anti-T7 phage tail antibody (Novagen, USA). The serum reactivity was detected by Cy5 
conjugated goat anti-human IgG antibody (Jackson ImmunoResearch, USA) and the ratio 
against the total amount of printed phage, which was detected by Cy3 conjugated goat anti-
mouse IgG antibody (Jackson ImmunoResearch, USA) was calculated. A two-step 
normalization strategy was used for the fluorescent signal ratios in order to eliminate 
variations introduced by custom production of microarrays and variable background 
reactivity of different sera. At first, the values in each slide (each serum) were normalized 
by the median of all printed spots for each fluorescent channel separately. Next, the Cy5 
and Cy3 signal intensities for each spot were divided by the median value of that spot 
within the print lot. For autoantibody frequency calculations, the cutoff value of specific 
seroreactivity was defined as four standard deviations above the average of 71 non-
recombinant phage controls. Statistical significance was calculated using "2 test.  
In Silico analysis 
To determine candidate CT or overexpressed antigens as well as structurally altered 
unconventional antigens, the following bioinformatics tools were exploited. For the 
analysis of EST tissue distribution Human EST database was downloaded from 
ftp://ftp.ncbi.nih.gov/genomes/ H_sapiens/ and each clone sequence was aligned against 
EST database using megablast algorithm, EST sequences with E-value <1e-30, >70% 
coverage and >97% identities were included in the further analysis. Repeat sequences were 
masked by applying filters for low complexity regions and human specific repeats. ESTs 
were classified as “cancer”, “cell line”, “normal”, “embryonic”, “germ cell” and “brain” by 
extracting tissue source information from their annotations. The EST frequency for each 
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antigen clone per category was calculated relatively to the total number of ESTs in that 
category. Those clones whose EST frequency in cancer and/or cell line categories was two-
fold higher than in normal tissue category were considered to be predominantly expressed 
in cancers, while those that showed 2-fold higher frequency in germ cells and/or 
embryonic tissue categories than in normal tissues were considered to be predominantly 
expressed in germ cells, and those with a 10-fold higher frequency in cancer and germ cell 
categories than in normal tissues were categorized as overexpressed in cancer and germ 
cells. 
For the prediction of protein structure motifs and coiled-coil domains MOTIF Search 
(http://motif.genome.jp/) and http://www.russell.embl-heidelberg.de tools were used. 
Analysis of alternative splicing isoforms and splice site prediction was performed using 
Spiday tool (http://www.ncbi.nlm.nih.gov/spidey/) and putative alternative ORFs were 
predicted using Translate tool at ExPASy Proteomics server 
(http://www.expasy.org/tools/dna.html). NCBI protein BLAST was used to search for 
possible sequence homologies of undefined ORF antigens representing novel genes.  
RNA extraction, cDNA synthesis 
Bead-based tissue homogenization was performed by using the FastPrep-24 
instrument and Lysing Matrix A (MP Biomedicals, USA) in 1ml of TRIsolution! 
(Applied Biosystems, USA) followed by the extraction of total RNA according to 
manufacturer’s protocol. RNA extracted from tissue material was treated with DNAse 
prior to cDNA synthesis according to manufacturer’s protocol (Applied Biosystems, USA). 
cDNA was synthesized by random hexamer priming from 2!g of total RNA by using 
RevertAidTM First StrandcDNA Synthesis Kit (Fermentas, Lithuania) according to 
manufacturer’s instructions. 
mRNA expression analysis 
Qualitative RT-PCR reaction mixtures contained 1x reaction buffer, 2.5mM MgCl2, 
0.1!M primers, 0.75U Taq DNA polymerase (Fermentas, Lithuania), and 1/60th of the 
prepared cDNA. Primers were designed to amplify the identified antigenic regions of 
analysed genes (Table S1). Amplification of all target and reference genes was performed 
at the same cycling conditions (30s at 94°C, 30s at 60°C, 30s at 72°C), except for the 
number of cycles that was adjusted individually according to corresponding mRNA 
abundance.  
Quantitative RT-PCR (qPCR) reactions were performed using 1/60th of cDNA 
reaction mixtures, ABSolute Blue" SYBR green Low ROX (Thermo Scientific, USA) on 
ABI7500 sequence detection system (Applied Biosystems). Appropriate primer 
concentrations were established by cDNA 4 log serial dilution curves to ensure 
amplification efficiency over 95%. Three most stable reference genes were determined 
among 7 most often used house keeping genes (GAPDH, ACTB, POLR2A, TUB3A, TBP, 
YWHAZ, PGK1) by using geNorm software for the set of various normal tissues, as well 
as for the sets of tumor-normal tissue pairs of each cancer type. To normalize the 
expression data a normalization factor was calculated for each cDNA from the expression 
values of the established stable reference genes that were (i) ACTB, POLR2A, TUB3A in 
the various normal tissue set, (ii) YWHAZ, ACTB, TBP in the gastric cancer set, (iii) 
YWHAZ, TBP, POLR2A in the melanoma set, and (iv) YWHAZ, PGK1, GAPDH in the 
breast cancer set. All reactions were performed in duplicates. The expression level of each 
gene was determined relative to its expression in testis. Statistical analysis of expression 
data was performed by the non-parametric Mann-Whitney U test and Wilcoxon signed 
rank test. 
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Description of antigen clone collection 
In our previous study aimed to define a repertoire of cancer antigens eliciting 
humoral responses in patients, T7 phage displayed cDNA expression libraries were 
constructed from 5 melanoma specimens, 11 gastric cancer specimens, 3 prostate cancer 
cell lines and 2 testis specimens. Phage clones recognized by serum IgGs were selected 
from these libraries via biopanning followed by immunoscreening using sera from 26 
melanoma, 22 gastric cancer, 22 prostate cancer, one breast cancer and 15 gastritis patients 
that resulted in the identification of 1328 different phage clones representing 1158 non-
redundant antigens ([9] and unpublished data). The sequence analysis of serum reactive 
clones showed that 60% of the collection is represented by cDNA clones, while 40% 
appear to be non-cDNA inserts including rRNA and, despite the vigorous DNAse 
treatment of mRNA before cloning, also intergenic regions, mtDNA, and microbial DNA 
fragments. In the applied vector system the insert is cloned as the 3’ fusion to the T7 phage 
surface protein 10B, hence both, fragments translated in their natural as well as unnatural 
ORFs can be displayed. The sequence analysis of recombinant peptides showed that 15% 
(198) of the clones were translated in their natural ORF, 2% (21) antigens were encoded by 
uncharacterized genes or novel transcript variants termed here as undefined ORF antigens, 
and 83% (1109) were clones translated as unnatural ORF peptides absent from any human 
protein.  
Natural ORF antigens represented 130 non-redundant antigens comprising 46 well-
characterized CT antigens like the members of CTAG, MAGE etc. families, 5 autoantigens 
such as ANXA11 [10], and AKAP12 [11] known to induce antibody production in 
autoimmune disorders, 20 antigens that have been previously identified by conventional 
SEREX, 34 antigens were from protein families whose other members have been detected 
by SEREX, and 25 were novel antigens against which no immune response has been 
reported before. We didn’t detect mutations in any of these cDNAs, but we found novel 
alternative splice variants (ASVs) for three genes, KIF27 (HM370398), TEF (HM370396), 
and UBR2 (HM370397), that were not annotated in the NCBI AceView database [12]. 
We introduced a category of antigens called the undefined ORF antigens that 
encompassed 13 clones representing uncharacterised ASVs translated as alternative or 
subdominant ORFs whose generation was predicted as theoretically possible by our 
bioinformatics approach that included search of translation initiation codons of the 
corresponding ORFs in alternative upstream exon combinations and predictions of internal 
ribosome entry sites (IRES) (see Materials and Methods). Also 8 clones representing 
putative novel genes supported by ESTs or a conventional splicing event and for which the 
ORF has not been characterised were attributed to the undefined ORF category. 
Selection of candidate antigens 
In order to identify novel potential therapy targets we further analysed only 
uncharacterised natural ORF antigens for which no comprehensive immunogenicity or 
expression data existed as well as undefined ORF antigens. To select the most promising 
candidates for further experimental analysis we ranked the novel natural ORF antigens 
using the following prioritization criteria: (i) frequency of cancer-related autoantibody 
response, (ii) CT-associated EST profile, (iii) functional role in oncogenesis, and (iv) 
structural features as cell surface localization or novel ASVs. 
To identify antigens with cancer-related autoantibody response we screened our 
custom phage-displayed antigen microarray comprising all non-redundant antigens (1158) 
and 71 non-recombinant phage clones as negative controls with sera from 173 gastric 
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cancer, 13 breast cancer, 190 melanoma patients, and 153 healthy individuals. The 
production of the microarray, data normalization and processing is described elsewhere 
([9] and Zayakin P et al., article in preparation, 2011). A cutoff value of 4 SDs above the 
mean serum signal intensity of non-recombinant phage spots was found to clearly 
discriminate between the presence and absence of specific autoantibodies to most of the 
antigens. This cutoff was validated experimentally by testing the reactivity of two 
CTAG1B reactive sera (signal intensities over 5 and 7 SDs above the mean signal intensity 
of non-recombinant phages) and two non-reactive sera against the CTAG1B by Western 
blot analysis. Antigens were classified as cancer-related and cancer-nonrelated according 
to their seroreactivity in each tumor type using cancer versus normal odds ratio (OR)>3.5 
as the discriminator (Table 1). The cancer-related antigens were further divided into four 
subcategories by the autoantibody frequency and ranks from 0 to 3 were assigned for each 
category as follows: (i) 3 – frequent, statistically significant antigens, (ii) 2 – moderately 
frequent, putatively cancer-specific antigens, (iii) 1 – cancer-associated antigens, and (iv) 0 
– rare, putatively cancer-specific antigens (Table 1). The latter group contains also the 
antigens that did not react with any serum in the tested set in order not to leave out the 
antigens that elicit rare, yet cancer-specific humoral response. Cancer-related autoantibody 
response was detected for 50 uncharacterised natural ORF antigens and nine undefined 
ORF antigens comprising five novel genes and four novel ASVs.  
To determine the antigens with CT-associated EST profile the tissue distribution of 
all ESTs complementary to a particular antigen was characterised using the information in 
the EST sequence annotation, and we established categories of EST distribution as 
described in Materials and Methods. Ranks were assigned to these categories as follows: 
(i) 3 – overexpressed in cancer and germ cells, (ii) 2 – predominant expression in germ 
cells or embryonic tissue, (iii) 1 – predominant expression in cancer or cell lines, (iv) 0 – 
no association to cancer or germ cells. 
To discern antigens with potential implications in oncogenesis we searched the 
published literature and introduced three categories that were ranked as follows: (i) 2 – 
known oncogenic function or potentially related to oncogenesis or stem cell biology with 
published circumstantial evidence, (ii) 1 – unknown relation to oncogenesis, (iii) 0 – 
known function, no relation to oncogenesis. As well such structural properties as the cell 
surface localization or novel ASV gave additional one point, while a point was subtracted 
if the antigen contained a coiled-coil domain as these structures are often recognised by 
cross-reacting antibodies. 
The total score obtained as the sum of the above criteria was used to rank the natural 
ORF antigens and the top 23 antigens were selected for further mRNA expression analysis 
(Table 2). The criteria for undefined ORF antigen selection were (i) the cancer-related 
serum response and (ii) no matching ESTs or testis and/or cancer-associated EST profile, 
and two putative novel splice variants and five putative novel genes were selected for 
further experiments (Table 3). The description of clone structure, translated peptides 
together with homology results from protein BLAST, and chromosomal localization of 
these antigens are indicated in Table 3. 
mRNA tissue distribution of selected antigens 
Natural ORF antigens 
 mRNA expression of the selected 23 natural ORF antigens was analysed in sets of 
various normal tissues and tumour-normal tissue pairs. Hofmann et al. has introduced 
terms to describe the expression pattern of CT genes and has separated them into two 
groups: genes that are expressed mostly in testis but are detected in low levels in other non-
germ line tissues are called testis-selective, and the ones expressed only in germ line 
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tissues and placenta are called testis-restricted [13]. All of the genes were initially analyzed 
by qualitative RT-PCR in 11 normal tissues and the ones that appeared testis-associated, 
were further verified by quantitative real time PCR (qPCR) in 14 various normal tissues. 
As a result six testis-associated genes were identified. ALLC, LRRC50, C11ORF20 and 
ESCO1 were detected mainly in testis, but also in some other non-germ line tissues, but 
qPCR data demonstrated that they together with C16ORF82, which initially appeared 
testis-restricted, can be ascribed to the testis-selective gene group (Fig. 1). C21ORF66 was 
detected exclusively in the testis sample and is a testis-restricted gene. Quantitative mRNA 
expression analysis didn’t confirm testis-selectivity for COPS4 and CCDC92 as appeared 
in the qualitative RT-PCR (Fig. 1a, b). One of the antigens – a novel ASV of TEF (here 
designated as TEF-ASV), is translated in its natural ORF, but lacks 105 amino acids from 
the natural protein caused by an alternative exon skipping event. This transcript was cloned 
from a testis cDNA library, however we failed to detect its expression in any of the 
analysed tissues including testis samples from four different individuals. The remaining 14 
genes were ubiquitously expressed (Fig. 1a).  
Next, all the antigens were quantitatively analyzed in sets of melanoma (8 primary 
tumors and 9 cell lines), gastric (n=15), and breast (n=18) tumor-normal tissue pairs. A 
gene was considered overexpressed in a tumor sample if the expression value in the tumor 
sample exceeded that of the adjacent normal sample by at least two fold and the average 
value of all normal samples by at least three fold to account for the interindividual gene 
expression variations as well as to include the data from commercial normal samples and 
to compare those melanoma samples and cell lines that didn’t have the adjacent normal 
sample. The expression values in tumor and normal sample groups per each tumor type 
were compared using the non-parametric Mann-Whitney U test for unpaired samples and 
Wilcoxon signed rank test for paired samples excluding the commercial normal sample, 
and a gene was considered significantly overexpressed if both tests gave a p-value <0.05. 
We found a statistically significant overexpression in cancer of two testis-selective genes – 
LRRC50 and ESCO1. LRRC50 was upregulated in 23% of melanoma, 30% of breast, and 
60% of gastric cancer specimens, but not melanoma cell lines (Fig. 2a, b), There was no 
correlation of the overexpression of LRRC50 to the histological type or ER status of breast 
cancer, but all were early stage tumors (stages I and II), while no correlation to the tumor 
histological type or stage was observed for gastric cancer and melanoma samples. ESCO1 
was upregulated in 53% of melanomas exceeding the level of other normal tissues by in 
average five times and often (in ~23% of cases) exceeding the level observed in testis (Fig. 
2b). 
The testis-selective genes ALLC, C11ORF20 and C16ORF82 showed upregulated 
expression in a few tumor samples, but didn’t meet statistical significance (Fig. 2a). 
Neither the testis-restricted gene C21ORF66 nor the novel transcript of TEF were detected 
in any of the analysed tumor samples. Among the 16 ubiquitous genes four were 
significantly upregulated in cancer – ACTR2 in melanoma, LIG1 and NOL8 in breast 
cancer and melanoma, and SPARC in gastric cancer (Fig. 2a, c).  
 
Undefined ORF antigens 
The analyses scheme was similar for the undefined ORF antigens. Normal tissue 
analysis revealed two novel testis-selective ASVs of CFL1 and COX6B2, one novel testis-
selective gene LOC284861, and two novel testis-restricted genes (LOC392843 and clone 
#232) (Fig. 3a, b). The expression of the putative novel genes clone #167 and clone #200 
were not detected in any normal tissues by RT-PCR (Fig. 3a), but clone #200 was detected 
in one of the four testis samples by qPCR (Fig. 3b) also ascribing it as a novel testis-
restricted gene, while clone #167 remained undetected. 
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Further expression analysis in melanoma and gastric tumor-normal tissue pairs 
showed that, although the statistical significance was not reached, the testis-selective 
transcripts, novel ASVs of CFL1 and COX6B2 and gene LOC284861, were upregulated in 
some cancer samples (Fig. 3c). The testis-restricted transcripts, LOC392843 and clone 
#232, were not detected in any sample. The clone #167 was first checked by conventional 
RT-PCR in sets of eight melanoma and gastric tumor tissues, but no positive samples were 
detected.  
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Most of the currently known clinically significant cancer antigens, such as NY-
ESO1, MUC1, p53, MAGEA3 etc. that are capable to elicit T-cell immunity both 
spontaneously and in clinical trials, also elicit spontaneous humoral responses in cancer 
patients [14], hence the presence of IgG class autoantibodies is likely to reflect the lack of 
immune tolerance against these antigens. In this study we attempted to determine whether 
there are any cancer antigens of potential immunotherapeutic value among the collection of 
over 1300 humoral antigens identified in a previous study using phage-display SEREX ([9] 
and unpublished results), which is to our knowledge the largest annotated antigenic clone 
collection to date. Previously uncharacterised natural ORF antigens with cancer-related 
serum response were subjected to further ranking by the cancer autoantibody frequency, 
EST profile, their putative involvement in oncogenesis and structural motifs by putting a 
positive mark on surface localized antigens as they allow the development of additional 
antibody-based therapeutics and novel splice variants as they might represent novel 
structurally altered antigens created by deregulated alternative splicing. The top 23 rated 
natural ORF antigens and five cancer-related undefined ORF antigens representing novel 
genes were selected for further mRNA expression analysis.  
LRRC50 is the top ranked antigen that was identified using a breast cancer serum for 
immunoscreening and further showed statistically significant overexpression and 
autoantibody response in this cancer type. Among the 13 breast cancer patients that had 
matching tumor and serum samples, four showed overexpression of LRRC50 in their 
tumors and two of these patients were LRRC50 antibody positive, while no corresponding 
antibodies were detected in sera from the 9 patients that didn’t show LRRC50 
overexpression in tumors. Autoantibodies associated with melanoma and gastric cancer 
were detected in approximately 9% of and 2% of sera, respectively. Evidence of the 
upregulation of LRRC50 in breast cancer and melanoma can also be found in the 
Oncomine database [15, 16]. Among various normal tissues it showed testis-selective 
expression pattern ascribing it as a novel member of the CT antigen group. There is not 
much known about the functions of LRRC50. Mutations in this gene have been reported to 
cause polycystic kidney disease in zebrafish [17], and situs inversus together with reduced 
muco-ciliary clearance of respiratory tract in humans [18], which are syndromes caused by 
the malfunction of motile cilia in the zebrafish kidney and embryonic nodal cells together 
with motile cilia-covered epithelia of the respiratory tract [19]. It is proposed that LRRC50 
is necessary for the assembly of dynein-arm complexes in the cytoplasm, which is crucial 
for intraflagellar transport that underlies both, ciliary signaling and motile functions [18]. 
The non-motile primary cilium has the same structure as the motile embryonic nodal cilia 
with the 9+0 axoneme [20], and has recently been appreciated as a crucial nexus for proper 
signaling during embryogenesis and adult tissue homeostasis through the Hedgehog, 
PDGFR!! and Wnt pathways [21], which are also implicated in various aspects of 
tumorigenesis [22-24]. It will be interesting to find out if the overexpression of LRRC50 in 
tumor cells can participate in the signaling pathways of the primary cilium that promote the 
malignant phenotype considering there are no motile cilia on most cancer cells. We, 
however, have observed the endogenous LRRC50 on the condensed chromosomes in 
mitotic cells of human teratocarcinoma cell line PA1, while the interphase cells were 
LRRC50 negative (unpublished observations), which might indicate to another possible 
link to oncogenesis. Its frequency of autoantibodies and overexpression in tumor tissues is 
comparable to the currently widely used immunotherapy target NY-ESO1 [25] suggesting 
a similar immunogenicity potential.  
Cancer autoantibodies recognising ESCO1 appear to be rare, but the frequency in 
melanomas is comparable to the well-known melanoma antigen MAGEA1 [26]. Also its 
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mRNA was significantly overexpressed in melanoma samples (~50%). Data deposited in 
the Oncomine database [16] shows substantial upregulation also in other cancer types like 
breast, colon, cervical, pancreatic cancer, etc. The expression pattern in normal tissues was 
testis-selective accounting it as a novel CT antigen. ESCO1 is an acetyltransferase 
important for sister chromatid cohesion during replication and DNA repair [27] by 
acetylating the components of the cohesion complex [28] and the repression of 
transcription [29]. The deregulated expression/function of ESCO1 has the potential to 
contribute to the genetic instability [28]. It has been proposed as the susceptibility gene of 
prostate cancer elevating the risk of the formation of the fusion oncogene TMPRSS2/ETS 
[30], and we have demonstrated here that it can be immunogenic in cancer patients. Further 
studies of the normal and oncogenic functions and T cell immunogenicity of these novel 
testis-selective antigens are warranted to evaluate their suitability as cancer 
immunotherapy targets. 
Additionally four annotated genes with unknown functions (ALLC, C11ORF20, 
C16ORF82, and C21ORF66) and four novel genes (LOC284861, LOC392843, clone #232, 
and clone #200) with cancer-related autoantibody response were identified as testis-
selective or restricted. We didn’t detect the expression of any of the testis-restricted 
transcripts (C21ORF66, LOC392843, clone #232, and clone #200) in the analysed tumor 
samples suggesting that these are either very rarely expressed in tumors or in very low 
levels. Genes specific to germ cell have been suggested to be involved in the control and 
establishment of stemness [31], thereto the peptide of the novel gene clone #232 is 80% 
identical to the stem cell gene SLAIN1. Other approaches like mRNA expression analysis 
of purified tumor stem cell populations, immunohistochemistry of cancer sections or flow-
cytometry of primary tumor cell cultures using antibodies against these antigens with co-
staining of stem cell markers should be used to determine if they might represent genes 
expressed in seldom cancer stem cells that could provide additional ground for their 
application as immunotherapy targets. We observed the overexpression of the testis-
selective genes (ALLC, C11ORF20, C16ORF82, LOC284861) in some tumour samples 
and these might potentially be novel CT antigens. There are 21 EST records that have 
yielded the model mRNA of LOC284861 and from these 17 are derived from testis or 
embryonic tissues, and the rest are from pooled tissues and one muscle-derived EST. The 
cloned antigenic peptide of LOC284861 is 124 amino acids long. No conserved domains 
were found, but it showed a 95% identity across the whole sequence length to a 
hypothetical protein from Pan troglodytes as well as a 79% homology to a hypothetical 
protein from Pongo abelii indicating that it might represent the natural ORF of this novel 
gene. 
Four of the 16 analyzed cancer-related antigens representing ubiquitous genes 
showed statistically significant overexpression in cancer – ACTR2, SPARC, LIG1 and 
NOL8, and have all been reported with implications in oncogenesis. The actin remodeling 
protein ACTR2 determines cell shape and influences cell motility [32], and has been 
shown to be overexpressed in colon [33], lung [34] and other tumor types as evidenced by 
the Oncomine database [16]. A multifunctional matrix-associated protein SPARC 
influences cell shape, inhibits cell-cycle progression, and regulates the synthesis of 
extracellular matrix [35, 36]. It has been shown to exhibit both, tumor-promoting [37] and 
tumor-suppressing [38, 39] activities. LIG1 encodes DNA ligase 1 that participates in 
DNA replication and the base excision repair process [40], and many studies have 
identified SNPs in this gene associated with various cancers like glioma [41], lung cancer 
[42], head and neck cancer [43] etc., as well it was shown as a candidate overexpressed 
gene in cervical cancer [44] and other tumor types by gene array data in Oncomine [16]. 
NOL8 is a nucleolar protein involved in the promotion of cell growth [45], and was shown 
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to be overexpressed in diffuse-type gastric cancer [46]. We have shown that these genes 
are overexpressed in cancer, however the elevated expression level is an unlikely cause of 
the immune recognition as the mRNA level in the overexpressed tumors didn’t exceed the 
level of other normal tissue types, thereto autoantibodies against ACTR2 were detected in 
a melanoma patient whose tumor didn’t overexpress this antigen. Hence they cannot be 
suitable immunotherapy targets unless molecular alterations leading to cancer-specific 
epitope formation can be identified, and the reasons of immunogenicity of these as well as 
of the rest of the ubiquitous antigens remain elusive. 
We also report here the identification of a large number of unnatural ORF peptide 
antigens derived from inserts of non-cDNA nature including intergenic regions, and we 
previously showed that the corresponding serum antibodies indeed recognize these 
unnatural peptides and not the natural ORF products of the corresponding genes [9]. 
Similar results have been reported by other groups using phage-display technology [47] 
and to a lesser extent also conventional SEREX, and likely indicate to a much broader 
transcriptome than previously considered supporting the recent acknowledgement of the 
wide variety of non-coding RNAs [48, 49]. It might be possible that the non-coding 
particularly the long non-coding RNA species could actually be recognized by ribosomes 
due to translation deregulation in cancer. However, the identified antigenic peptides most 
likely represent mimotopes of other antigens including proteins with altered structure or 
lipid and carbohydrate epitopes, the latter two representing exclusively B-cell epitopes 
[50]. Lately also peptide mimotopes have been suggested for cancer vaccine development 
as they have the immunogenic potential to elicit stronger recognition of cancer antigens of 
non-protein nature like the tumor-associated carbohydrate antigens already studied for the 
GD2 disialoganglioside and CEACAM-5 glycoprotein, as well as provide a compact 
immunization agent that can be coupled to additional stimulants of immune response in 
order to achieve an enhanced recognition of protein antigens [51]. 
We suspect that the large majority of the subdominant and alternative ORF peptides 
generated from sense direction cDNA inserts also represent mimotopes, nevertheless, there 
might be true novel unconventional or cryptic peptide antigens among them that are 
created by transcriptional mechanisms including alternative promoters, splicing defects, 
chromosomal translocations or translation deregulation through frameshift mutations or 
recognition of alternative IRES [47, 1]. Germ cells in testis possess one of the most diverse 
transcriptomes due to vastly rich alternative splicing. We have previously suggested that 
the deregulation of alternative splicing in cancer can result in the recognition of testis-
restricted splice sites, leading to the production of immunogenic isoforms of otherwise 
tolerated proteins [52, 53]. We analyzed here the expression of antigens representing novel 
splice variants that showed a possible translation initiation upstream of the alternative ORF 
to see how often such transcripts are created in normal and cancerous tissues, and report 
here the identification of novel testis-selective splice variants for CFL1 and COX6B2. 
These transcripts were upregulated in ~20% of cancer samples, yet the statistical 
significance wasn’t achieved. Nevertheless it suggests that the splice sites normally 
recognized in testis can also be recognized in cancer, but it is necessary to determine the 
full length structure of these transcripts and to approve the existence of the identified 
peptides to define these as novel cryptic peptide antigens. We recently showed the 
existence of a CT splice variant-specific humoral immune response for a sperm associated 
antigen SPAG17 [54]. We suggest that such antigens are designated to a separate category 
called CT-spliced antigens, as the mechanism of their production is different from the CT 
antigens namely splicing errors rather than transcription deregulation. However, the 
application of most of such transcripts in immunotherapy seems unlikely as their 
expression can be very heterogeneous in the same tumor due to splicing events in each 
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individual cell that are not inherited across cell divisions, and the antigen is produced in 
low level simply because the transcript represent only a fraction of the total mRNA pool of 
the corresponding gene. 
In conclusion, we have undertaken a comprehensive gene expression analysis of the 
antigens eliciting humoral immune response in cancer patients that revealed several 
previously uncharacterized antigens with restricted expression in normal tissues. Among 
them 2 novel testis-selective antigens, LRRC50 and ESCO1, showed significant 
upregulation in cancer tissues and warrant further exploration of T cell immunogenicity. 
Four testis-selective antigens including three annotated genes with unknown function, 
ALLC, C11ORF20, C16ORF82, and one novel gene, LOC284861, were overexpressed in 
some tumour samples and might represent novel CT antigens. The upregulation of novel 
testis-selective alternative splice variants of CFL1 and COX6B2 was detected in a few 
tumor samples suggesting that splice sites characteristic to immunoprivileged tissues can 
be also recognized in cancer due to deregulated splicing and might yield immunogenic 
isoforms of tolerated proteins or tumor-specific cryptic peptide antigens, and we propose to 
designate such antigens as CT-spliced antigens. 
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Table 1 The classification of antigens by autoantibody frequency in each tumor type 
 
Number of antigens 
Gastric cancer Melanoma Breast cancer Antigen 
category 
Antigen 
subcategory Criteria Rating
a 
NO ND UO NO ND UO NO ND UO 
Significantly 
cancer-associated, 
high frequency  
p<0.05b,or 
HD=0, 
Ca>10% 
3 2 1 4 8 2 14 4 0 14 
Putatively cancer-
specific, moderate 
frequency 
HD=0, 
Ca>1!10%, 
p>0.05 
2 18 1 83 19 2 108 5 0 36 
Putatively cancer-
specific, rare 
HD=0, 
Ca!1% 1 40 2 396 53 4 366 46 7 440 
Cancer-
related 
Cancer-associated HD>0, OR"3.5 0 8 3 23 1 4 20 15 5 74 
Cancer non-related HD>0, OR<3.5 - 62 14 381 49 9 380 60 9 323 
 
Used abbreviations: NO – natural ORF, ND – undefined ORF, UO – unnatural ORF, HD – antibody 
frequency in healthy controls, Ca – antibody frequency in cancer patients, OR – odds ratio for autoantibody 
frequency in any type of cancer and healthy controls. 
a The score given for each of the introduced antigen subcategories applied in further antigen prioritization 
scheme is indicated. 
b p value was calculated by the !2 test 
 
 
 
  !"#
T
ab
le
 2
 S
el
ec
te
d 
na
tu
ra
l O
R
F 
an
tig
en
s 
 
                    
U
se
d 
ab
br
ev
ia
tio
ns
: G
C
 –
 g
as
tri
c 
ca
nc
er
, M
 –
 m
el
an
om
a,
 B
C
 –
 b
re
as
t c
an
ce
r, 
G
ID
 –
 g
as
tro
in
te
st
in
al
 in
fla
m
m
at
or
y 
di
se
as
e,
 H
D
 –
 h
ea
lth
y 
do
no
r, 
%
 - 
an
tib
od
y 
fr
eq
ue
nc
y,
 P
-v
al
 –
 p
 v
al
ue
 fo
r f
re
qu
en
cy
 d
iff
er
en
ce
 o
f c
an
ce
r v
er
su
s h
ea
lth
y 
co
nt
ro
ls
 c
al
cu
la
te
d 
by
 th
e 
!2
 te
st
 a
nd
 b
ol
de
d 
if 
<0
.0
5,
 O
R
 –
 o
dd
s r
at
io
 fo
r a
ut
oa
nt
ib
od
y 
fr
eq
ue
nc
y 
in
 c
an
ce
r v
er
su
s h
ea
lth
y 
co
nt
ro
ls
, I
nf
 –
 in
fin
ity
, N
aN
 –
 n
ot
 a
va
ila
bl
e.
 
a  T
ot
al
 sc
or
e 
ob
ta
in
ed
 b
y 
su
m
m
in
g 
th
e 
po
in
ts
 g
iv
en
 fo
r: 
Se
ro
lo
gy
: 3
 –
 si
gn
ifi
ca
nt
ly
 c
an
ce
r-
as
so
ci
at
ed
, h
ig
h 
fr
eq
ue
nc
y;
 2
 –
 p
ut
at
iv
el
y 
ca
nc
er
-s
pe
ci
fic
, m
od
er
at
e 
fr
eq
ue
nc
y;
 1
 –
 c
an
ce
r-
as
so
ci
at
ed
; 0
 –
 p
ut
at
iv
el
y 
ca
nc
er
-s
pe
ci
fic
, 
ra
re
. 
ES
T 
pr
of
ile
: 3
 –
 c
an
ce
r a
nd
 g
er
m
 c
el
l-a
ss
oc
ia
te
d;
 2
 –
 g
er
m
 c
el
l-a
ss
oc
ia
te
d;
 1
 –
 c
el
l l
in
e 
or
 c
an
ce
r-
as
so
ci
at
ed
; 0
 –
 n
o 
as
so
ci
at
io
n 
to
 c
an
ce
r o
r g
er
m
 c
el
ls
. 
M
ot
ifs
: 1
 –
 c
el
l s
ur
fa
ce
 lo
ca
liz
at
io
n 
or
 n
ov
el
 a
lte
rn
at
iv
e 
sp
lic
e 
va
ria
nt
; -
1 
– 
co
ile
d 
co
il 
do
m
ai
ns
. 
Fu
nc
tio
n:
 2
 –
 p
ot
en
tia
lly
 o
nc
og
en
ic
, w
ith
 p
ub
lis
he
d 
ci
rc
um
st
an
tia
l e
vi
de
nc
e;
 1
 –
 u
nk
no
w
n 
re
la
tio
n 
to
 o
nc
og
en
es
is
; 0
 –
 k
no
w
n 
fu
nc
tio
n,
 n
o 
re
la
tio
n 
to
 o
nc
og
en
es
is
 
In
iti
al
ly
 id
en
tif
ie
d 
Se
ru
m
 re
sp
on
se
 d
at
a 
Sc
or
es
 
M
 
G
C
 
B
C
 
H
D
 
A
nt
ig
en
 
cD
N
A
 
so
ur
ce
 
Se
ru
m
 
%
 
P-
va
l 
O
R
 
%
 
P-
va
l 
O
R
 
%
 
P-
va
l 
O
R
 
%
 
Se
ro
-
lo
gy
 
ES
T 
pr
of
ile
 
M
ot
ifs
 
Fu
nc
-
tio
n 
T
ot
al
 
  s
co
re
a  
LR
R
C
50
 
Te
st
is
 
B
C
 
8.
95
 
0.
00
1 
In
f 
1.
73
 
0.
29
3 
In
f 
15
.3
8 
0.
00
1 
In
f 
0 
3 
3 
 
2 
8 
SE
N
P1
 
Te
st
is
 
M
 
3.
16
 
0.
07
5 
In
f 
1.
73
 
0.
29
3 
In
f 
15
.3
8 
0.
00
1 
In
f 
0 
3 
2 
 
2 
7 
C
O
PS
4 
Te
st
is
 
M
 
1.
58
 
0.
32
9 
In
f 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
2 
2 
 
2 
6 
R
N
F1
4 
Te
st
is
+G
C
 
G
C
 
1.
05
 
0.
57
5 
In
f 
2.
31
 
0.
16
8 
In
f 
0 
- 
N
aN
 
0 
2 
2 
 
2 
6 
SL
U
7 
Te
st
is
 
M
 
5.
26
 
0.
04
1 
8.
11
 
1.
73
 
0.
70
7 
2.
67
 
15
.3
8 
0.
01
1 
23
.6
9 
0.
65
 
3 
2 
 
1 
6 
SP
A
R
C
 
G
C
 
G
C
 
1.
05
 
0.
57
5 
In
f 
0.
58
 
0.
95
4 
In
f 
0 
- 
N
aN
 
0 
2 
2 
 
2 
6 
A
C
TR
2 
G
C
 
G
C
 
1.
05
 
0.
57
5 
In
f 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
2 
0 
1 
2 
5 
C
11
O
R
F2
0 
Te
st
is
 
M
 
0.
53
 
0.
57
2 
0.
81
 
2.
89
 
0.
28
6 
4.
45
 
0 
0.
11
3 
0 
0.
65
 
1 
3 
 
1 
5 
C
21
O
R
F6
6 
G
C
 
G
C
 
0 
- 
N
aN
 
1.
73
 
0.
29
3 
In
f 
0 
- 
N
aN
 
0 
2 
2 
 
1 
5 
C
C
D
C
92
 
Te
st
is
 
M
 
7.
37
 
0.
00
8 
11
.3
5 
2.
31
 
0.
45
1 
3.
56
 
7.
69
 
0.
38
8 
11
.8
5 
0.
65
 
3 
2 
-1
 
1 
5 
R
FW
D
2 
M
 
M
 
0 
0.
91
9 
0 
0 
0.
95
6 
0 
7.
69
 
0.
38
8 
11
.8
5 
0.
65
 
1 
2 
 
2 
5 
ZN
F2
82
 
G
C
 
G
C
 
2.
11
 
0.
19
6 
In
f 
2.
89
 
0.
09
9 
In
f 
0 
- 
N
aN
 
0 
2 
2 
 
1 
5 
TE
F 
Te
st
is
 
M
 
3.
16
 
0.
07
5 
In
f 
0 
- 
N
aN
 
0.
79
 
0.
12
9 
In
f 
0 
2 
0 
1 
1 
4 
C
16
O
R
F8
2 
G
C
 
G
C
 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
0 
3 
 
1 
4 
ES
C
O
1 
Te
st
is
+G
C
 
G
C
 
0.
53
 
0.
91
7 
In
f 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
0 
2 
 
2 
4 
LI
G
1 
Te
st
is
 
M
 
1.
58
 
0.
32
9 
In
f 
0.
58
 
0.
95
4 
In
f 
7.
69
 
0.
12
9 
In
f 
0 
2 
0 
 
2 
4 
N
O
L8
 
Te
st
is
 
M
 
2.
11
 
0.
19
6 
In
f 
1.
16
 
0.
53
2 
In
f 
0 
- 
N
aN
 
0 
2 
0 
 
2 
4 
R
3H
D
M
2 
G
C
 
G
C
 
2.
11
 
0.
19
6 
In
f 
0.
58
 
0.
95
4 
In
f 
0 
- 
N
aN
 
0 
2 
0 
 
2 
4 
R
PL
7A
 
G
C
 
G
C
 
2.
63
 
0.
12
0 
In
f 
1.
16
 
0.
53
2 
In
f 
0 
- 
N
aN
 
0 
2 
0 
 
2 
4 
R
PL
P1
 
G
C
 
G
C
 
0.
53
 
0.
91
7 
In
f 
1.
16
 
0.
53
2 
In
f 
0 
- 
N
aN
 
0 
2 
0 
 
2 
4 
R
PS
19
 
G
C
 
G
C
 
1.
58
 
0.
32
9 
In
f 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
2 
0 
 
2 
4 
A
IF
1 
G
C
 
G
C
 
0 
- 
N
aN
 
0.
58
 
0.
95
4 
In
f 
0 
- 
N
aN
 
0 
0 
0 
1 
2 
3 
A
LL
C
 
G
C
 
G
C
 
0.
53
 
0.
91
7 
In
f 
0.
58
 
0.
95
4 
In
f 
0 
- 
N
aN
 
0 
0 
2 
 
1 
3 
 !"#
T
ab
le
 3
 S
el
ec
te
d 
un
de
fin
ed
 O
R
F 
an
tig
en
s 
                          
U
se
d 
ab
br
ev
ia
tio
ns
: G
C
 –
 g
as
tri
c 
ca
nc
er
, M
 –
 m
el
an
om
a,
 B
C
 –
 b
re
as
t c
an
ce
r, 
H
D
 –
 h
ea
lth
y 
do
no
r, 
PC
 –
 p
ro
st
at
e 
ca
nc
er
, %
 - 
an
tib
od
y 
fr
eq
ue
nc
y,
 P
-v
al
 –
 p
 v
al
ue
 fo
r 
fr
eq
ue
nc
y 
di
ff
er
en
ce
 o
f c
an
ce
r v
er
su
s h
ea
lth
y 
co
nt
ro
ls
 c
al
cu
la
te
d 
by
 th
e 
!2
 te
st
 a
nd
 b
ol
de
d 
if 
<0
.0
5,
 O
R
 –
 o
dd
s r
at
io
 fo
r a
ut
oa
nt
ib
od
y 
fr
eq
ue
nc
y 
in
 c
an
ce
r v
er
su
s 
he
al
th
y 
co
nt
ro
ls
, I
nf
 –
 in
fin
ity
, N
aN
 –
 n
ot
 a
va
ila
bl
e,
 c
hr
 –
 c
hr
om
os
om
e,
 +
st
r –
 p
lu
s s
tra
nd
, -
st
r –
 m
in
us
 st
ra
nd
, S
TO
P 
– 
tra
ns
la
tio
n 
te
rm
in
at
io
n 
co
do
n 
 
In
iti
al
ly
 id
en
tif
ie
d 
Se
ru
m
 re
sp
on
se
 d
at
a 
M
 
G
C
 
B
C
 
H
D
 
 
A
nt
ig
en
 
na
m
e 
cD
N
A
 
so
ur
ce
 
Se
ru
m
 
%
 
p-
va
l 
O
R
 
%
 
p-
va
l 
O
R
 
%
 
p-
va
l 
O
R
 
%
 
D
es
cr
ip
tio
n;
 a
cc
es
si
on
 n
um
be
r 
C
FL
1 
Te
st
is
 
M
 
1.
05
 
0.
57
5 
In
f 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
N
ov
el
 a
lte
rn
at
iv
e 
5'
sp
lic
e 
si
te
 o
f i
nt
ro
n 
1 
el
on
ga
tin
g 
ex
on
 
1 
in
 A
ce
vi
ew
 tr
an
sc
rip
t c
; p
ep
tid
e 
of
 a
 p
ut
at
iv
e 
su
bd
om
in
an
t O
R
F;
 H
M
37
03
99
. 
N
ov
el
 
sp
lic
e 
va
ria
nt
s 
C
O
X
6B
2 
Te
st
is
 
M
 
4.
74
 
0.
01
9 
In
f 
2.
31
 
0.
16
8 
In
f 
0 
- 
N
aN
 
0 
Pu
ta
tiv
e 
no
ve
l 5
’s
pl
ic
e 
si
te
 o
f i
nt
ro
n 
6 
el
on
ga
tin
g 
ex
on
 7
 
of
 A
ce
vi
ew
 tr
an
sc
rip
t j
; p
ep
tid
e 
of
 a
 p
ut
at
iv
e 
su
bd
om
in
an
t O
R
F;
 H
M
37
04
04
. 
LO
C
28
48
61
 
Te
st
is
+G
C
 
G
C
 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
- 
N
aN
 
0 
H
yp
ot
he
tic
al
 g
en
e 
su
pp
or
te
d 
by
 B
C
03
93
13
, f
ra
gm
en
t o
f 
A
ce
vi
ew
 tr
an
sc
rip
t b
-u
; p
ot
en
tia
l n
at
ur
al
 O
R
F 
pe
pt
id
e;
 
B
C
03
93
13
 
LO
C
39
28
43
 
Te
st
is
 
M
 
0 
- 
N
aN
 
0.
58
 
0.
95
4 
In
f 
0 
- 
N
aN
 
0 
H
yp
ot
he
tic
al
 g
en
e 
m
od
el
 m
R
N
A
 X
R
_0
41
60
3.
2,
 c
on
ta
in
s 
no
ve
l e
xo
n 
in
 in
tro
n 
10
 o
f t
hi
s m
od
el
 m
R
N
A
; f
ra
m
e 
3 
pe
pt
id
e 
of
 th
e 
pr
ed
ic
te
d 
pr
ot
ei
n;
 H
M
37
04
05
. 
C
lo
ne
 #
23
2 
Te
st
is
 
PC
 
4.
21
 
0.
09
5 
6.
48
 
6.
36
 
0.
01
9 
9.
79
 
0 
0.
11
3 
0 
0.
65
 
C
on
ve
nt
io
na
lly
 sp
lic
ed
 -s
tr 
se
qu
en
ce
 o
f c
hr
 5
, t
hi
s 
re
gi
on
 c
on
ta
in
s f
ea
tu
re
s o
n 
th
e 
+ 
st
ra
nd
: P
C
D
H
B
19
P 
an
d 
pr
ed
ic
te
d 
PC
D
H
B
15
 p
re
cu
rs
or
 (h
m
m
86
45
24
), 
U
ni
G
en
e 
cl
us
te
rs
 H
s.5
70
89
8,
 H
s.1
30
75
7,
 H
s.2
87
79
3,
 
H
s.5
70
89
8;
 1
4 
aa
, c
on
ta
in
s S
TO
P,
 p
ut
at
iv
e 
na
tu
ra
l O
R
F 
pe
pt
id
e,
 8
0%
 id
en
tit
y 
to
 st
em
 c
el
l g
en
e 
SL
A
IN
1;
 
H
O
00
03
21
. 
C
lo
ne
 #
20
0 
Te
st
is
 
M
 
0 
- 
N
aN
 
1.
73
 
0.
29
3 
In
f 
0 
- 
N
aN
 
0 
C
on
ve
nt
io
na
lly
 sp
lic
ed
 -s
tr 
se
qu
en
ce
 o
f c
hr
 1
1,
 th
is
 
re
gi
on
 c
on
ta
in
s f
ea
tu
re
s o
n 
th
e 
+ 
st
ra
nd
: p
re
di
ct
ed
 g
en
e 
hm
m
16
84
75
4,
 U
ni
G
en
e 
cl
us
te
r H
s.4
18
45
0;
 6
6 
aa
, n
o 
ST
O
P,
 p
ot
en
tia
l n
at
ur
al
 O
R
F 
pe
pt
id
e,
 n
o 
ho
m
ol
og
y 
to
 
an
y 
kn
ow
n 
pr
ot
ei
ns
; H
O
00
03
22
. 
N
ov
el
 
ge
ne
s 
 
C
lo
ne
 #
16
7 
Te
st
is
 
M
 
9.
47
 
0.
01
3 
4.
8 
6.
94
 
0.
07
7 
3.
51
 
15
.3
8 
0.
09
0 
7.
8 
1.
94
 
C
on
ve
nt
io
na
lly
 sp
lic
ed
 -s
tr 
se
qu
en
ce
 o
f c
hr
 3
, t
hi
s 
re
gi
on
 c
on
ta
in
s f
ea
tu
re
s o
n 
th
e 
- s
tra
nd
: p
re
di
ct
ed
 
al
te
rn
at
iv
e 
is
of
or
m
 o
f R
PL
32
 (h
m
m
61
00
90
3)
, a
nd
 o
n 
th
e 
+s
tr:
 h
yp
ot
he
tic
al
 g
en
e 
hm
m
12
94
90
4,
 U
ni
G
en
e 
cl
us
te
rs
 H
s.2
65
17
4 
an
d 
H
s.3
43
66
4;
 5
5 
aa
, c
on
ta
in
s 
ST
O
P,
 p
ot
en
tia
l n
at
ur
al
 O
R
F,
 5
0%
 h
om
ol
og
y 
to
 
pr
ed
ic
te
d 
hu
m
an
 p
ro
te
in
 h
C
G
19
99
48
1;
 H
O
00
03
23
. 
!"#!
!"#$%&'(&#&)*+'!
Fig. 1 The expression analyses of natural ORF antigens in various normal tissues. A RT-
PCR was performed on 11 various normal tissues. The shading intensity relatively 
corresponds to the intensity of the gel band. White – not detected, light gray – weak 
intensity band, medium gray – medium intensity band, black – strong intensity band. B 
qPCR was performed on 14 various normal tissues to verify testis-associated expression 
pattern of genes detected in RT-PCR. Y axis represents percentage of the testis level and is 
indicated in logarithmic scale. C qPCR results of testis-selective genes LRRC50 and 
ESCO1 relatively to the testis sample in linear scale 
 
Fig. 2 The expression analyses of natural ORF antigens in tumor tissues. qPCR was 
performed in sets of melanoma (M) (8 primary tumors, 9 cell lines and 5 unpaired normal 
skin samples), gastric (G) (15), breast (B) (18) tumor-normal tissue pairs. A Volcano plot 
of qPCR expression data of all analyzed genes and tumor sample sets. Y axis represents 
minus log10 of normally approximated p value obtained by non-parametric Mann-Whitney 
test. Dashed line crossing Y axis represents the 0.05 p-value. X axis represents log2 of 
obtained fold changes between average tumor and normal sample sets. Dashed lines 
crossing X axis represent up and downregulation by 2 fold. B The expression values of 
novel CT antigens are indicated. The median values with interquartile ranges are displayed 
as box plots (dark grey – tumour tissues, light grey – cell lines, white – normal tissues) 
with Tukey whiskers overlaid with individual sample values as a scatter dot plot. Normally 
approximated p-values obtained by non-parametric Mann-Whitney test are indicated if 
<0.05. Numbers below the tumor type designation indicate the overexpressed tumor 
samples out of all analysed. C The expression values of potential overexpressed antigens 
are indicated. The median values with interquartile ranges are displayed as box plots (dark 
grey – tumour tissues, light grey – cell lines, whilte – normal tissues) with Tukey whiskers 
overlaid with individual sample values as a scatter dot plot. Normally approximated p-
values obtained by non-parametric Mann-Whitney test are indicated if <0.05. Numbers 
below the tumor type designation indicate the overexpressed tumor samples out of all 
analysed 
 
Fig. 3 The expression analyses of undefined ORF antigens. A RT-PCR was performed on 
11 various normal tissues. The darkness of the shading relatively corresponds to the 
intensity of the gel band. White – not detected, light gray – weak intensity band, medium 
gray – medium intensity band, black – strong intensity band. B qPCR was performed on 14 
various normal tissues to verify testis-associated expression pattern of genes detected in 
RT-PCR. Y axis represents percentage of the testis level and is indicated in logarithmic 
scale. C qPCR was performed in sets of melanoma (M) (8 primary tumors, 9 cell lines and 
5 unpaired normal skin samples), and gastric (G) (8) tumor-normal tissue pairs. The 
individual sample values are shown as a scatter dot plot connecting paired tumor (dark 
grey) and normal (white) samples as well as cell lines (light grey) in tumor types that 
exhibited specimens with upregulated expression 
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Table S1. Primer sequences used in antigen mRNA expression analysis. 
 
Analysis Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
PGK1 CTTAAGGTGCTCAACAACATGG ACAGGCAAGGTAATCTTCACAC 
POLR2A GGGTCATCTTCCCAACTGGAG CACCAGCTTCTTGCTCAATTCC 
TBP CCACTCACAGACTCTCACAAC CTGCGGTACAATCCCAGAAC 
ACTB AATCTCATCTTGTTTTCTGCGC AGTGTGACGTGGACATCCG 
GAPDH GGGTCTTACTCCTTGGAGGC GTCATCCCTGAGCTAGACGG 
TUBA3-R TATGGCAAGAAGTCCAAGCTG TACCATGAAGGCACAATCAGAG 
YWHAZ CCTGCATGAAGTCTGTAACTGAG GACCTACGGGCTCCTACAAC 
Reference 
genes 
ACTR2 ATTGCTGGGAGGGATATAAC TTTCTAAGGCCAGTTTCTGC 
ACTR2 ATTGCTGGGAGGGATATAAC TTTCTAAGGCCAGTTTCTGC 
AIF1 CATGTCCCTGAAACGAATGC TAGGATGGCAGATCTCTTG 
ALLC ACTGCTTCCAGTGACCAAGT GTGTGTTAAGGGTTTGCTTTG 
C11ORF20 AGCCTTCGAAAGTGTCGCTC CCTCGCAGACCTCGGACAG 
C1ORF82 GAATGAAGCAGGAAGGAGAG GCTGCACGCTGGAAACAT 
C21ORF66 CTGGAGAACAGGATGAAGAG CTATAAGGAATGCCATAGG 
CCDC92 AGCTGGAAGCCCAACTGAAAG CAGGTAGGCGATGGTGCTG 
COPS4 CTGGAGCAGAACAACTAGAAG CAAATGAAATGACTCTAGGCTG 
ESCO2 CTGCAATCTGCGGGATCAGTC GTACTGTGTTGCAAACAGC 
LIG2 AGGAGTGGAATGGAGTGGTG TGGGAGAGGTGTCAGAGAGG 
LRRC50 CAAAGAGATGCTGCACCACTC CTATGATGCTTTCGGTGCTGG 
NOL8 TTTACCACAGTCCTCATTCC ACAAACAGAGGATCAGTAGC 
R3HDM2 GAGCAGCACAGACAGCGAAC GACCTGGTTGCACACTTCTG 
RFWD2 AGTCTCTAGTATTGAATTTGACC CATTCTCAGGGTAATGAATATCC 
RNF14 GGAACTCCCATAGAGAAATTAG CCCAAATATCGTCGTCAACATC 
RPL7A GAATTTTGGCATTGGACAGG CTGGGTGAACTGGTTAATCG 
RPLP1 CCAACGTCAACATTGGGAG GGTTTAGTCAAAAAGACCAAA 
RPS19 GGAAAAGGACCAAGATGGC GTTCTAATGCTTCTTGTTGGC 
SENP1 CAGTGAAGCATTTCGCCTGAC AACGTTTCACTGCCTGATAACC 
SLU7 TCCAGATGAACATGTCCAGCC TCTCCCCACTGGTGTTTTGG 
SPARC GCAGAGGTGACTGAGGTATC CCGTGTTTGCAGTGGTGGTT 
TEF-ASV AGGCGCGCCTCGAATCTTC AGCAAACTTGTGCTTCCGAGG 
Natural 
ORF 
antigens 
ZNF282 GAAGAACCTTGTGTGTGGGAG CAGAAATTGGGGAGTCGGT 
CFL1 GGTATGCTCTGCAAGGCCTC CTTCTTGCGCTTCTTCACCTC 
Clone #167 TGGCTTTGATGTTGAGTCTCC AAAATACGAAAACCAGTCAGG 
Clone #200 CCAAATAGCTGGATTACAGAA GTGGTTGATGTCATTGTTTG 
Clone #232 GAGGCGAGGGGCAGAATC GCACTTAATGAACGAAGGGGAG 
COX6B2 CCAGAGCCTTGACGAATGCAC CAGGAGGCTGCTGTGGCTG 
EVI5L AGCTACAGGAGCAGCAGG GCGCTTGTCTCTGGGTTC 
LO392843 CCCCGCTGAGGTCTTTGTG CCAAATGTATCCCTATGATCTG 
Undefined  
ORF 
antigens 
LOC284861 TTCTCCAGTGTCAATGGCTCA ACACTGTACAAGACATCTGTAA 
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Sperm-associated Antigens as Targets for Cancer
Immunotherapy: Expression Pattern and Humoral
Immune Response in Cancer Patients
Karı¯na Silin¸a,* Pavel Zayakin,* Zane Kalnin¸a,* La¯sma Ivanova,* Ir %ena Meistere,*
Edgars Endzelin¸sˇ,* Artu¯rs A¯bols,* Aivars Stengr %evics,w Ma¯rcis Leja,w Kristı¯ne Ducena,z
Viktors Kozirovskis,y and Aija Lin %e*
Summary: The identification of novel cancer-related and immuno-
genic proteins is still a challenge to be faced to improve anti-
gen-specific tumor immunotherapy. The category of so-called
cancer-testis (CT) antigens is one of the most perspective groups of
proteins for anticancer immune response activation as normally
they are expressed in immunoprivileged tissues and are immuno-
genic if aberrantly generated in tumors. The heterogeneous group
of proteins called sperm-associated antigens (SPAG) might
encompass novel CT antigens owing to their common expression
in male germ cells, their ability to elicit immune response
underlying infertility, and lately proposed oncogenic properties.
We carried out a comprehensive analysis of the expression pattern
in various normal and cancerous tissues and assessed the frequency
of spontaneous humoral immune response against members of the
SPAG group in cancer patients using phage-displayed antigen
microarrays. Our results show that out of 15 analyzed SPAG genes
only SPAG1, SPAG6, SPAG8, SPAG15, and SPAG17 are
predominantly expressed in testis, whereas the others are ubiqui-
tously expressed with only a testis-associated alternative splice
variant of SPAG16. mRNA expression of SPAG1, SPAG6, and
alternative splice variants of SPAG8, SPAG16, and SPAG17 was
elevated in various tumors with frequencies ranging from
approximately 10% to 70%. The upregulation of SPAG6 in lung
and breast cancer was confirmed by immunohistochemical analysis
of tumor and normal tissue microarrays. Cancer-associated
spontaneous humoral immune response was detected against
SPAG1, SPAG6, SPAG8, and a novel testis-specific splice variant
of SPAG17 and ascribe these as novel CT antigens that potentially
are applicable as immunotherapeutic targets and serologic
biomarkers.
Key Words: sperm-associated antigen, CT antigen, CT-spliced
antigen, antigen microarray, cancer immunotherapy
(J Immunother 2011;34:28–44)
Tumor antigen-specific immunotherapy holds a greatpotential to eradicate cancer in a highly specific and
nontoxic manner, and allows direct monitoring of immune
response, which is crucial for understanding immunologic
mechanisms that underlie tumor regression in vivo.1
However, the considerably low efficacy in clinical trials
has hampered the translation of such therapy approaches
into clinical practice and is caused by the selection of tumor
escape variants through inefficient antigen presentation,
the loss of antigen expression and the immunosuppressive
activities of tumor, its stroma and/or innate, and adaptive
tolerogenic immune cells.2,3 Attempts have been made to
overcome the above hurdles by combining antigen targeting
with blocking of tolerance, adding adjuvants, altering
ways of antigen delivery, TCR-based gene therapy etc.,
but there is still a risk of tumor escape through down-
regulation of target antigen expression in case the antigen is
not necessary for tumor survival and if polyclonal T-cell
activation by epitope spreading was not achieved.4 Hence,
the need to develop polyvalent antigen targeting ap-
proaches as one of the means to avoid the selection of
tumor escape variants, and to cover the heterogeneity of
tumors, and the need to determine the protective antigens
in tumors that do not express the currently exploited targets
like WT1, MUC1, Her-2/neu, NY-ESO-1, and others5 puts
the discovery of novel tumor antigens in the frontline of
successful antigen-specific immunotherapy development.
Cancer-testis (CT) antigens are perspective candidates
for cancer immunotherapy, as naturally they are expressed
in immunoprivileged tissues, but are detected in various
neoplastic lesions, and they can induce spontaneous
immune responses when aberrantly produced in tumors as
there is no or weak central tolerance against proteins
restricted to immunoprivileged sites. Emerging evidence
suggests that CT antigens may possess functions related to
stemness owing to their expression during germ cell and
embryonic development, hence, providing space for crucial
oncogenic properties in cancer cells.6 One of the most
successful antigen-specific immunotherapy targets to
date is the CT antigen NY-ESO-15; its targeting has
shown to underlie tumor regression and induce integrated
immune system activation involving both, cellular and
humoral responses.7–10Copyright r 2010 by Lippincott Williams & Wilkins
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During the last 2 decades, a group of proteins called
sperm-associated antigens (SPAG) has grown to reach
15 members—SPAG1,11 SPAG2/UAP1,12 SPAG4,13
SPAG5,14–16 SPAG6,17 SPAG7,18 SPAG8,19 SPAG9,20
SPAG10/MFGE8,21 SPAG11B,22 SPAG12/NHP2L1,23
SPAG13/SSFA2,24 SPAG15/SPAM1,25 SPAG16,26 and
SPAG17.27 For further simplicity in this report, we use
the names of the SPAG group even if they differ from the
official gene name. These are functionally and evolutionary
distinct proteins with a common expression in testis or
sperm, and humoral immune response against some have
been shown to underlie infertility. Several of them have
been candidates for treating infertility23 and for the
development of immunocontraception.28 Lately also, a
role in tumorigenesis has been ascribed to several SPAG
proteins, for example, SPAG1 has been shown to be a
progression marker of pancreatic cancer and promote cell
motility.29 Decreased expression of SPAG5, a mitotic
spindle protein, also known as astrin, is associated with
good prognosis for estrogen receptor positive breast cancer
patients as determined by cDNA microarray data anal-
ysis.30 In our earlier study of large-scale identification of
humoral tumor antigens, we found SPAG8 to react with
sera from melanoma patients,31 and it has been shown to be
overexpressed in cervical carcinoma.32 SPAG9 or JLP has
been reported to facilitate migration and invasiveness of
renal cell carcinoma33 and proposed as an early marker for
breast34 and cervical35 cancers. Besides, it was shown to be
an AML36 and epithelial ovarian cancer-specific antigen
and was suggested for cancer immunotherapy applica-
tions,37 and together with SPAG4 are designated as CT
genes by the CT Database.38 The vastly studied SPAG10
also known as lactadherin or the milk fat globule protein
MFGE8 was identified as a breast cancer-specific antigen
and was considered as a perspective serologic diagnostic
marker and a radioimunotherapy target.39,40 Elevated level
of SPAG15 or testis-specific hyaluronidase PH-20 might
contribute to the metastatic potential of breast and
laryngeal cancer.41–45 Besides, several SPAG proteins have
been related in one way or another to the primary cilium,
which is a crucial regulator of Hedgehog, PDGFaa, and
WNT signaling pathways that can underlie various aspects
of tumorigenesis.46,47 Noteworthy, several of the SPAG
proteins have been shown to be located on the sperm
surface, which mediates infertility in patients with corre-
sponding sperm agglutinating antibodies.11,19 If SPAG
proteins were also present on the tumor cell surface,
novel-specific antibody therapeutics could be developed.
Hence, SPAGs might represent a novel group of CT
antigens with functional implications in cancer formation
and might have a potential to be novel targets for tumor
immunotherapy. However, many SPAG proteins have been
analyzed in a narrow focused way concerning infertility.
The aim of this study was to gain view on the expression
profile and the frequency of spontaneous humoral immune
responses against SPAG proteins by using phage-displayed
antigen microarrays to determine if any member of the
SPAG group might fulfill the requirements for a novel
tumor immunotherapy target.
MATERIALS AND METHODS
Patient Material, Cell Lines
Tumor and adjacent normal tissue specimens were
obtained from operation material of gastric, colon,
melanoma, and breast cancer patients undergoing surgery
in Latvian Oncology Centre and stored in RNALater
(Applied Biosystems). Lung tumor specimens were ob-
tained during standard diagnostic bronchoscopy procedure
at Pauls Stradins Clinical University Hospital and stored in
RNALater. All patients have signed an informed consent,
and the study has been approved by the Central Commis-
sion of Medical Ethics of Latvia.
Sera were collected from the same patients whose tissue
specimens were collected. Additional serum samples of
melanoma, lymphocytic leukemia, gastric, lung, colon, breast,
and thyroid cancer patients and healthy individuals with
no known history of cancer, infertility, and autoimmune
disorders were provided by the Genome Database of the
Latvian population and sera from melanoma, gastric, and
prostate cancer patients were kindly provided by the Skin
Cancer Unit in German Cancer Research Center, the Clinic of
Gastroenterology, Hepatology and Infectious Diseases, Otto-
von-Guericke University Magdeburg, Norwegian Radium
Hospital, and Onyvax Vaccine Therapies Ltd, UK.
RNA Extraction, cDNA Synthesis
Bead-based tissue homogenization was done by using
the FastPrep-24 instrument and Lysing Matrix A (MP
Biomedicals) in 1mL of TRIsolution (Applied Biosystems)
followed by the extraction of total RNA according to
manufacturer’s protocol. RNA from melanoma cell lines
was kindly provided by Skin Cancer Unit in German
Cancer Research Center. RNA of various normal tissues
was purchased from Applied Bisystems, USA and Biocat,
Germany. Total RNA was treated with DNase I using
DNA-free DNase treatment and removal reagents (Applied
Biosystems). cDNA was synthesized by random hexamer
priming from 2 mg of total RNA by using RevertAidTM
First StrandcDNA Synthesis Kit (Fermentas, Lithuania)
according to manufacturer’s instructions.
mRNA Expression Analysis
Qualitative RT-PCR reaction mixtures contained 1!
reaction buffer, 2.5mM MgCl2, 0.1mM primers (Table 1),
0.75U Taq DNA polymerase (Fermentas, Lithuania), and
1/60th of the prepared cDNA. Amplification of all target
and reference genes was done at the same cycling conditions
(45 s at 941C, 30 s at 581C, 45 s at 721C), except for the
number of cycles that was determined individually accord-
ing to mRNA abundance (Table 1).
Quantitative RT-PCR (qPCR) reactions were done
using 1/60th of cDNA reaction mixture, ABSolute Blue
SYBR green Low ROX (Thermo Scientific) and ABI7500
sequence detection system (Applied Biosystems). Appro-
priate primer concentrations were established by serial
dilution curves to ensure amplification efficiency over 95%
(Table 1). To normalize the expression data a normal-
ization factor was calculated for each cDNA from the
expression values of the 3 most stable reference genes
(ACTB, POLR2A, TUB3A) determined among 7 most
often used housekeeping genes (GAPDH, ACTB, POL-
R2A, TUB3A, TBP, YWHAZ, PGK1) by using geNorm
software.48 All reactions were carried out in duplicates.
The statistical analysis of the expression data from
tumor and normal samples was done using the nonpara-
metric Mann-Whitney U test.
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Immunohistochemical Analysis
of Tissue Microarrays
Paraffin-embedded tissue microarrays (TMA) of various
normal tissues (duplicated 45 tissues, A700 (III), AccuMax
Array triplicated 33 tissues, FDA994, US Biomax, Inc.) and
melanoma, gastric (ME481t and ST805t, US Biomax, Inc.),
lung, and breast [A716 (III) and A712 (13), Accu Max Array]
cancers were used for standard immunohistochemistry
analysis including melanin bleaching procedure (Melanin
Bleach Kit, Polysciences, Inc.) for normal tissue and
melanoma TMAs according to manufacturers protocol. In
brief, after standard deparaffination and hydration, TMAs
were incubated in melanin bleaching solutions, rinsed, and
continued with peroxidase quenching. Antigen retrieval was
done by heating the TMA in 0.01-M citric acid, pH 6.0
(SIGMA-Aldrich, Germany) for 15 minutes. Commercial
primary antibodies for SPAG6 (mouse monoclonal antibody,
SantaCruz Inc), and for SPAG8 (rabbit polyclonal antibody,
Proteintech Group, Inc.) were used at the dilution 1:50 and
incubated overnight at +41C. Secondary antibodies (HRP
conjugated antimouse IgG antibody and antirabbit IgG
antibody, SIGMA-Aldrich, Germany) were used at the
dilution 1:100 for 1 hour at +371C. DAB (SIGMA-Aldrich,
Germany) was used for color development and counter-
stained with hematoxylin (SIGMA-Aldrich, Germany).
Analysis of Autoantibody Responses
The antigenic regions of SPAG proteins were pre-
dicted using algorithms developed by Welling et al49 for
SPAG1, SPAG6, SPAG8, SPAG9, SPAG16, and SPAG17,
which, together with full CDS regions of well-known CT
antigens NY-ESO-1 (CTAG1B), MAGEA1, HORMAD1,
and SSX2 were amplified using high-fidelity PCR enzyme
mix (Fermentas, Lithuania) from testis cDNA. Several
different transcripts were obtained for SPAG6 (designated
as SPAG6-A, B, and A1), SPAG9 (designated as SPAG9-A
and C), and SPAG17 (designated as SPAG17-A and A1).
All fragments were cloned into T7Select 10-3b Phage
Display vector (Novagen) (Table, Supplemental Digital
Content 1, http://links.lww.com/JIT/A84 for cloned anti-
gens with corresponding amino acid positions). StrepII tag
(Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) was inserted into Hin-
dIII and NotI sites located downstream the cDNA cloning
site of the vector DNA to monitor the copy number of the
recombinant proteins on each phage. Obtained recombi-
nant phages together with 9 nonrecombinant control
phages were amplified, purified, and printed in triplicate
on nitrocellulose slides (Whatman, GE Healthcare) to
create an antigen microarray, which was screened with sera
from 39 breast, 24 lung, 33 colon, 28 thyroid, 172 gastric
(stage I—33, II—20, III—31, IV—37, not determined—53),
52 prostate cancer, 163 melanoma (stage I—22, II—23,
III—22, IV—22, not determined—74), and 28 lymphocytic
leukemia patients and 127 patients of gastrointestinal
inflammatory diseases (gastric ulcer—17, duodenum ul-
cer—20, gastritis and duodenitis—10, acute hemorrhagic
gastritis—13, chronic atrophic gastritis—48, dyspepsia—
11, Crohn disease—8) and 147 healthy donors. The
production and processing of antigen microarrays were
done as described earlier.31 In brief, the microarray slides
were incubated with patients’ sera and mouse anti-T7 phage
tail antibody (Novagen). The serum reactivity was detected
by Cy5 conjugated goat anti-human IgG antibody (Jackson
ImmunoResearch) and the ratio against the total amount of
printed phage, which was detected by Cy3 conjugated goat
anti-mouse IgG antibody (Jackson ImmunoResearch) was
calculated. A 2-step normalization strategy was used for the
fluorescent signal ratios to eliminate variations introduced
by custom production of microarrays and variable back-
ground intensities of different sera. At first, the values in
each slide (each serum) were normalized by the median of
all printed spots for each fluorescent channel separately.
Next, the Cy5 and Cy3 signal intensities for each spot were
divided by the median value of that spot within the print
lot. The threshold value of a specific antibody response for
each antigen was defined as 4 standard deviations above the
TABLE 1. Primers and Cycling Conditions Used in mRNA Expression Analyses
Gene Forward Primer, 50-30 Reverse Primer, 50-30
RT-PCR
Cycles
qPCR Ratio
F/R (nM)
SPAG1 GAAAAGCATCTTCAAGCCTTGG GGAGGTCAAGCACCAAGTTTG 35 100/100
SPAG4 TGGGTCTCCAGTAGTCTCTGA TCCTCTGCACGACCAGTCG 35 —
SPAG5 CGCAGAGCAGGTTCAAACAC GGAGAGGCACTTGAATGGGA 38 —
SPAG6 AGCAATGGCAGTCATCATTTC GGATGAATGGTCGGGAACTT 35 50/100
SPAG8 CAAGCATGCAGGATGGCTCT ATGGCTTCACGCTTCCCTCG 35 100/100
SPAG8-e2L CTACAACTGGGAGGAAGAGAG GTGGCTGGTACGAGTCTTTC 35 100/100
SPAG9 AGACCCGAGTGGAATCTTTAG GTTGATCACTCCCTGAGAGC 35 —
SPAG9-C CTCATACCAGCCTGAAGGTC CCATCGGGTCCTTTGATCTT 35 100/50
SPAG11B CACCCAGCCTCACTCCATC CACTTTGCCCTGGAGAATGG 35 —
SPAG12 CAAGAAGCTACTGGACCTCG GATGCACAAACACGCGAGG 35 —
SPAG13 GCACCACTGACAATACCATCC CACGACTATCAACACTGTCACT 35 —
SPAG15 GTTGCTCTGGGTGCTTCTG GGTCCTCGTTCCTCACACA 35 100/50
SPAG16 CGGAAAACAGTTCTTCCTTC AGACTGAAAGCAATCAAGAG 35 100/100
SPAG16-L CTGTCTATATGGGATGCAAGAAC GACCGTTACTCCACTTAAAACTA 35 50/100
SPAG17 AACAGAAATCCTCAAGTGTGC TGTGTTCACTTTTCCTCCAAC 35 100/100
SPAG17-A GGAACATTGCTCTCCACTCC GCTAATCGTCTTCTCCTCGC 35 50/100
SPAG17-A1 CAACATGAGTCTCTGGGTAA GCTAATCGTCTTCTCCTCGC 38 100/100
SSX2 GCTCAAATACCAGAGAAGATCC GTGGCCTTGAAACCTAGTTTAG 35 100/50
ACTB AATCTCATCTTGTTTTCTGCGC AGTGTGACGTGGACATCCG 25 100/100
PolR2A GGGTCATCTTCCCAACTGGAG CACCAGCTTCTTGCTCAATTCC — 100/100
TUBA3 TATGGCAAGAAGTCCAAGCTG TACCATGAAGGCACAATCAGAG — 100/100
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average of 70 empty phage controls. Statistical significance
was calculated using w2 test. To validate SPAG17-A1 splice
variant-specific antibodies, an antigen array comprising
phage particles expressing SPAG17-A, SPAG17-A1, an
unrelated-antigen HORMAD1, and empty phages was
tested with serial 3-fold dilutions of 2 SPAG17-A1 positive
gastric cancer sera. The normalized values were further
normalized against StrepII signal detected by anti-Sterp II
tag antibody (StrepMAB-Immo, IBA, Germany) to correct
for copy number variations of recombinant proteins per
phage particle.
RESULTS
Selection of Candidate CT Genes
Some of the SPAG genes have been studied extensively
whereas for others only the coding sequence is known,
hence, we carried out data mining in Human Protein
Atlas,50,51 Oncomine,52,53 Genevestigator,54,55 BioGSP,56,57
and Entrez Gene58 databases and the published literature to
select CT gene candidates for experimental validation. The
criteria for selecting a SPAG gene for further expression
analyses were CT-associated expression profile, possible
functional implications in oncogenesis and the cell surface
localization. The decision was based on the obtained
information summarized in Table 2 and included SPAG1,
SPAG4, SPAG5, SPAG6, SPAG8, SPAG9, SPAG11B,
SPAG15, SPAG16, and SPAG17. SPAG12 and SPAG13
were included to affirm the ubiquitous expression repre-
sented by the above mentioned online resources.
All SPAG genes are alternatively spliced as evidenced
by the NCBI AceView database.136 For the expression
analysis, primers were designed to amplify a common
region of all known transcripts. Additional sets of primers
were designed to amplify earlier reported testis-associated
splice variants of SPAG986 (designated as SPAG9-C),
SPAG16134 (designated as SPAG16-L), SPAG8 isoform
earlier found to elicit antibody responses in melanoma
patients31 (designated as SPAG8-e2L), and SPAG17 splice
variant containing the predicted antigenic region (desig-
nated as SPAG17-A). In addition, we identified novel
transcripts during the cloning of the antigenic regions of
SPAG6 and SPAG17 and designated them as variations of
corresponding transcripts in the AceView nomenclature
namely SPAG6-A1 and SPAG17-A1 (Figure, Supplemental
Digital Content 2, http://links.lww.com/JIT/A85 for all
alternative transcripts, amplicon positions, and cloned
antigenic regions).
mRNA Expression Pattern in Normal Tissues
To describe the expression pattern of SPAG genes, we
use the terms defined by Hofmann et al137 where CT genes
that are expressed mostly in testis but are detectable in low
levels in a few other nongerm line tissues are designated
as testis-selective, and the ones present only in germ line
tissues and placenta are called testis-restricted. Expression
of the selected SPAG genes together with the well-known
CT antigen SSX2 as a control of testis-restricted expression
(according to the CTDatabase38) was first analyzed by
qualitative RT-PCR in a panel of 14 different normal
tissues (Fig. 1A). SPAG1, SPAG6, SPAG8, SPAG8-e2L,
FIGURE 1. The mRNA expression of sperm-associated antigens (SPAG) in various normal tissues. A, RT-PCR was carried out on a set of
14 various normal tissues and the amplification products were visualized in a 1.2% agarose gel. B, qPCR was done on a set of 13 various
normal tissues and testis samples from 4 different individuals. Mean quantities are displayed. Y axis represents percentage of the testis
expression level in logarithmical scale. C, The average quantity of total SPAG (white bars) and corresponding splice variants
obtained from 4 different testis samples is displayed. Black bars—SPAG8-e2L, SPAG16-L, SPAG17-A, striped bar—SPAG17-A1. Y axis
represents percentage of the ACTB expression level in logarithmic scale. Error bars represent standard error of the mean. BM indicates
bone marrow; Bra, brain; Bre, breast; Co, colon; H, heart; Ki, kidney; Li, liver; Lu, lung; M, size marker; N, no template control;
Pa, pancreas; Sk, skin; Sp, spleen; St, stomach; Te, testis (60, 64, 99 designate 3 additional testis samples); Tr, trachea; Ty, thymus.
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FIGURE 2. The mRNA expression of sperm-associated antigens (SPAG) in various tumors. A, RT-PCR was carried out on sets of 6 breast
(B), colon (C), gastric (G), lung (L) cancer, and melanoma (M) tumor samples. Amplification products were visualized in a 1.2% agarose
gel. Numbers 1-6 designate tumor tissues of cancer patients, TE-commercial normal testis, N-no template control, M-size marker. B,
qPCR was carried out on sets of breast, colon, gastric, lung cancer, and melanoma samples (dark gray boxes), 9 melanoma cell lines
(light gray boxes), and adjacent normal tissues and corresponding commercial normal samples (white boxes). Boxes show median with
interquartile ranges for each sample set with Tukey whiskers, black dots represent the average value of the sample set, open circles
designate expression values of individual tissue samples. Y axis represents percentage of the testis expression level in logarithmic scale.
Single asterisk designates statistical significance reached within 1 tumor type, 2 asterisks—across all tumor types. One-tailed normal
approximated P values, calculated using the nonparametric Mann-Whitney U test, are indicated if significant. Numbers below the tumor
type designation indicate the number of overexpressed tumor samples out of all analyzed.
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SPAG16-L, SPAG17, and SPAG17-A showed testis-selective
expression, and SPAG15 and SPAG17-A1 seemed to be
testis-restricted. These were further validated by qPCR in a
cDNA set composed of 13 different normal tissues and
testis samples from 4 different individuals. Testis-selectivity
was confirmed for all analyzed SPAG transcripts (Fig. 1B),
however, SPAG1 showed considerably high expression in
normal colon. A minute amount of SPAG15 was observed
in thymus, heart, and breast and renders it testis-selective.
SPAG17-A1 was approved as testis-restricted. The remain-
ing SPAG4, SPAG5, SPAG9, SPAG9-C, SPAG11B,
SPAG12, SPAG13, and the common region of SPAG16
were present in many normal tissues in comparable levels
with that of the testis sample (Fig. 1A) and this observation
was confirmed by qPCR for SPAG9-C (data not shown)
and SPAG16 (Fig. 1B). The objective expression level of
testis-selective SPAG gene transcripts was determined in 4
different testis samples (Fig. 1C) by comparing it with the
level of ACTB. It is shown that the most prominently
expressed SPAG gene in testis is SPAG16 reaching about
30% of the ACTB level, whereas the testis-selective
transcript SPAG16-L comprises around 6% of the total
SPAG16. The transcripts containing the predicted antigenic
regions of SPAG8 (SPAG8-e2L) and SPAG17 (SPAG17-
A) represent approximately 80% and approximately 40%
of the corresponding total mRNA, respectively, whereas
the testis-restricted transcript SPAG17-A1 represents only
0.02% of the total SPAG17.
mRNA Expression in Tumor Tissues
Next, we carried out a qualitative RT-PCR screening
experiment in melanoma, gastric, colon, lung, and breast
cancer specimens from 6 patients in each tumor type
(Fig. 2A) to determine whether any of the testis-associated
SPAG transcripts are present in tumors. It is evident that
the mRNA pattern varies in different cancer types among
SPAGs, SPAG1, and SPAG8-e2L are the most frequent,
detected in about 80% of samples. SPAG6 and SPAG17-A
can be detected in about 50%, and SPAG15, SPAG16-L,
and the testis-restricted transcript SPAG17-A1 are the least
frequent transcripts detected in 10% to 20% of analyzed
tumor samples.
To confirm upregulation of the testis-associated
SPAGs in the respective tumor types, their expression was
examined by quantitative RT-PCR in larger panels of
tumor and adjacent normal tissue pairs. The expression
level in tumor samples was compared with the adjacent
normal tissue and to the average signal detected in all
corresponding normal samples including the commercial
normal sample to account for the interindividual expression
variations and for cases when the adjacent normal tissue
was not available (such as for lung cancer biopsies and
melanoma cell lines). Expression of a SPAG gene was
considered upregulated in a tumor sample if it exceeded
that of the adjacent normal sample by at least 2-fold and
the average amount in all normal samples by at least 3-fold.
We could detect overexpression of all SPAG genes in tumor
samples of various tumor types, however the level of
SPAG15 in overexpressed tumor samples is below 1%
of the testis level (Fig. 2B). Overexpression in 12.5%
melanoma samples was found only for SPAG6 and
SPAG17-A, whereas no SPAG gene expression was
upregulated in colon cancer sample set (Fig. 2B). All
SPAG genes analyzed in breast cancer showed elevated
expression level with frequencies varying from 14%
(SPAG17-A1) to 43% (SPAG1), and overexpression in
gastric cancer was noted for all except SPAG17-A1 from
9% (SPAG6, SPAG8-e2L) to 45% (SPAG17-A) of samples
(Fig. 2B). The most prominent upregulation of SPAG genes
is seen in lung cancer ranging from approximately 30%
(SPAG6, SPAG17-A1) to 70% (SPAG1, SPAG17-A)
(Fig. 2B).
Protein Expression Analysis
To evaluate the expression of testis-selective SPAG
genes at the protein level, we used immunohistochemistry
on tissue microarrays comprising various normal tissues
and paired breast and lung tumor-normal and unpaired
gastric tumors and normal stomach tissues. The choice
of analyzed proteins was limited to the availability of
commercial antibodies. SPAG6 was not detected in any of
the 45 normal tissues represented on TMAs (from 2
different commercial providers in 2 repeated experiments),
including lung and spermatozoa (Fig. 3A). However, its
expression was observed in 7 out of 12 breast cancers and
1 adjacent normal breast specimen (Fig. 3B, normal tissue
panel). All positive tumor samples showed distinct perinu-
cleolar staining (Fig. 3B, arrows in the tumor images) and
mostly weak nuclear staining with strong signals in 2 out of
7 tumors (Fig. 3B). A more prominent signal was observed
in 11 out of 12 lung cancer specimens strongly staining
either nucleus alone or also cytoplasm and little amount in
all adjacent normal lung samples with exclusively nuclear
localization (Fig. 3C) just as in the adjacent normal breast
sample. The positive tumors could be divided by the
proportion of the positive cells, 8 out of 11 samples showing
around or less than 50% and 3 out of 11 staining close to
100% of cells (Fig. 3C), however, no correlation of tumor
stage or metastatic status was noted.
SPAG8 was observed only in discrete cells in the
parabasal layer of ectocervix (Fig. 3D), acinar, and ductal
epithelium of the breast (Fig. 3E, normal tissue panel) and
stomach fundus glands (Fig. 3F), whereas all other normal
tissues including testis, skin, and other stratified squamous
cell epithelia such as that of esophagus or larynx were
negative (data not shown). The subcellular localization is
mostly cytoplasmic, but in the cells of fundus glands also
the nucleus is stained and in ectocervix also possibly the
plasma membrane. Its expression was also detected in 60%
of breast tumors (7 out of 12) with a strong staining
characteristic to nonmetastatic lesions (3 out of 3), whereas
metastatic breast carcinomas (assessed by the presence
of dissemination to lymph nodes) were less prominently
stained (4 out of 9) and showed a possible surface
localization in some cells (2 out of 4 positive cases)
(Fig. 3D, arrows in tumor panel pictures). SPAG8 in
gastric cancer (Fig. 3E) was only rarely detected by a strong
signal and a decreased frequency of positive cases was
noted with advancing stage: from 55% of stage II (11 out of
20) to 44% of stage III (8 out of 18). All inflammatory,
metaplastic, and dysplastic samples and a single stage I case
were positive and the single stage IV case and 10 lymph
node metastases were negative. Surface localization was
suspected in 1 case (gastric adenocarcinoma, stage II)
(Fig. 3E, arrow in tumor image). We observed no SPAG8
protein expression neither in 40 malignant melanoma
tissues nor in 8 unpaired normal skin samples (data not
shown).
J Immunother ! Volume 34, Number 1, January 2011 Sperm-associated Antigens as Targets for Cancer Immunotherapy
r 2010 Lippincott Williams & Wilkins www.immunotherapy-journal.com | 35
 !!"  
Frequency of Autoantibodies
To analyze the immunogenicity of the cancer-asso-
ciated SPAG proteins and the earlier described cancer
serum marker SPAG9-C33–37 in cancer patients, we
determined the frequency of IgG class autoantibodies in
sera from 539 cancer patients, 127 patients with inflamma-
tory gastrointestinal disorders and 147 cancer-free indivi-
duals by using custom phage-displayed antigen microarray.
The frequency of cancer autoantibodies against SPAG1,
SPAG6-A and A1, SPAG9-C, and the novel testis-
restricted splice variant SPAG17-A1 are comparable with
the CT antigen HORMAD1 and higher than against
MAGEA1 and SSX2, whereas no sera reacted with
SPAG6-B and SPAG17-A transcripts (Table 3, Fig. 4A).
FIGURE 3. Protein expression of sperm-associated antigens (SPAG) 6 and 8. Immunohistochemical (IHC) analysis was done on paraffin-
embedded tissue microarrays using anti-SPAG6 and anti-SPAG8 antibodies, HRP-conjugated secondary antibodies, DAB color
development, and hematoxylin counterstaining. Black lines designate scale bars of 10 mm. A, SPAG6 IHC analysis in normal testis (left)
and normal lung (right). B, SPAG6 IHC staining in normal breast (N) and paired tumor (T) tissues; arrows indicate cells with
perinucleolar staining. C, SPAG6 IHC staining in normal lung (N) and paired tumor (T) tissues. D, SPAG8 IHC staining in normal stratified
squamous cell epithelium of ectocervix; arrows indicate discrete strongly stained cells with possible surface staining. E, SPAG8 IHC
staining in normal breast (N), and paired tumor (T) tissues, arrows indicate tumor cells with possible surface staining. F, SPAG8 staining
in normal stomach (N), arrows indicate discrete strongly stained cells, and unpaired gastric tumor (T) tissues, arrows indicate tumor cells
with possible surface staining.
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SPAG9-A and SPAG16-L were detected also by sera from
healthy donors and gastritis patients in comparable frequencies
with the tumor sera suggesting an inflammation rather than
cancer-related response (Table 3). The most often recognized
was SPAG8-e2L with high titer antibodies (antibody signal
over 3) in 1 out of 167 melanoma sera (stage I) and low titer in
4 out of 167 melanoma, 3 out of 172 gastric, 1 out of 28
lymphocytic leukemia, 1 out of 52 prostate cancer, and 1 out
of 28 thyroid cancer sera (stages I-III), and 4 out of 127
gastrointestinal disease patients (3 atrophic gastritis and 1
duodenum ulcer) and 1 out of 147 healthy donors (Fig. 4A,
Table 3). Cancer-specific autoantibodies against SPAG17-A1
were detected in 3 out of 172 gastric cancer patients (1 stage III
and 2 stage IV patients), whereas the major isoform SPAG17-
A was very weakly recognized with the corresponding sera
antibody signals just below the serum positivity threshold
(Fig. 4A). SPAG17-A1 isoform lacks 171 amino acids
compared with SPAG17-A (Table and Figure, Supplemen-
tal Digital Contents 1 and 2, http://links.lww.com/JIT/A84
and http://links.lww.com/JIT/A85) and hence, might be
represented on the phage surface in a more efficient way
leading to increased antibody signals. To exclude the
possibility that differential serum reactivity against these 2
splice isoforms is owing to variable amount of recombinant
protein on the phage surface and to determine the titer of
the anti-SPAG17-A1 autoantibodies, we carried out addi-
tional screening with serial 3-fold dilutions of 2 positive
gastric cancer sera on a separate array containing 5
replicates of SPAG17-A, SPAG17-A1, and irrelevant
antigen HORMAD1 and the antibody signal intensities
were normalized not only against the total amount of
printed phage by anti-T7 phage tail antibody, but also
against the copy number of recombinant protein per phage
particle by anti-Strep Tag antibody (Materials and Meth-
ods). The presence of the anti-SPAG17-A1-specific anti-
bodies was approved and the antibody signals are detected
at the sera dilution higher than 1:2700 (Fig. 4B).
DISCUSSION
The specificity and oncogenicity of a potential cancer
antigen are the dominant criteria for choosing it for further
evaluation of immunogenicity and therapeutic functions as
defined in the recent guidelines of prioritizing antigens for
immunotherapy.5 We analyzed online expression databases
and published literature to define those SPAG genes that
might match the above criteria and to select the candidate
CT genes for experimental validation. Five of the SPAG
genes (SPAG2, SPAG7, and SPAG10, SPAG12, SPAG13)
were presented as ubiquitous by literature data and data
deposited in online gene array databases, and this expres-
sion pattern was experimentally confirmed for SPAG12 and
SPAG13. Qualitative mRNA expression analysis showed
that SPAG4 is most abundant in pancreas fitting the earlier
published results69 and several other normal tissues, hence,
while being a possible marker of various neoplasias,69 it
cannot be included in the CT gene category. SPAG5 was
ubiquitously expressed differing from the earlier reported
testis-selective distribution,15,53 but in concordance with its
functional involvement in centrosome integrity70–74 and the
protein expression pattern presented in HPA.51 Among the
most studied is SPAG9 or JLP, a scaffolding protein that is
involved in various signaling events along the MAPK87 and
TNF-a or NF-kB138 pathways and is important for sperm
development89 and retinoic acid-mediated endodermal
differentiation.93 In addition, the overexpression of a
distinct testis-associated splice variant of SPAG9 (desig-
nated by AceView database136 as SPAG9-C) is suggested to
be important for tumorigenesis and proposed as a tumor
immunotherapy target.33–35,37 We show, however, that,
despite the dominant expression in testis, SPAG9-C is
present in various normal tissues in comparable levels and it
cannot be considered as a CT antigen with implications in
immunotherapy.
We continued the expression analyses of testis-
selective SPAG genes in various tumor types and showed
upregulation in cancer tissues of all except SPAG15.
Earlier, SPAG15 has been shown as overexpressed in
around 60% of breast cancer cases,43 as well upregulation is
noted in lung cancer by Oncomine,53 however, no expres-
sion was detected in these tumors in our sample set. A
larger sample size and/or other tumor types should be
analyzed to see whether SPAG15 can be classified as a CT
gene. According to the results of our expression analysis
TABLE 3. The Frequency of Reactive Sera Against SPAG Proteins in Cancer Patients, Gastritis Patients, and Healthy Individuals*
Antigen B (39) C (33) G (172) L (24) LE (28) M (163) P (52) T (28) All Ca (539)w GI (127) HD (147)
SPAG1 0 3 0 4.2 0 0 0 0 0.4 0 0
SPAG6-A 0 0 0 0 0 0 2 0 0.2 0 0
SPAG6-A1 0 0 0.6 0 0 0.6 0 0 0.4 0 0
SPAG6-B 0 0 0 0 0 0 0 0 0 0 0
SPAG8-e2L 0 0 1.7 0 3.6 3.1 2 3.6 2 3.1 0.7
SPAG9-A 0 0 1.2 0 0 0 0 0 0.4 0 0.7
SPAG9-C 0 0 0 0 0 0.6 0 0 0.2 0 0
SPAG16-L 0 0 0.6 0 3.6 0.6 5.8 0 1.1 3.1 2
SPAG17-A 0 0 0 0 0 0 0 0 0 0 0
SPAG17-A1 0 0 1.7 0 0 0.6 0 0 0.7 0 0
CTAG1B 10 6 7 12.5 7 10.4 9.6 10.7 8.9 0 0.7
HORMAD1 0 0 3.5 0 3.6 0.6 0 0 1.5 1.6 0
MAGEA1 0 0 0 0 0 0.6 0 0 0.2 0 0
SSX2 0 0 0 0 0 0.6 2 0 0.4 0 0
*The number of tested sera is indicated in brackets under the tested tumor type, and the frequency of reacting sera is indicated in percents.
wAll Ca—frequency of antibody responses across all tumor types.
B indicates breast cancer; C, colon cancer; Ca, cancer; G, gastric cancer; GI, gastrointestinal inflammatory diseases; HD, healthy donors; L, lung cancer;
LE, lymphocytic leukemia; M, melanoma; P, prostate cancer; T, thyroid cancer.
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SPAG1, SPAG6, SPAG8, and SPAG17 genes are the new
members of the CT gene category, whereas only distinct
isoforms of SPAG16 (SPAG16-L) are testis-selective.
Tumor antigen-targeted immunotherapy trials have
shown that the expansion of antigen-specific CTLs does not
necessarily correlate with tumor regression,139 whereas the
proper activation of antigen-specific T helper cells has a
great potential to underlie tumor control and eradica-
tion.140 The presence of specific class switched autoanti-
bodies in patients’ sera against tumor antigens is indicative
of spontaneous cell activation against the particular antigen
and the detection of such autoantibodies can be used to
FIGURE 4. Autoantibody responses in sera of various cancer patients, gastritis patients, and healthy donors. A, Autoantibody reactivity
against SPAG proteins and the well-known CT antigens was determined by screening phage-displayed antigen microarray with sera
from 39 breast (B), 33 colon (C), 172 gastric (G), 24 lung cancer (L), 163 melanoma (M), 28 lymphocytic leukemia (LE), 28 thyroid (T),
52 prostate cancer (P) patients and 127 patients of gastrointestinal inflammatory diseases (GI), and 147 healthy donors (HD).
Normalized average values of triplicate recombinant phages are displayed. The serum positivity threshold is defined as 4 standard
deviations above the average signal of 70 nonrecombinant phage controls and is designated as a line across the graphs. B, Two gastric
cancer sera MGB62 and 43-F4 showing strong reactivity against the novel splice variant SPAG17-A1 and not the dominant isoform
SPAG17-A were used in serial 3-fold dilutions for screening of antigen microarray containing these phages and an irrelevant antigen
HORMAD1. The obtained signals were normalized against the total amount of printed phage and the amount of recombinant surface
protein per each phage. Y axis represents autoantibody signal values, X axis represents serum dilution, error bars designate standard
deviations of 5 recombinant phage replicates. Average antibody signals for clone of SPAG17-A1, 2 clones of SPAG17-A, and 2 clones of
irrelevant antigen HORMAD1 are displayed.
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monitor the frequency of such responses in cancer patients.
To do this, we used the phage-displayed antigen microarray
system developed in our lab31 and created a custom SPAG
antigen microarray for serum screening of various cancer
patients. Overall, the frequency of autoantibodies against
SPAGs is low, yet higher than that of the well-known CT
antigens such as MAGEA1 and SSX2. Humoral response
against SPAG1, SPAG6, and the novel testis-restricted
splice variant SPAG17-A1 was specific to cancer patients,
and cancer-associated in the case of SPAG8 ascribing these
genes as novel members of the CT antigen group, while
anti-SPAG16-L antibodies are equally present in healthy
individuals and gastritis patients leaving its CT antigen
status in question.
SPAG1, a protein involved in G protein coupled
receptor signaling during spermatogenesis and fertiliza-
tion59,60 and sperm mtDNA degradation in zygote,62,63 has
been earlier shown to be a progression marker of pancreatic
cancer and a cell motility factor.29 We, for the first time
show here that SPAG1 can be immunogenic and is up-
regulated prominently in lung and breast cancers, however,
relatively high expression in normal colon was also
detected, which correlates with gene array results presented
by the Genevestigator tool,55 noting that its application for
immunotherapy might not be straightforward.
The fresh appreciation of an organelle present on most
mammalian cells—the nonmotile primary cilium—as an
important signal transduction hook-up has lead to the
notion that centrosome and basal body (the nucleation
center of ciliary microtubules) are interexchanging struc-
tures that respond to cell cycle regulation, and that cilium
is necessary for the proper function of such crucial signal-
ing pathways as the Hegdehog, Wnt and PDGFalfa,
disruption of which results in various developmental
disorders and cancer.141 The proteome of primary cilium
has now extended to more than 2500 proteins, many of
which are shared between basal body and centrosome
and are involved in cell cycle checkpoints.142,143 It is
interesting to note that 8 of the 15 SPAG genes: SPAG2,
SPAG4, SPAG5, SPAG6, SPAG8, SPAG15, SPAG16, and
SPAG17 have been shown to participate in centrosome
and/or cilium-related events.
Initially identified as a sperm acrosome protein
recognized by sperm agglutinating antibodies and necessary
for sperm-egg binding,19,80 SPAG8 has also been shown to
participate in G2/M phase regulation delaying the exit form
mitosis when overexpressed in CHO-K1 cells and coloca-
lizes with microtubule organizing center (MTOC) in
prophase and spindle microtubules during metaphase.83
MTOC nucleates microtubules in both, cilium (basal body)
and mitotic spindle (centrosome), and it would be of
interest to determine whether the disbalanced expression of
SPAG8 might participate in ciliary or mitotic defects. A
relation of SPAG8 to oncogenesis comes from a study, in
which cDNA microarrays showed a 5-fold overexpression
in the more aggressive HPV18-type cervical carcinoma
when compared with normal cervical epithelium.32 It is
interesting to note that our IHC results showed strong
cytoplasmic and possibly membranal staining of distinct
cells in the parabasal layer of ectocervix and, considering
the frequency of the stained cells, they might correspond to
the stem cells of this squamous-stratified epithelium. The
basal and parabasal level of ectocervix is thought to be the
location of the cervical squamous epithelium stem cells144
and the HPV-induced cervical carcinogenesis is thought to
arise from the deregulation of these stem cells.145 It would
be interesting to see if SPAG8 colocalizes to the same cells
as the currently suggested cervical stem cell markers CK17
and p63145 and whether its MTOC-related activities could
be involved in the development of HPV-induced cervical
cancer. In addition, we saw the staining of distinct cells in
the glandular epithelia of the breast and stomach and the
overexpression in the corresponding tumors was seen with a
tendency to decrease with tumor stage and was not detected
in any of the metastasis samples. In accordance with this
observation, the autoantibodies were found mostly in sera
of chronic atrophic gastritis that is an early preneoplastic
condition, and sera of gastric cancer and melanoma
patients with stages I to III. It is tempting to speculate
that overexpression of SPAG8 could be advantageous for
tumor evolvement in certain contexts but it is lost during
tumor progression possibly owing to immune selection.
With this in mind, autoantibodies against SPAG8 could be
used as an early cancer biomarker; however, targeting of
SPAG8 in tumor immunotherapy might be jeopardized.
Nevertheless, the possible relation to stem cell functions
and surface localization might provide another axis of
treatment approaches using this antigen.
First described in Chlamydomonas flagellum SPAG6,
SPAG16-L, and SPAG17 have been shown to mutually
interact at the central apparatus of sperm axoneme—a
central duplet of microtubules that is characteristic to the
motile cilia, but is absent from nonmotile primary cilia, and
are necessary for flagellar motility.117,135 The expression of
SPAG6 has been described in tracheal and bronchial
epithelium77 and detected in other motile cilia-covered
epithelia of the respiratory tract as presented by gene array
data,55 in addition, it has been shown as a dynamically
exchanging basal body component.146 A double knockout
mouse model of SPAG6 and SPAG16-L showed early
mortality of litters owing to severe phenotypes of hydro-
cephalus and pneumonia indicating to their importance
in proper functioning of mucus and fluid-propelling motile
cilia, but not polycystic kidneys or left-right axis defects
characteristic to nonmotile and nodal ciliopathies.147 It is
not known how these proteins contribute to the motility of
mammalian cilia, as the ultrastructure of axonemes in the
deficient animals is normal.147
Only a few studies have related these proteins to
cancer. SPAG6 was reported to be overexpressed in the
bone marrow of AML patients and suggested as a marker
for minimal residual disease and relapse,78 whereas
SPAG17 has been suggested as a potential candidate gene
of thyroid cancer susceptibility.148 We have shown the
overexpression of SPAG6 mRNA in breast and lung cancer
specimens and verified this by IHC analysis. We also
detected SPAG6 protein in 1 out of 12 adjacent normal
breast samples and all adjacent normal lung alveoli
samples, while none of these tissues from cancer-free
individuals were positive. Whether the presence of SPAG6
in these adjacent normal samples represents a factor of
early premalignant transformation or is a particular tumor
microenvironment-induced phenomenon, remains to be
determined. Taking into account the functional involve-
ment of SPAG6 in the motile cilia of the brain and the
respiratory tract, it’s targeting in cancer immunotherapy
raises caution. Our IHC results showed, however, that the
overexpressed SPAG6 protein in breast and lung cancer
had perinucleolar, nuclear, and cytoplasmic subcellular
localization patterns, indicating to other possible functions
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of SPAG6 besides participation in the motile cilium. The
observed humoral immune response in cancer patients
against transcripts of SPAG6 might also suggest that its
ectopic overexpression can be immunogenic. Further
studies are warranted to reveal the functional significance
of SPAG6 overexpression and to define the molecular
alterations underlying its ectopic expression and possibly
motile cilium-unrelated activities in cancers, and might
result in the identification of epitopes distinct from the
normal ciliary SPAG6 providing ground for tumor-
associated SPAG6 targeting.
SPAG17 showed testis-selective expression pattern
and was upregulated in lung and gastric tumors, whereas
its minor splice variant SPAG17-A1 was testis-restricted
and present in a portion of lung and breast tumors, but it is
not yet clear whether the low-level mRNA of SPAG17-A1
could result in significant quantity of protein; nevertheless,
exactly this isoform is recognized by high titer autoanti-
bodies in late-stage gastric cancer sera. The low-antibody
signal against SPAG17-A in SPAG17-A1 reactive sera
might represent a weak cross-reactivity between these splice
variants. Testis is an organ with one of the most diverse
transcriptomes owing to vastly rich alternative splicing. We
and other researchers have earlier suggested that the
deregulation of alternative splicing in cancer can result in
the recognition of such testis-restricted splice sites, leading
to production of immunogenic isoforms of otherwise
tolerated proteins.149–151 We show here for the first time a
testis-restricted splice variant-specific immune response and
suggest that such antigens are designated to a separate
category called CT-spliced antigens. Further studies of
SPAG6 and SPAG17 alternative isoform expression in
various tumors and the capability to elicit protective
T helper and/or CTL responses in patients bearing
SPAG-positive tumors are warranted and ongoing.
Furthermore, it would be of interest to find out whether
these SPAG proteins might also participate in primary
cilium regulated signaling pathways related to oncogenesis
if their natural organelle—the motile cilium—is absent.
In conclusion, we have determined the expression
pattern of SPAG genes in various normal tissues and
showed that only 5 of the 15 genes in the SPAG group are
actually testis-selective, although the earlier considered CT
genes SPAG4 and SPAG9 are expressed in several normal
tissues in comparable levels with the testis. Expression
analysis in various tumor types revealed upregulation of
SPAG1, SPAG6, SPAG8, the splice variants SPAG16-L,
SPAG17-A, and novel testis-restricted alternative splice
variant SPAG17-A1. Cancer-related humoral immune res-
ponse was found against SPAG1, SPAG6, SPAG8, and
SPAG17-A1, thus showing these as novel CT antigens that
might be useful as cancer serum biomarkers. In addition,
transcripts of SPAG6 and SPAG17-A1 are potential
candidates for cancer immunotherapy.
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Supplemental Digital Content 1. Table – recombinant T7 phage displayed antigens used 
for microarray production. 
 
Antigen Length of cloned antigen, aa Aa position in full length sequence Genbank accession number 
CTAG1B  105 1-105 NM_139250.1 
HORMAD1 289 34-312 NM_032132.3 
MAGEA1 129 1-129 NM_004988.4 
SPAG1 215 1-215 NM003114 
SPAG6-A1 235 217-451 HM370395 
SPAG6-A 293 217-509 NM012443 
SPAG6-B 242 217-458 NM172242 
SPAG8-e2L 91 9-99 NM001039592 
SPAG9-A 127 234-360 NM001130528 
SPAG9-C 113 234-346 NM003971 
SPAG16-L 223 409-631 NM024532 
SPAG17-A 286 708-993 NM206996 
SPAG17-A1 115 708-822 HM370394 
 
Supplemental Digital Content 2. TIFF – Non-redundant alternative transcripts and RT-
PCR amplification and phage-displayed antigenic regions. 
 
 
The schematic structure of the unique alternative transcripts of SPAG genes deposited in the NCBI AceView database as well as 
transcripts identified by us (SPAG6-A1, SPAG17-A1) and other authors (SPAG1 with reference in parenthesis) is displayed. The size 
ratios of the exon and intron items are not proportional to their actual size ratios. An exon was considered as alternative (white boxes) if 
there was at least one complete transcript lacking it. The transcript nomenclature and complete or incomplete ends (approved 
transcription initiation and/or termination sites) are as in the AceView database. The amplification of isoform-specific regions (green 
boxes) was ensured by using primers in the unique exons or exon-exon border spanning primers. 
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Spontaneous T cell immune response against an antigen indicates to an increased 
possibility to induce a response against that antigen also in therapy. The molecular and 
immunological techniques used to analyse spontaneous as well as therapy-induced T cell 
responses are mostly based on the assessment of T cell proliferation potential, produced 
cytokine profile and the ability to lyse the antigen positive target cells. The analysis of 
antibody responses has been routinely used by infectologists already for a long time with 
the most popular method being ELISA, and one of the most widely used T cell activation 
assays is based on the same principle and is called ELISPOT. This assay can give 
information also about the functional and cytolytic activity of tested T cells by utilising 
various cytokine as well as granzyme B and/or perforin-specific detection antibodies127. 
We collected PBMCs from five healthy donors, 11 breast and 11 gastric cancer 
patients. A pool of viral peptides and the well-known immunogenic CT antigen NY-ESO-1 
were chosen to develop T cell activation protocol, and two of the promising candidate 
antigens LRRC50 and SPAG8 were selected for spontaneous CTL response analysis by 
using IFN! ELISPOT (Mabtech, Sweden) in patients with upregulated antigen expression 
in their tumour tissues or with autoantibody response.  
3.6.1 The optimisation of T cell pre-sensitisation assay 
As tumour antigen-recognising T cells tend to be very rare in patients blood, ex vivo 
(directly from blood) ELISPOT has been reported to work poorly, thus T cell pre-
sensitisation with antigenic peptides is suggested to amplify the specific effectors. 
However, several different T cell pre-sensitisation protocols exist. Major variations are 
introduced by (i) the cytokine usage (IL-2 alone or in combination with IL-7), (ii) number 
of peptide restimulation cycles (one versus several (2 and more), with or without additional 
APCs), (iii) T cell numbers per stimulation (from 5x105 total PBMCs to 5x105 of purified 
CD8+ T cells), (iv) peptide purity, length and final concentration in the stimulation, as well 
as (v) target cell types in ELISPOT (EBV transformed B cells, PHA stimulated CD4+ 
cells, autologous PBMCs, T2 cell lines etc.), not to mention (vi) reagents from different 
manufacturers that can influence the outcome of the stimulation. We took part as one of the 
international partner laboratories in a project aimed at the development of standardized 
ELISPOT assay and the obtained results are reported in the original paper IV. However 
this project didn’t address the variations in the pre-sensitization step of the T cell analysis. 
The initial protocol was designed to compare the impact of the number of peptide 
stimulations on the expansion of antigen specific effector CTLs in PBMCs of five healthy 
donors. Three stimulations were compared to two and to one and the results were 
determined by IFN! ELISPOT using pool of peptides from CMV, EBV and flue viruses 
(CEF) (CTL Ltd, USA). It is evident that a single stimulation yields the highest number of 
reactive cells comparing to two and three stimulations with viral control peptides, and was 
chosen as the further work setting (Figure 8A). Secondly, it demonstrated that the 
stimulated cells have expanded significantly comparing to the non-stimulated samples 
(CD8+ T cells extracted from freshly thawed PBMCs on the day of ELISPOT) showing 
that the chosen pre-sensitisation setting is appropriate for effector CTL in vitro propagation 
(Figure 8A). 
However, the number of viral peptide-specific CTLs in PBMCs is relatively very 
high (5-20%) and this analysis doesn’t grant the detection of rare cancer antigen-specific 
CTLs (<0.01%). Hence we used one of the most immunogenic tumour antigens NY-ESO-1 
to test this protocol on a NY-ESO-1 serum-positive gastric cancer patient and five healthy 
donors for the presence of specific CTLs. Figure 8B displays the obtained results from 
!""#!
duplicated IFN! ELISPOT wells from two separate experiments. The CTL activation was 
observed in one healthy donor, indicating that the elaborated experimental setting allows to 
detect the presence of rare tumour-antigen specific CTLs, however it is not clear if 
effector/memory or naïve CD8+ T cells were activated. 
 
 
 
!"#$%&'()!"#$%&%'($%)*!)+!,!-.//!(-$%0($%)*!#1)$)-)/2!
3456!,!-.//'!7.1.!'.#(1($.8!+1)&!$)$(/!9:;3'!<'%*=!&(=*.$%-!>.(8'!(*8!<'.8!+)1!#.#$%8.!'$%&</($%)*'2!,!-.//!(-$%0($%)*!7('!(*(/?'.8!
(+$.1! @A! 8(?'! )+! -</$<1.! >?! BCD!! EFBG9",H! 7I%-I! 7('! 8.0./)#.8! (+$.1! )0.1*%=I$! %*-<>($%)*! <'%*=! >%)$%*%/($.8! (*$%JBCD!! 8.$.-$%)*!
(*$%>)8?!(*8!G$1.#$(0%8%*JGK9!-)*L<=($.!7%$I!:3B9MD:,J#/<'!'<>'$1($.!+)1!-)/)<1!8.0./)#&.*$2!9/($.'!7.1.!'-(**.8!(*8!(*(/?'.8!>?!
$I.!3,F!E<1)#.!G-K*(/?'%'!'.10%-.!<'%*=! B&&<*)G#)$!N2A2O2!')+$7(1.2!,I.!'#)$!*<&>.1! %*!$I.!*.=($%0.!-)*$1)/!7.//'!7('!'<>$1(-$.8!
+1)&!$I.!'#)$!*<&>.1!%*!$I.!'$%&</($%)*!7.//'2!,I1.'I)/8!)+!3,F!(-$%0($%)*!7('!'.$!('!$7%-.!$I.!*<&>.1!)+!'#)$'!%*!$I.!*.=($%0.!-)*$1)/!
7.//'!#/<'!$.*!'#)$'2!P!(Q%'!%*8%-($.'!'#)$!*<&>.1'2!*!RQ@AR!3456!,!-.//'!+1)&!+%0.!I.(/$I?!8)*)1'!7.1.!'..8.8!%*!.(-I!)+!$I1..!7.//'!
+)1! .(-I! 8)*)1! (*8! '$%&</($.8!7%$I! %11(8%($.8! (<$)/)=)<'! 345J34RJ! 9:;3'! SRQ@ANT! #</'.8!7%$I! #)'%$%0.! -)*$1)/! 0%1(/! #.#$%8.! #))/!!
S3ECT!S@µ;!.(-I!#.#$%8.T!)*!-</$<1.!8(?!@2!G.-)*8!(*8!$I%18!7.//'!7.1.!'$%&</($.8!7%$I!#.#$%8.!#</'.8!K93'!(88%$%)*(//?!+)1!.%$I.1!
)*.!)1!$7)!$%&.'!)*!8(?'!R!(*8!UH!1.'#.-$%0./?2!K+$.1!@A!8(?'!@M@A$I!)+!$I.!-</$<1.8!-.//'!7.1.!'..8.8!%*!.(-I!)+!$I1..!BCD!!EFBG9",!
#/($.!7.//'!(*8!#.#$%8.!#</'.8!(<$)/)=)<'!9VKJ'$%&</($.8!34R6!,!-.//'!S@ANM7.//T!7.1.!(88.8!('!$(1=.$!-.//'!%*!'.1<&!+1..!&.8%<&!$)!
$7)!7.//'! +)1! ,! -.//! (-$%0($%)*! (*(/?'%'H! (*8! $(1=.$! -.//'!7%$I)<$! #.#$%8.!7.1.! (88.8! $)! $I.! $I%18!7.//! +)1! *.=($%0.! -)*$1)/2! 3)/)*'!
1.#1.'.*$!$I.!(0.1(=.!'#)$!*<&>.1!)+!$I.!+%0.!8)*)1'!(*8!.11)1!>(1'!%*8%-($.!'$(*8(18!.11)1!)+!$I.!&.(*!(&)*=!$I.!+%0.!8)*)1'2!W!(Q%'!
1.#1.'.*$'!$I.!*<&>.1!)+!'$%&</($%)*'!#.1!-</$<1.X!@'$!Y!'%*=/.!'$%&</($%)*!)*!-</$<1.!8(?!@H!Z'$!Y!$7)!'$%&</($%)*'H!7%$I!$I.!'.-)*8!
'$%&</($%)*!)*!-</$<1.!8(?!RH!O!Y!$I1..!'$%&</($%)*'H!7%$I!$I.!$I%18!'$%&</($%)*!)*!-</$<1.!8(?!UH!DG!Y!*)*J'$%&</($.8!+1.'I/?!$I(7.8!
(*8! '.#(1($.8! 3456! ,! -.//'2! +! RQ@AN! 3456! ,! -.//'! +1)&! +%0.! I.(/$I?! 8)*)1'! (*8! )*.! =('$1%-! -(*-.1! #($%.*$! 7.1.! '$%&</($.8! 7%$I!
%11(8%($.8!(<$)/)=)<'!345J34RJ!9:;3'!SRQ@ANT!#</'.8!7%$I!DPJEG"J@!#.#$%8.!#))/!S@µ;!.(-I!#.#$%8.T!(*8!-</$<1.8!+)1!@A!8(?'2!K+$.1!
@A!8(?'!@MO!)+!$I.!-</$<1.8!-.//'!7.1.!'..8.8!%*!.(-I!)+!$I1..!BCD!!EFBG9",!#/($.!7.//'!(*8!#.#$%8.!#</'.8!(<$)/)=)<'!9VKJ'$%&</($.8!
34R6!,! -.//'! S@ANM7.//T!7.1.!(88.8!('! $(1=.$! -.//'! %*! '.1<&! +1..!&.8%<&!$)! $7)!7.//'! +)1!,! -.//! (-$%0($%)*!(*(/?'%'H! (*8! $(1=.$! -.//'!
7%$I)<$!#.#$%8.!7.1.!(88.8!$)!$I.!$I%18!7.//!+)1!*.=($%0.!-)*$1)/2!3)/)*'!1.#1.'.*$!$I.!(0.1(=.!'#)$!*<&>.1!+1)&!$7)!.Q#.1%&.*$'!
+)1!.(-I!%*8%0%8<(/2!E11)1!>(1'!%*8%-($.!'$(*8(18!8.0%($%)*!)+!$I.!1.#/%-($.'2!W!(Q%'!1.#1.'.*$'!#($%.*$!(*8!I.(/$I?!8)*)1!-)8.'2!
3.6.2 Selection of patients for T cell activation analysis 
To select patients for the analysis of spontaneous CTL responses we looked for those 
showing (i) overexpression of LRRC50, SPAG8 or NY-ESO-1 mRNA in tumours by using 
qPCR (Figure 9), and (ii) the presence of corresponding autoantibodies in their sera by 
using phage-displayed antigen microarrays (Table 6). A gene was considered as 
overexpressed in a tumor sample if the expression value in the tumor sample exceeded that 
of the adjacent normal sample by at least two fold and the average value of all normal 
samples by at least three fold to account for the interindividual gene expression variations. 
A prominent overexpression of NY-ESO1 was observed in two breast cancer patients 
(Figure 9A) of stages I and IIIA (Table 3). We didn’t detect any expression of NY-ESO-1 
in any available gastric cancer specimens (data not shown). The upregulation of SPAG8 
was observed in two breast cancer specimens with early stage disease (I and II), while no 
prominent overexpression was seen in gastric cancer tissues for which the paired PBMC 
samples were available (Figure 9B), however the patient with the highest SPAG8 level in 
the tumour tissue was selected for T cell activation assay. LRRC50 was elevated in cancer 
! ""#!
tissues of four patients with breast cancer and three patients with gastric cancer (Figure 9C) 
stages I-IV. Table 6 displays the summary of obtained mRNA expression and autoantibody 
data, and the patients selected for T cell activation analyses of the corresponding antigens. 
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Table 5. Summary of mRNA expression and autoantibody data in patients with 
collected PBMC samples. 
 
Overexpression in tumour Serum autoantibodies Cancer type Patient number NY-ESO1 SPAG8 LRRC50 NY-ESO1 SPAG8 LRRC50 T cell activation assay 
Breast 18 - - - - - - - 
 19 - - + - - + LRRC50 
 21 - - - - - - - 
 22 + + - - - - NY-ESO-1, SPAG8 
 23 - - - - - - - 
 24 - + + - - - SPAG8, LRRC50 
 25 - - - - - - - 
 26 - - - - - - - 
 27 + - - - - - NY-ESO-1 
 28 - - + - - + LRRC50 
 30 - - + - - - LRRC50 
Gastric 478 - - + - - - LRRC50 
 479 NA NA NA - - - - 
 480 - - - - - - - 
 482 - - + - - - LRRC50 
 483 NA NA NA - - - - 
 484 - - + - - - LRRC50 
 485 NA NA NA + - - NY-ESO-1 
 486 NA NA NA + - - NY-ESO-1 
 487 NA NA NA - - - - 
 488 - - - - - - - 
 489 - - - - - - SPAG8 
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3.6.3 Analysis of naturally occurring antigen-specific CD8+ T cells in breast and gastric 
cancer patients. 
We selected the patients indicated in Table 4 as well as five healthy donors for the 
LRRC50, SPAG8 and the control antigen NY-ESO-1-specific naturally occurring CTL 
activation analyses by using IFN! ELISPOT using the CEF peptide pool as the positive 
control. We didn’t detect any plausible LRRC50 or NY-ESO-1-specific CTL responses, 
but this initial analysis showed SPAG8-specific CD8+ T cell amplification in one gastric 
cancer patient (G489) (Figure 10). None of the healthy donors showed any response to the 
tested cancer antigens (data not shown) except for NY-ESO-1 (Figure 8B). 
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4 Discussion 
During the adaptive immune response effector lymphocytes engage in a complex 
mutual regulatory network, which ensures the fine-tuning of the dominant effector mode 
differentiating mostly into type 1 and type 2 responses, as well as regulates the extent and 
duration of the immune response. Such regulatory loops are necessary to fine-tune the 
defence against the vast universe of pathogens and to ensure the best balance between the 
destructive and self-preserving capacities of the immune system128, sort of a “most benefit, 
least damage” principle. Recent studies have revealed a cornucopia of inter-relationships 
between adoptive lymphocytes and tumour cells, tumour stroma and cells of the innate 
immunity that are important for the course of malignancy resulting in either predominantly 
preventive or promoting influences as dictated by the polarisation into type 1 or type 2 
responses, respectively103. For example, Th1 cells have evolved to fight intracellular 
pathogens by promoting CTL activation at the site of infection, while Th2 cells are the 
major regulators of extracellular pathogen eradication promoting IgE class antibody 
production and attracting eosinophils and granulocytes – potent inflammatory effectors of 
the innate immunity to the infection site, hence the opposing contribution to cancer 
development by determining cytolytic versus inflammatory environments103. Thereto the 
type 1 or Tc1 (conventional) CTLs have been recognised as more potent effectors of 
tumour cell eradication than the Tc2 cytotoxic CD8+ T cells129 as they showed prolonged 
survival, efficient cytotoxicity and skewing Th cells towards type 1 response130. However 
the type 2 Th and CTL effectors have also been shown to be important for tumour 
clearance in certain circumstances76. These data collectively indicate that one needs not 
only to induce an immune response against a tumour, but also trigger the “right type” of 
immune response in the right context to achieve a clinical benefit106. 
CTLs have been in the spotlight in attempts to induce a protective cytolytic response 
owing to their perforin and granzyme B mediated tumour cell killing abilities important in 
fight against all tumours, but especially those that have downregulated cell-cell contact-
dependant death receptor (as FAS, TRAIL, etc.) signalling. A lot of studies have 
concentrated to the identification of antigens and their CTL epitopes for immune 
stimulation. However, CTLs themselves don’t posses a considerable capacity to induce 
further amplification of immune response due to various intrinsic self-tolerance 
mechanisms as AINR27 etc. This together with the local suppressive tumour 
microenvironment are mostly the reasons why initial immunotherapies utilising simply 
MHCI-binding peptides as CTL epitopes or the administration of antigen-specific in vitro 
propagated CD8+ T cells didn’t deliver the expected hopes. 
The understanding of Th cells as the orchestrators of both, the differentiation and 
amplification of the immune response, has shifted the attention towards CD4+ T cell 
adaptive therapy that has a potential to provide polyclonal, integrated B cell and CTL 
activation131. Besides, a direct cytolytic activity of CD4+ T cells has been readily 
demonstrated, hence these cells could provide a substantial improvement in current 
immunotherapy statistics132. The scene has become increasingly complicated, however, 
with the identification and characterisation of a myriad of functionally distinct Th cell 
subsets as well as the mechanisms of DC maturation into various phenotypes that can 
differentially influence effector cells133. For example, activated Th17 cells that have been 
considered as important players in organ-specific autoimmune diseases are the major 
producers of IL-21, a cytokine shown to have positive effect on anti-tumour CTLs134, and 
the differentiation of this subset is dependant on high TGF! levels that is a major 
suppressive cytokine135. Another recent capacity of type 2 cytokine IL-4 together with 
TGF! is to inhibit the differentiation of Treg cells that are important anti-tumour immunity 
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suppressors, but instead induce the formation of IL-9 producing effector cells or Th9 
cells136 that again, depending on the context, can be regulatory or inflammatory133.  
Also B cells have provided new surprises starting from the discovery of regulatory 
subtypes to their importance in Th cell stimulation besides their primary task as antibody 
producers68,137, and no longer should be referred to as “B for boring”. Analogously to T 
cells, they can modulate dendritic cells by promoting or inhibiting their maturation as well 
as skew Th cell subset differentiation at the tumour site depending on the secreted 
cytokines and antibodies, and again the tumour promoting capacity is more ascribed to the 
Be2 subtype cells, while protective – to the Be1 type effectors76,138. The role of anti-tumour 
antibodies, however, is under intense debate. These antibodies have been correlated with 
pro-tumour and pro-inflammatory roles, poor prognosis and increased tumour burden76, as 
well as to quite contrary observations related to increased survival and better prognosis139. 
It should be bared in mind that the outcome of antibody presence in the tumour 
microenvironment is dictated by (i) the secreted Ig class subtype and the balance of 
activating versus inhibitory Fc receptors on other effector cells recognising antibody-
containing immune complexes on tumour cells70 and of course by (ii) the surrounding 
cytokine milieu103. Here mentioned players are just a tip of the iceberg of the complex 
nature of the immune response involving also the innate mechanisms, and hence also the 
concept of the “right adjuvant”, or closer the “right cocktail of adjuvants” to activate DCs 
and mount the protective type immune response together with dampening of suppressor 
cell activities is crucial for successful immunotherapy development106. 
Besides the “right immune response” and the “right adjuvants” the importance also 
lays on the target itself – “the right antigen” or the combination of those must be 
recognised in order to ensure tumour eradication without inducing autoimmunity and 
avoiding tumour escape106. The comprehension of the destructive power of the adaptive 
immunity as well as the initial animal experiments with chemically inducible tumours 
suggested that the most suitable anti-tumour targets are the mutated neoantigens formed in 
cancer due to profound genetic instability because (i) these are tumour-specific without the 
risk of destroying healthy tissues and (ii) they wouldn’t be centrally tolerated140. A shift in 
this paradigm came in the middle of 90’ties when melanoma rejection in patients was 
shown to be mediated by wild-type melanocyte protein-specific CD8+ T cells, as well as 
studies demonstrating the manifestation of vitiligo only for patients with regressing 
tumour, providing evidence for the induction of protective immune response against the 
so-called tumour-associated antigens that are self-proteins overrepresented in tumours141. 
Tumour-associated antigens possess a threat to induce autoimmunity, hence only antigens 
shared between tumours and immunoprivileged sites or non-vital organs might be 
considered for therapy targeting by forced blocking of tolerance and bearable collateral 
damage142. The major advantage of the tumour-associated over tumour-specific antigens is 
that they are shared among many tumours and may provide the opportunity to develop a 
cost-effective cancer vaccine, while tumour-specific antigen targeting implies (i) the 
necessity to characterise each patient’s tumour as well as to generate the tumour-specific 
targets that most often are unique to each patient 1 or (ii) the application of whole tumour 
vaccines that don’t allow the monitoring of therapy induced-immune responses. However, 
until now there is no consensus on which of these two antigen categories are more suitable 
for the development of immunotherapy used in every-day practice. Recently guidelines for 
the prioritisation of antigens applicable in clinical trials have been published and state that 
the ideal therapy target is both, tumour-specific and shared among many tumours6 
emphasising the need to balance the beneficial treatment outcome with cost-effectiveness 
and labour-intensiveness. The top five antigens rated using these guidelines developed by a 
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large panel of experts are the CT antigen WT1, followed by MUC1, two viral antigens 
LMP2 and HPV E6 E7, and the tumour-specific antigen EGFRvIII6. 
In this work we have tried to approach the “right antigen” problem. Knowing that in 
order to produce IgG class-switched antibodies a B cell has to receive proper help from a 
CD4+ T cell that has been activated by the same antigen, and considering the involvement 
of B cells in modulation of T cell activities, the antigens identified by the utilisation of IgG 
antibody-based approaches may yield important therapeutic targets. Studies utilising 
cDNA expression library screening with cancer patients’ sera or the SEREX approach have 
yielded the identification of therapeutically significant cancer antigens like NY-ESO-1143, 
and provide ground for the usefulness and potential of this system to discover novel 
immunotherapy candidate genes. As well the fact that a spontaneous B cell response is 
observed against antigens currently used in immunotherapy trials indicates that antigens 
eliciting humoral response might have a better chance to induce immune response also in 
therapy. We applied phage-display based SEREX to identify a comprehensive set of 
tumour antigens that could be used in early diagnosis, prognosis and prediction of therapy 
outcome for melanoma, breast, gastric, and prostate cancers (144 and unpublished results), 
which resulted in the identification of 1328 antigenic clones representing 1158 non-
redundant antigens. In this study we attempted to characterise the identified antigens and 
determine whether there might be any therapeutic targets among them that correspond to 
the established criteria for a potential immunotherapy target antigen6. 
The antigen collection is comprised of conventional natural ORF antigens (15%), 
undefined ORF antigens (2%) that include uncharacterised splice variants and novel genes, 
and clones translated as unnatural peptides (83%). Such a large number of unnatural ORF 
antigens has also been reported by other groups using phage-display technology145 and to a 
lesser extent also conventional SEREX. We looked into more detail of the recognition of 
these peptides to see if the corresponding antibodies indeed react with this unnatural 
product of a gene and not with its natural ORF counterpart that could had been displayed 
on the phage due to possible mutations in the phage genome causing translational shift, and 
we showed that the unnatural peptides were undeniably recognised by the reacting sera 
(see original paper I). 
Around one half of the unnatural peptides are derived from inserts of non-cDNA 
nature including intergenic regions despite stringent DNAse treatment prior to cDNA 
library construction144, which might indicate to a broader transcriptome than previously 
anticipated supporting the recent acknowledgement of the wide world of non-coding 
RNAs146,147. It is not known whether any of the non-coding, particularly the long non-
coding, RNA species could actually be used by the translation machinery as a result of 
deregulation in cancer and most likely represent mimotopes of other antigens like proteins 
with changed structure including altered PTMs or lipid and carbohydrate epitopes; the 
latter two represent mostly B-cell epitopes148. 
The concept of mimotopes developed subsequently after the realisation that antibody 
cross-reactivity is a common phenomenon because a limited degree of similarity between 
an epitope and a paratope is sufficient to allow the peptide to bind to an anti-protein 
antibody149. The great proportion of mimotopes among the identified phage-displayed 
antigens might be explained by the fact that the vast majority of protein epitopes are the so-
called conformational or discontinuous epitopes dictated by the natural conformation of the 
protein149, and there are several reasons why the probability for an antibody to meet its 
mimotope in this system is much higher than to meet its true discontinuous epitope: (i) it is 
often that these epitopes are not preserved on the recombinant phage because usually only 
a fragment of the whole protein is cloned as well as due to the lack of eukaryotic PTMs in 
the bacterial cloning system, and (ii) there is a plethora of out-of-frame peptides in the 
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phage-displayed cDNA library due to the randomness of cloning creating a sufficient 
diversity of peptides resembling the true discontinuous and PTM-mediated epitopes. This 
also answers the question why there are so few natural ORF antigens among the identified 
clones – as there is only a fragment of a protein displayed on the recombinant phage this 
antigen might more often represent true linear epitopes, which are per se more rare than the 
discontinuous ones. This notion is also supported by our results showing that only one out 
of eight tested phage-displayed natural ORF antigens represented a discontinuous epitope 
(see original paper I). 
Lately peptide mimotopes have been suggested for cancer vaccine development as 
they can have the immunogenic potential to elicit stronger recognition of cancer antigens 
of both, protein and non-protein nature like the tumour-associated carbohydrate antigens 
GD2 disialoganglioside and CEACAM-5 glycoprotein, as well as provide a compact 
immunisation agent that can be coupled to additional stimulants of immune response84. 
However, to consider the use of a mimotope instead of its corresponding epitope for 
therapeutic applications it is also necessary to show that this peptide can induce the 
formation of the antibodies recognising the initial protein and not just bind the same 
antibody as the antibody-binding pockets may be different for both peptides and hence the 
immunisation may not yield the response recognising the mimicked antigen 149. There were 
several unnatural peptide antigens in our collection that were recognised by cancer sera 
antibodies with statistical significance (Zayakin P et al., article in preparation) and there 
might be potentially useful therapeutic mimotopes among them. 
The natural ORF antigen category comprised 130 non-redundant antigens among 
which 46 were well-characterized CT antigens like the members of CTAG, MAGE etc. 
families, 5 were autoantigens such as ANXA11 150, and AKAP12 151 known to induce 
antibody production in autoimmune disorders, 20 were antigens that have been previously 
identified by conventional SEREX, 34 antigens were from protein families whose other 
members have been detected by SEREX, and 25 were novel antigens against which no 
immune response has been reported before. The analysis of the natural ORF antigen clone 
sequences revealed that all of them were wild-type proteins and no mutations were found, 
but uncharacterised alternative splice variants (ASVs) were detected for three antigens. 
Also it is not excluded that mutations, splicing defects, chromosomal translocation or 
altered PTMs outside the cloned region could have caused structural changes revealing 
otherwise hidden regions to the antigen presentation machinery leading to the immune 
recognition of an otherwise tolerated protein149, however this was not studied in the current 
work. Another reason of the immunogenicity of a wild-type protein is its ectopic 
expression or overrepresentation in cancer. To identify novel potential immunotherapy 
targets we selected all uncharacterised antigens and subjected these to a number of 
prioritization criteria in order to select the most interesting candidates for mRNA 
expression analyses. First, antigens recognised by cancer-related autoantibodies were 
identified by using our custom antigen microarray comprising 1158 antigens and non-
recombinant phage controls for screening of sera from 190 melanoma, 173 gastric, and 13 
breast cancer patients as well as 153 healthy donors. 50 natural ORF antigens showing 
cancer-related autoantibodies were further prioritised by the autoantibody frequency in 
cancer patients, their EST profile comparing normal to tumour and germ cell tissues, their 
putative involvement in oncogenesis and their structural motifs, putting a negative mark on 
coiled-coil domains, which are known as structures often recognised by cross-reactive 
antibodies, and a positive mark on surface localised antigens as they allow the 
development of additional antibody-based therapeutics. 23 top rated natural ORF antigens 
and five cancer-related undefined ORF antigens representing novel genes were subjected 
to mRNA expression analysis in various normal tissues and tumour-normal tissue pairs of 
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melanoma, gastric and breast cancer patients to determine whether the altered expression 
level might be the reason of immune recognition in cancer and to discern possible 
therapeutic targets (see original paper II). 
We report here for the first time the connection of LRRC50 to cancer, and have 
shown it as a frequent breast and melanoma cancer antigen. Previous studies analysing 
patients with situs inversus and reduced muco-ciliary clearance of the respiratory tract have 
identified truncating mutation in LRRC50152 what relates it to the proper functions of 
motile cilia during both, embryogenesis and adulthood 153. A closely related structure – the 
non-motile primary cilium has been shown to be crucial for proper signalling during 
embryogenesis and adult tissue homeostasis through the Hedgehog, PDGFR!! and Wnt 
pathways 154, which are also deregulated in various cancers155-157. As there are no motile 
cilia on most cancer cells it would be interesting to determine if the overexpression of 
LRRC50 in tumour cells can participate in the signalling pathways of the primary cilium 
that promote the malignant phenotype. Our initial studies also indicate to the participation 
of LRRC50 in mitosis (unpublished observations), which might suggest another possible 
link to oncogenesis. The second novel CT antigen ESCO1 is an acetyltransferase involved 
in sister chromatid cohesion and DNA repair 158, and if its expression or function is 
deregulated it may contribute to the genetic instability 159. We have demonstrated for the 
first time a cancer-associated immune response against ESCO1 with significant 
overexpression in melanomas. Further analyses of protein expression in cancer and normal 
tissues and the oncogenic potential of these genes will allow to assess their suitability for 
immunotherapy. 
Cancer-related autoantibody response and testis-associated expression among normal 
tissues were detected for four annotated genes with unknown functions (ALLC, 
C11ORF20, C16ORF82, and C21ORF66) and four novel genes (LOC284861, 
LOC392843, clone #232, and clone #200). The expression of the testis-selective genes, 
ALLC, C11ORF20, C16ORF82, and LOC284861, were also upregulated in some tumour 
samples and these might potentially be novel members of the CT antigen group. The testis-
restricted transcripts, C21ORF66, LOC392843, clone #232, and clone #200, were not 
detected in any analysed tumour samples, however they have been recognised by tumour 
autoantibodies and a larger sample size or different and more sensitive approaches directed 
to analysis of cancer stem cell population should be used to determine if they might 
represent genes expressed by seldom cancer stem cells as the germ cell-specific genes have 
been suggested to be involved in the control and establishment of stemness28,90. 
The cancer-related antigens ACTR2, SPARC, LIG1 and NOL8 have all been 
previously reported with potential implications in oncogenesis including cell motility160, 
metastasis through affecting extra-cellular matrix161,162, genetic instability163, and cellular 
growth164, respectively. We have shown that these genes are overexpressed in cancer, 
however the mRNA level in the overexpressed tumours didn’t exceed the level of other 
normal tissue types. We suspect that the immunogenicity of these proteins is defined by 
other molecular alterations, and they cannot be suitable immunotherapy targets unless 
cancer-specific epitopes can be identified. 
Among the 50 cancer-related natural ORF antigens there was also SPAG8, a sperm 
surface protein and a member of the sperm associated antigen group. SPAG proteins are 
expressed in germ cells and can induce immune response leading to infertility. Recently, 
implications in oncogenesis have also been demonstrated for several SPAG proteins, hence 
we decided to characterise this group of proteins to determine if there might be novel CT 
antigens among them with possible application in immunotherapy. The mRNA expression 
analysis showed that out of the 15 members only five genes SPAG1, SPAG6, SPAG8, 
SPAG15, SPAG17 and distinct isoforms of SPAG16 (SPAG16-L) were testis-associated. 
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All of these except SPAG15 were also upregulated in tumour tissues and cancer-related 
autoantibodies were found for SPAG1, SPAG6, SPAG8 and a testis-restricted splice 
variant of SPAG17 by screening a custom SPAG antigen microarray with sera from 543 
patients with various cancers assigning these as novel CT antigens. SPAG6, SPAG16-L 
and SPAG17 have been shown to be necessary for the motility of sperm flagella165,166 and 
other motile cilia of the human body, including epithelia of the brain and respiratory tract. 
167,168. Similarly to LRRC50 it would be of interest to determine if these proteins may 
participate in the non-motile cilium-mediated signalling and tumourigenic events. SPAG8 
has been shown to participate in the regulation of mitosis169, which could link it to the 
possible involvement in oncogenesis. In normal tissues this protein was detected only in 
rare cells of the parabasal layer of ectocervix and the glandular epithelia of the breast and 
stomach, and considering the frequency of the positive cells, they might be the stem cells 
of these epithelia providing additional ground for the therapeutic potential of this antigen 
(see original paper III). 
We and also other authors have suggested that deregulated alternative splicing in 
cancer can lead to the producing untolerised protein isoforms170-172 (see original paper IV). 
However, strictly cancer-specific splice variants generated by the recognition of the so-
called cryptic splice sites have been rarely reported in connection to their immunogenicity. 
One such example is demonstrated for the gene, HMSD, that possesses an intronic SNP in 
a consensus splice site leading to a novel immunogenic splice variant173. The data of 
alternative transcripts deposited in the AceView database174 as well as our previous 
bioinformatics analysis (unpublished data) suggest that such immunoprivileged tissues as 
testis and brain posses the largest variety of alternative transcripts among other normal 
tissues, and we proposed that it could be more often that alternative splicing deregulation 
created immunogenic protein isoforms in cancer due to ectopic recognition of such tissue-
restricted splice sites. To evaluate the possibility of alternative splicing deregulation to be 
the cause of the immunogenicity of antigens representing novel ASVs we also analysed 
their mRNA expression in various normal and tumour-normal tissue pairs. We showed that 
novel splice variants of CFL1 and COX6B2 were testis-selective and also elevated in some 
cancer samples, while the novel transcript of TEF that was frequently recognised by cancer 
antibodies and the novel ASV of EVI5L were not detected in any sample, and further 
experiments are necessary to relate the deregulation of alternative splicing to the 
immunogenicity of these antigens. Another novel testis-restricted splicing isoform with 
overexpression in cancer was identified for SPAG17, and for the first time we 
demonstrated a testis-restricted splice variant-specific humoral immune response in cancer 
patients. We suggest that such antigens are designated to a separate category called CT-
spliced antigens, as the mechanism of their production is different from the CT antigens 
namely alternative splicing errors rather than transcription deregulation. However their 
potential for immunotherapy application needs to be studied further as their expression can 
be very heterogeneous in the same tumour dictated by the splicing events in each cell that 
are not inherited across cell divisions and they are met in lower level simply because they 
represent only a fraction of the total mRNA pool of the corresponding gene, nevertheless 
they can provide novel tumor-specific targeting approaches with defined epitopes as well 
as might represent functionally important protein alterations in cancer. 
To assess naturally occurring T cell responses against two immunotherapy candidate 
antigens LRRC50 and SPAG8 we chose to apply one of the most sensitive and commonly 
used T cell activation methods - the ELISPOT assay. There are many different protocols 
for the activation and culturing of T cells prior to ELISPOT as well as for the ELISPOT 
procedure itself that can lead to different results among various laboratories and poor 
reproducibility. We participated in an international collaboration project, NEUCAPS, 
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which was aimed to determine the main reasons of the variability of obtained ELISPOT 
results among several laboratories and to develop a standardised, reproducible and robust 
ELISPOT assay (see original paper V). The protocol developed as a result of this project 
was adapted for our T cell analysis. However, to detect rare tumour antigen-specific T 
cells, it is necessary to propagate them prior to ELISPOT assay by at least 10 days of 
culture in the presence of the target antigen. In order to determine the best conditions for 
the T cell pre-sensitisation, we optimised the number of peptide additions used for T cell 
activation and found that a single stimulation gave the highest number of reacting cells. 
This setting was suitable also for the detection of NY-ESO-1-specific CD8+ T cells. Six 
breast and six gastric cancer patients were analysed for the presence of naturally occurring 
CTLs against LRRC50 and SPAG8, and SPAG8-specific CTL response was detected in 
one gastric cancer patient. However, the population of naïve CTLs was not subtracted prior 
to CD8+ T cell stimulation, thereto the mRNA level of SPAG8 in the tumour tissue of the 
gastric cancer patient didn’t exceed the level in the adjacent normal tissues raising 
suspicion that naïve CTL activation was induced. The stimulation should be repeated with 
a RA45+ depleted CD8+ T cell population to draw certain conclusions, nevertheless this 
result shows that the pool of the predicted SPAG8 peptides contains some that can indeed 
bind to the MHCI molecules and that SPAG8 is capable to induce a CTL response. 
In order to successfully manipulate adoptive immune response one has to decipher 
the extremely complex, mutually regulating interactions among a large variety of B, T and 
DC cell subsets together with other not less diverse innate immune cells, and this has been 
one of the most challenging and difficult tasks in modern biology and medicine. It has to 
be kept in mind that most of the immune regulatory processes are still in the “model” 
phase, and these models are constantly being challenged from various sides and at various 
levels. For example, a recent publication revealed that the migration of naïve CD8+ T cells 
to tumour sites takes place, thereto these cells could be activated in situ that was 
independent of draining lymph nodes or even antigen presenting cells showing that 
tumours can support the differentiation of antigen-specific CTL effectors175 circumventing 
the “mechanical” tolerance aspect, the “Danger Model”, as well as the three signal 
activation paradigm. Besides, many “black holes” still exist in our understanding on (i) the 
role of various recently described T helper cell subsets in the anti-tumour immune 
response, on (ii) B cell activation and antibody production against cancer antigens, 
including the interactions with various T helper cell subsets, as well as on (iii) the 
regulation of CTL activation and T cell tolerance including antigen-specific T regulatory 
cell inhibition, and many more, which constitute our future scientific interests. Although 
only rare success stories of adaptive immunotherapy have been met, now at least we realise 
what we don’t understand and can start to address these issues marking the entrance into 
the finishing straight of the marathon for the “right antigen”, “right adjuvant”, and “ right 
immune response”106,176. 
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5 Conclusions 
• A large majority of 1328 serum-reactive recombinant phage clones represented 
antigens translated as unnatural ORF peptides - 83%, followed by wild-type antigens - 
15%, and 2% constituted undefined ORF clones comprising putative novel genes and 
uncharacterised novel splice variants. 
• Cancer patients’ autoantibodies recognise the unnatural ORF peptides and not their 
natural ORF counterparts. 
• Large-scale serum profiling of the antigen collection revealed cancer-related humoral 
immune response against 50 novel wild-type antigens and 8 undefined ORF antigens. 
• The elaborated antigen prioritization scheme allowed the selection of 30 most 
promising candidate antigens for a comprehensive gene expression analysis to identify 
novel potential immunotherapy targets. 
• mRNA expression analysis in various normal tissues revealed (1) six testis-selective 
genes (predominantly expressed in germ cells and placenta): ALLC, C16ORF82, 
C11ORF20, ESCO1, LRRC50, and the uncharacterised gene LOC284861, (2) two 
novel testis-selective alternative splice variants for CFL1 and COX6B2, and (3) four 
testis-restricted genes (exclusively expressed in germ cells or placenta): C21ORF66, 
uncharacterised genes LOC392843, clones #200 and #232. 
• mRNA expression analysis in various cancer tissues revealed two novel cancer-testis 
(CT) antigens with potential application in cancer immunotherapy: LRRC50 was 
overexpressed in 23%-60% of various cancers, and ESCO1 – in 53% of melanoma 
samples. 
• Among the 30 candidate antigens 16 were ubiquitous wild-type self-proteins and the 
reasons of immunogenicity of these antigens in cancer patients remain elusive. 
• Expression analysis of the 15 members of the sperm-associated antigen group revealed 
five testis-selective genes: SPAG1, SPAG6, SPAG8, SPAG15, and SPAG17; four of 
them were identified as novel CT antigens: SPAG1, SPAG6, SPAG8, and SPAG17, 
which may have a potential application in tumour immunotherapy. 
• A specific humoral immune response in cancer patients was demonstrated against a 
testis-restricted alternative splicing isoform of SPAG17 that, together with other 
immunogenic alternative splicing isoforms shared between germ cells and cancer, can 
be ascribed to a novel group of cancer antigens called CT-spliced antigens. 
• The elaborated protocol of T cell activation analysis including CD8+ and CD4+ T cell 
separation from peripheral blood, in vitro pre-sensitisation and ELISPOT was capable 
to detect tumour-antigen specific CTL responses. 
• SPAG8-specific naturally occurring CTLs were detected in one gastric cancer patient 
suggesting that therapy-induced immune recognition of this antigen could be possible. 
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Main thesis of defence 
 
I The exploration of humoral immune response in cancer patients can reveal 
clinically significant tumour antigens. 
 
II The group of SPAG proteins contains ubiquitous genes and genes predominantly 
expressed in testis that are significantly upregulated in cancer, elicit humoral immune 
response and can be qualified as novel CT antigens with potential implications in tumour 
immunotherapy. 
 
III  The pattern of alternative splicing variants partially overlaps in tumours and germ 
cells that contributes to the generation of immunologically untolerised protein isoforms in 
cancer cells. 
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